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DISSERTATION ABSTRACT 
Michael Francisco 
Doctor of Philosophy 
Department of Human Physiology 
June 2020 
Title: Thermal Loading Modalities and Cutaneous Active Vasodilation 
 
 In humans, the primary response to increasing internal temperature is increased 
cutaneous blood flow along with sweating. These reflexes facilitate heat dissipation to the 
environment by expanding the thermal gradient between the core and the periphery of the 
body. The known mechanisms and transducers of cutaneous active vasodilation (CAVD) 
have been largely characterized by supine passive whole-body heating models and 
applied to our understanding of exercise heat loading. The goal of this dissertation was to 
assess the mechanisms of CAVD in response to varying thermal loading modalities and 
postures. First we sought to determine if posture could alter the nitric oxide component of 
CAVD. Second, we sought to confirm the cholinergic co-transmitter theory of active 
vasodilation during whole-body passive heating and expand these findings to exercise 
heat loading. Lastly, we sought to identify unknown vasoactive substances associated 
with cholinergic nerve co-transmission. Twenty four subjects were assigned to 
participated in one of two study protocols.  
Protocol 1 assessed neuronal and endothelial nitric oxide synthase (nNOS and 
eNOS) isozyme contributions to the nitric oxide component of CAVD during passive 
whole-body heat loading in the seated and supine positions. We found that eNOS is the 
 v 
primary mediator of NO during CAVD (Chapter IV). This finding conflicts with the 
findings of other studies, which have shown that the NO component of passive whole-
body heat loading is mediated by nNOS. 
Protocol 2 assessed the cholinergic co-transmitter theory of CAVD during 
exercise and passive whole-body heat loading. As discussed in Chapter V, we found that 
both thermal loading modalities result in CAVD through cholinergic nerve transmission, 
and that vascular transduction of active vasodilator nerve activity was similar between the 
two modalities. 
The studies described herein provide evidence that CAVD is widely the same 
regardless of how thermal loading is accomplished. Despite exercise and passive whole-
body heat loading having largely different hemodynamic and thermodynamic profiles, 
the afferent signals they share in common and those that delineate them do not appear to 
impact the mechanisms and transducers of CAVD as was originally thought. 
This dissertation includes published and unpublished co-authored material. 
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CHAPTER I 
INTRODUCTION 
 
Background 
Successful human temperature regulation is largely dependent on cutaneous 
vasomotor adjustments in nonglabrous (hairy) skin that act to expand or contract 
convective heat transfer between internal tissues and the periphery. Modulation of this 
thermal gradient ultimately determines heat loss and/or heat conservation between the 
periphery and the environment. Control of skin blood flow in nonglabrous skin is 
mediated by noradrenergic vasoconstrictor nerves and cholinergic active vasodilator 
nerves (46, 175, 176). Passive thermal loading in the supine position and the 
accompanying hyperthermia can increase skin perfusion from  approximately 5-10% of 
cardiac output to  approximately 50-70% of cardiac output (98, 178, 179, 181). The initial 
rise in skin blood flow during passive whole-body heating is due to vasoconstrictor 
withdrawal followed by increased vasodilator nerve activity known as cutaneous active 
vasodilation (CAVD) (46, 175). The active vasodilator nerves are responsible for 
approximately 80-95% of the abovementioned increase in skin blood flow during whole-
body heat stress (98, 162). Many models of the structure and function of the CAVD 
system have been put forth. For example, it was previously thought that the skin blood 
flow response to whole-body heat stress was secondary to the sweating (sudomotor) 
response. Current convention holds that the CAVD system consists of a single set of 
nerves that release acetylcholine and other unknown substances (the co-transmission 
theory). This set of nerves is thought to be responsible for both sweating (sudomotor) and 
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CAVD activity during heat stress (78, 114). Alternatively, there is some evidence to 
suggest skin blood flow and sudomotor responses to heat stress are controlled by 
independent cholinergic nerves (38), however it is now thought that independent neural 
control is not likely (146). Due to the large role of the active vasodilator nerves in the 
skin blood flow response to whole-body heat stress, CAVD has been well studied in the 
supine human, but is still not entirely understood. For example, It is still unknown which 
vasodilator pathway(s) is responsible for the majority (approximately 50-70%) of the skin 
blood flow response to heat stress. 
Currently nitric oxide (NO) is the principal identified vasodilator pathway 
contributing to CAVD (188, 189). It has been previously shown that pharmacological 
blockade (nonspecific) of NO synthase attenuates CAVD by approximately 30-45% in 
young healthy individuals during whole-body passive heating (148, 188, 189). 
Previously, the neuronal nitric oxide synthase (nNOS) isozyme has been implicated in the 
nitric oxide (NO) component of CAVD (117). Conversely, more recent work has 
demonstrated that the endothelial nitric oxide synthase (eNOS) isozyme is responsible for 
the NO component of CAVD during exercise (148). It was suggested that these disparate 
findings may be due to differences in active vasodilator nerve firing rates or increases in 
circumferential strain (associated with eNOS activity (138)) that are associated with 
exercise but not passive whole-body heat loading (148). These studies highlight distinct 
mechanistic differences in CAVD that may be dependent on the thermal loading modality 
used. Specifically, exercise and passive whole-body heating are largely different 
hemodynamic stressors that result in similar thermoregulatory reflexes. The afferent 
signals they share in common and those that delineate them may impact the mechanisms 
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and transducers of CAVD; yet these signals and their impact on CAVD are not well 
understood. For example, differences in the NOS isozyme contributions during upright 
exercise and supine whole-body passive heating may simply be due to differences in 
posture affecting the mechanisms of cutaneous vasodilation secondary to differences in 
afferent input (e.g. baroreception). 
Nevertheless, previous convention still holds that the mechanisms of CAVD 
operate in a similar manner regardless of the mode by which an individual is thermally 
loaded (98). As such, the known mechanisms and transducers of CAVD have been 
largely characterized by supine passive whole-body heating models and applied to our 
understanding of exercise heat loading. The contradictory findings mentioned above 
suggest these preconceived notions to be incorrect.  More research is needed to determine 
the similarities and differences of CAVD when thermal loading modalities are varied.   
 
Statement of the problem 
No studies have investigated the effects of posture on the NO component of 
CAVD. It is conceivable that posture (e.g. orthostasis) could explain differences in the 
NOS isozymes responsible for the NO component of CAVD during seated dynamic 
exercise and supine passive whole-body heating. It is also unknown if posture affects the 
relative contribution of NO to CAVD. Additionally, the most convincing evidence for the 
current co-transmission model of CAVD is derived from a singular study (114). This is 
problematic because these findings have not been independently corroborated, and the 
current model of co-transmission is based on a small sample size (observations in six 
individuals). It is unknown if this model extends to exercise heat loading or if cholinergic 
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co-transmission behavior is altered or absent from CAVD during exercise.  Lastly, the 
substance(s) co-transmitted with acetylcholine are unknown.   
Therefore, this dissertation had three aims. The first aim was to determine if 
postural effects could explain the observed differences in the NOS isozyme responsible 
for the NO component of CAVD during exercise and passive whole-body heating. The 
second aim was to confirm the cholinergic co-transmitter theory of active vasodilation 
during whole-body passive heating and expand these findings to exercise heat loading. 
The third aim was to identify unknown vasoactive substances associated with cholinergic 
nerve co-transmission. 
In order to address these aims, we performed two separate studies. Study Protocol 
1 was designed to determine the contribution of nNOS and eNOS isozymes to cutaneous 
vasodilation during passive whole-body heating in the supine and seated positions (aim 
1). We hypothesized that the NO component of CAVD during passive whole-body 
heating in the supine and seated positions would both be mediated by the nNOS isozyme. 
We also hypothesized that passive heating in the seated position would attenuate the 
overall skin blood flow response compared to passive heating in the supine position; but 
would not change the relative contribution of NO to reflex cutaneous vasodilation. 
Protocol 1 results are discussed in detail in Chapter IV.   
Study Protocol 2 was designed to determine the extent to which cholinergic 
nerve activation mediates CAVD during passive whole-body heating and exercise heating 
(aim 2), and to identify unknown vasoactive substances associated with CAVD (aim 3). 
We hypothesized that the same cholinergic nerves are responsible for CAVD during 
passive whole-body heating and exercise heating. Secondarily, shotgun proteomics of 
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collected dialysate samples from the dermis was used in an attempt to identify unknown 
vasoactive substances that may be co-transmitted with ACh from active vasodilator 
nerves in the skin. Due to the 2020 Covid 19 pandemic, completion of dialysate 
proteomics analyses has been delayed indefinitely. Study Protocol 2 results are discussed 
in detail in Chapter V.  
 
Significance 
CAVD has been extensively studied in the supine human during passive whole-
body heating. Very few studies have sought to characterize the mechanisms and 
transducers of CAVD unique to whole-body passive heating and delineate them from 
exercise heating. The research described in this dissertation was the first to 1) examine 
postural influences on the NO component of CAVD, 2) examine the cholinergic co-
transmitter theory of CAVD during exercise heating, and 3) utilize shotgun proteomics in 
an attempt to identify unknown vasoactive substances associated with CAVD. While this 
line of research has no immediate clinical implications, chronic exercise and heat 
exposure have both been shown to improve cardiovascular health. Understanding the 
basic physiological similarities and differences underlying these stressors will improve 
our understanding of how they each elicit improvements in health. Additionally, this 
research has contributed to our understanding of the similarities and differences in human 
temperature regulation during exercise as well as passive whole-body heat loading. 
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CHAPTER II 
REVIEW OF THE LITERATURE 
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Introduction 
It is widely accepted that heat regulation in humans is modulated through 
cutaneous vasomotor adjustments, sweating, and thermogenesis (shivering). The 
importance of cutaneous vasomotor adjustments to thermal balance is unparalleled, as 
skin blood flow (SkBF) modulates convective heat transfer between the body core and 
skin surface where it then interfaces with the environment. The expansion or contraction 
of the thermal gradient from the core to the periphery via skin blood flow is therefore 
critical to increasing heat dissipation during environmental heat exposure or exercise, as 
well as reducing heat dissipation during exposure to cold environmental temperatures.  
At rest, the skin receives approximately 5-10% of cardiac output; yet when 
maximally dilated (e.g. during passive heat stress in the supine position), the skin is 
estimated to receive up to approximately 6-8L/min, accounting for 50-70% of cardiac 
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output (CO) (98, 178, 179, 181). Of this profound increase in skin blood flow, cutaneous 
active vasodilation (CAVD) is responsible for  approximately 80-95% (98, 180). The 
ability of the cutaneous vasculature to change from very low to very high blood flows is 
best understood as it pertains to thermoregulation. The cutaneous vascular bed is also 
involved in other cardiovascular adjustments by contributing to total peripheral resistance 
in a variety of situations, such as orthostasis and exercise. This is particularly true in a hot 
environment, as a competition exists between thermoregulatory and non-
thermoregulatory reflexes (exercise, blood pressure regulation, etc.). While CAVD has 
been the independent focus of many studies during supine passive whole-body heating, 
relatively few studies have characterized the mechanisms and transducers of CAVD 
during orthostatic challenge (postural) or exercise. The complexity of the mechanisms 
involved in this system alone have made it difficult to understand CAVD in its entirety. 
The integration of multiple cardiovascular cues (e.g. exercise and posture) during thermal 
loading have also made it harder to understand CAVD.  
This dissertation sought to: 
1) examine the influences of posture on the nitric oxide component of CAVD 
2) assess the contribution of sympathetic cholinergic nerve activation to the skin 
blood flow responses associated with CAVD during exercise and passive whole-
body heat loading 
3) identify unknown vasoactive substances associated with CAVD 
In this chapter, the role of CAVD as a thermoregulatory process in humans will 
be reviewed. First, the importance of CAVD in modulating heat loss and the heat balance 
equation, thermo-sensing neurons that generate thermal cues (central & peripheral), and 
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the cutaneous neurovascular anatomy relevant to thermoregulation will be discussed. 
Second, we will present what was thought and what is now known about the mechanisms 
of CAVD in non-glabrous (hairy) skin, as this vasculature accounts for the majority of 
thermoregulatory heat loss via the CAVD system. Finally, we will summarize factors that 
can modify CAVD, such as sex hormones, posture, and exercise. 
 
Thermal Regulation and the Heat Balance Equation 
In humans, the skin surface is the boundary between the environment and the 
internal body. The thermal interaction between the environment and the body is described 
by the heat balance equation, defined as:  
 
S = M – (± W) ±  (R + C) – E (Eq 1) 
 
where S is the rate of storage of body heat, M is the rate of metabolic energy production, 
E is the rate of evaporative heat transfer, W is the rate of work, R is the rate of radiant 
heat exchange, and C is the rate of convective heat transfer (+ = gain, - = loss) (57).  
Blood flow from deep tissues to the skin surface transfers heat via convection. In 
the absence of sweat, elevations in SkBF will bring skin temperature closer to internal 
temperature, while reductions in skin blood flow will bring skin temperature closer to 
environmental temperature. In this way, the body is able to control sensible heat loss (via 
R and C) by controlling skin blood flow. In the presence of sweat, increases in skin 
temperature from increasing skin blood flow are reduced by the cooling effects of 
sweating, such that sensible heat loss (via R and C) is minimal. Instead, skin blood flow 
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is responsible for carrying heat to the skin where it can then be removed by sweat 
evaporation (via E). Therefore, sweating and CAVD are intrinsically linked and work in 
concert to effectively eliminate heat from the human body. The connection between 
sweating (sudomotor activity) and skin blood flow is discussed in more detail elsewhere 
(58). 
 
Thermal Cues 
While it is known that the reflex drive for increasing skin blood flow during 
thermal stress resides in the central nervous system, the specific thermal sensitive sites 
that detect internal and external temperature are not clearly defined. What is known is 
that the preoptic-anterior hypothalamus (PO/AH) in the brain is a primary site for 
thermoregulation with a lesser role for the spinal cord and peripheral thermoreceptors 
(12, 13). It is believed that this is where information about internal and surface 
temperatures are integrated and an appropriate efferent signal is generated. 
The Preoptic Anterior Hypothalamus 
The hypothalamus has been identified, through lesion and stimulation studies, as a 
participant in body temperature regulation since the late 1800’s. It is now considered a 
critical site of central thermosensitivity (68), but other regions such as the spinal cord, 
splanchnic region, and skeletal muscle have been implicated in playing a role in 
temperature regulation (90, 130). The highly perfused hypothalamus is capable of rapidly 
responding to changes in blood temperature due to its low thermal inertia (perfusion per 
unit of organ mass) (72). Early animal studies have demonstrated that within the 
hypothalamus the PO/AH is the primary controller of thermoregulatory responses (69, 
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101). For example, warming the carotid blood or irrigating the third ventricle with warm 
saline has been shown to produce panting as well as cutaneous vasodilation (69, 101, 
156). Within the hypothalamus there are 3 basic pools of neurons that have been 
characterized by their firing rates during local temperature changes. These include warm-
sensitive neurons, cold-sensitive neurons, and temperature-insensitive neurons. Warm-
sensitive neurons account for approximately 30% of the neuronal population and cold-
sensitive neurons account for less than 5% of the neuronal population. Stimulation and 
lesion studies done by Kanosue et al. suggest that warm-sensitive neurons form the 
predominant thermoregulatory responses to all thermal stimuli (104, 105). Warm-
sensitive neurons control heat loss, heat retention, and heat production outputs coming 
from the hypothalamus. More recent electro-physiologcal studies have shown that 
neurons in the PO/AH not only detect hypothalamic temperature but also receive and 
integrate input from thermoreceptors in the skin and spinal cord (Fig 2.1) (13). With this 
integrated information, the PO/AH can engage in thermoregulatory processes such as 
cutaneous vasomotor and sudomotor adjustments. In brief, the thermo-effector 
(sympathetic) signal for skin vascular control (158) leaves the PO/AH and inputs to the 
periaqueductal gray matter and ventral tegmental area of the midbrain. These midbrain 
areas directly feed onto the raphe/peripyramidal area of the medulla where the effector 
signal is then passed on to preganglionic neurons located in the intermediolateral column 
of the spinal cord. The effector signal is then passed on to postganglionic neurons in the 
sympathetic ganglia ultimately leading to the skin vasculature.  
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Figure 2.1. Adapted from Boulant (13). Model describing the 3 basic types of hypothalamic 
neurons on the basis of their firing rate responses to changes in preoptic temperature (Tpo). Warm-
sensitive neurons increase their firing rates during increases in preoptic temperature. Cold-sensitive 
neurons increase their firing rate during decreases in preoptic temperature. Temperature-insensitive 
neurons do not change their firing rates when Tpo is changed. Warm-sensitive neurons have afferent 
synaptic input from skin and spinal thermoreceptors and are thought to be responsible for 
thermoregulatory responses. (+ = excitation, - = inhibition) 
 
The Skin and Periphery 
Environmental temperature is directly detected by sensory neurons via their 
projections in the skin where it is then relayed to the PO/AH for integration (Fig 2.1). 
Importantly, thermal cues in the cutaneous tissue are conveyed via non-myelinated C 
fibers and myelinated Aδ fibers. The actual detection of these thermal cues by the sensory 
neurons depends on the ion conductance of specific channels in a temperature-dependent 
manner. More recently, transient receptor potential vanilloid receptor (TRPV) channels 3 
and 4 have been put forth as constitutive sensors of non-noxious warm stimuli. 
Interestingly, TRPV3 and TRPV4 channel expression is low in sensory neurons but is 
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abundant in epidermal and hair-follicle keratinocytes (32, 166, 193, 211). These 
observations have led to the hypothesis that temperature sensation is mediated by 
keratinocytes, which communicate with sensory neurons via the release of ATP and/or 
nitric oxide (NO) (143, 151, 155). 
 
Cutaneous Anatomy 
The cutaneous vasculature is arranged into a superficial and deep plexus that run 
parallel to the skin surface (15). The majority of the cutaneous blood vessels reside in the 
superficial plexus which is 1-2mm from the skin surface. Below the superficial plexus, in 
the lower dermal region, resides the deep plexus which consists of larger vessels that are 
formed from perforating vessels from deeper tissues. Ascending arterioles connect the 
deep and superficial plexuses as well as lateral vessels to sweat glands and hair follicles. 
The superficial plexus contains terminal arterioles, papillary loops (capillaries), and 
venules. The papillary loops provide a large surface area and are pivotal to heat exchange 
(15) and are also highly controlled by innervated arterioles. This basic vascular 
architecture is found in both glabrous and non-glabrous skin. Arteriovenous anastomoses 
(AVA) are found predominantly in glabrous skin (43, 89). AVAs are direct connections 
between the arterioles and venules that lie deep to papillary loops. AVAs allow blood to 
shunt the papillary loops and are therefore less efficient with heat transfer due to their 
small surface area and location in the dermis (15). 
Four different sensory nerves have been identified in skin. These fiber types 
include myelinated Aα fibers, myelinated Aβ fibers, myelinated Aδ fibers, and 
unmyelinated C fibers. Type C and Aδ fibers are responsible for temperature sensing, but 
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respond to a variable range of stimuli (osmotic changes, mechanical stimulation, UV 
light, and chemical stimuli) and signal the central nervous system via the dorsal root 
ganglia and the spinal cord (177). Besides sensory neurons in the skin, autonomic fibers 
also exist (177).  
Autonomic fibers innervate arterioles, AVAs, erector pili muscles, hair follicles, 
and both eccrine and apocrine sweat glands. In humans, the vasculature and sweat glands 
are innervated by both cholinergic and noradrenergic autonomic neurons. However, 
specific innervation varies by region. In nonglabrous skin, noradrenergic vasoconstrictor 
nerves as well as a cholinergic vasodilator system control skin blood flow to 
thermoregulatory challenges. The adrenergic vasoconstrictor system imparts a tonic 
vasoconstriction in the skin during thermoneutral conditions and can become active 
during cold stress. The cholinergic active vasodilator system is activated in response to 
elevations in internal temperature. In glabrous skin, adrenergic nerves innervate arterioles 
feeding papillary loops. Thermoregulatory activity in these areas is regulated by changes 
in adrenergic vasoconstrictor activity (28, 94, 106).  
 
Responses to Hyperthermic Challenge 
 Regardless of the manner by which an individual becomes hyperthermic (via heat 
exposure and/or heat production), the same thermoregulatory reflexes attempt to 
attenuate and even reverse rising internal temperature. These reflexes involve increasing 
both skin blood flow and sweat rate in proportion to internal temperature (8) and can be 
modified by a variety of factors such as hydration status, circadian rhythm, and skin 
temperature. These modifiers will be discussed later in the chapter. However, the method 
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by which individuals are heat stressed in the laboratory can affect factors such as the 
timing, mechanisms, and effectiveness of the thermoregulatory reflexes. As such, a brief 
discussion of passive whole-body heat loading versus exercise heat loading and the basic 
cardiovascular adjustments is warranted. 
 When exposed to a hot environment, skin temperature (Tsk) begins to rise as the 
thermal gradient between the skin and the environment diminishes. This rise in Tsk 
reduces the gradient for heat transfer between the core tissues and the environment such 
that internal temperature will rise. The initial rise in core temperature causes an increase 
in skin blood flow that is mediated by vasoconstrictor withdrawal (46, 175) and the 
magnitude of this initial response is dependent on the environmental conditions (53). As 
internal temperature continues to rise, there is a marked increase in skin blood flow and 
sweating in non-glabrous skin that is the result of exceeding regulated body temperature 
to activate the CAVD system (94, 98, 176). In these areas, cutaneous active vasodilation 
can account for approximately 80-95% of the rise in skin blood flow that accompanies 
heat stress (98) (180). 
 If submerged in water (such as a hot tub or jacuzzi), the overall response is similar 
to that described above, but the thermodynamics and potential hemodynamics of the 
system have changed. For instance, the thermal conductivity of water is roughly 20 times 
larger than that of air (0.58 W/m/°C and 0.024 W/m/°C respectively) such that the rate at 
which internal temperature rises will be faster due to the increased rate of heat transfer 
and absence of evaporative cooling via sweating. In this system, loss of E combined with 
increasing skin blood flow will facilitate heat storage and inhibit heat dissipation. 
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 The initial cutaneous vascular response to acute exercise involves a transient non-
thermoregulatory reduction in skin blood flow that is mediated by increased sympathetic 
vasoconstrictor activity (11). As exercise progresses, the ensuing heat from cellular 
metabolism generates a thermal load that increases core temperature and initiates a 
thermoregulatory response similar to that described above. Differences in the 
mechanisms of CAVD and regulation of skin blood flow during passive and exercise heat 
stress are discussed in select sections below.  
 
Transducers of CAVD 
This section will review the history of CAVD research to provide a contextual 
framework for this dissertation. Briefly, research on the nerves associated with cutaneous 
vasodilation in response to thermal loading has been ongoing since the 1930’s. There has 
been no further research on active vasodilator nerve activation in the last ~10 years and 
the current model of the cholinergic co-transmission theory of CAVD is now 25 years 
old. 
Early Evidence for Reflex Cutaneous Vasodilation 
The first evidence that skin blood flow was reflexively mediated came from 
Lewis & Pickering (140) and Gibbon & Landis (59) who observed that partial immersion 
of a limb or both forearms in warm water caused an increase in blood flow to the non-
immersed limbs (legs or contralateral limb). It was posited by Lewis & Pickering that 
dual vasoconstrictor and vasodilator nerves may exist in the skin; however, conclusive 
evidence was not obtained until 1938 in a classic study by Grant & Holling (63). In this 
study, skin temperature was measured as a surrogate for skin blood flow in the forearm 
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and it was found that increasing forearm blood flow in response to whole body heating 
could be abolished by nerve blockade or sympathectomy (Figure 2.2). In addition, they 
noted that sympathectomy or nerve blockade caused a slight elevation in skin blood flow 
during normothermia.  
 
Figure 2.2. From Grant and Holling (63). Vascular effects of blocking internal cutaneous nerve on 
forearm skin temperature during body heating. Forearm temperatures were measured on Radial (R) 
and Ulnar (U) sides of the forearm. Procaine and adrenaline were injected around the cutaneous 
nerve above the elbow (Time point A) and resulted in anaethesia in the ulnar side of the arm. 
 
Together, these findings demonstrated that cutaneous arterioles in non-glabrous 
skin had sympathetic vasodilator and vasoconstrictor nerves. These investigators also 
noted that sweating and the reflex increase in skin blood flow were initiated around the 
same time (or rise in body temperature) during heat stress, and proposed the notion that 
sudomotor activity was responsible for active dilation (this hypothesis is discussed in 
more detail later). Work by Edholm et al. (46) and Roddie et al. (175) confirmed the 
findings of Grant & Holling demonstrating that the initial rise in SkBF during whole 
body heating was due to vasoconstrictor withdrawal followed by vasodilator nerve 
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activity. Roddie et al. also demonstrated that administration of atropine (a muscarinic 
antagonist) abolished sweating but only reduced forearm vasodilation in response to body 
heating. This provided the first evidence that the sudomotor and active vasodilator 
systems may be mediated by a cholinergic mechanism. More recently, work by Kellogg 
et al. was able to verify and further characterize the dual efferent neural branches that 
innervate the cutaneous arterioles as a noradrenergic vasoconstrictor system and a non-
adrenergic vasodilator system (109). These investigators found that application of 
bretylium tosylate (a prejunctional noradrenergic antagonist) via iontophoresis abolished 
vasoconstriction induced by cold stress but did not attenuate the vasodilator response 
induced by heat stress.  
When the aforementioned studies are considered, a number of conclusions can be 
drawn. First, Lewis and Pickering demonstrated that increases in skin blood flow 
following heat stress are a neurally-mediated thermoregulatory response. Second, there is 
a noradrenergic vasoconstrictor system and a non-adrenergic vasodilator system. Third, 
cutaneous vasodilation and sweating are temporally linked and involve a sympathetic 
cholinergic mechanism.  
Continued use of pharmacological agents and new techniques such as intradermal 
microdialysis have shed light on the complexity and mechanistic redundancy present in 
CAVD, also highlighting the difficulty associated with its study.  
The Bradykinin Hypothesis 
Grant and Holling’s observation that sweating and skin vasodilation appeared to 
be temporally linked (63) led to the hypothesis that the mechanism of CAVD was 
secondary to sudomotor activity. However, it was unknown if CAVD was caused by the 
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excitation of a specific nerve or by the release of vasoactive substances from the activated 
sweat glands (54, 63).  
Fox and Hilton (54) believed that bradykinin, a polypeptide with vasodilator 
properties (52) and formed by the sweat gland, was the causative agent in CAVD similar 
to the vasodilation that follows salivary gland activation (76). To test this hypothesis, 
they measured markers of bradykinin in sweat and subdermal interstitial fluid during 
whole-body heat stress. These authors showed an increase in the bradykinin forming 
enzyme, kininogenase, in both the interstitium and in the sweat that coincided with 
CAVD during whole-body heating (54). More evidence supporting the bradykinin 
hypothesis was provided by the observation that individuals with anhidrotic ectodermal 
dysplasia, a rare syndrome in which sweat glands are congenitally absent, did not 
experience CAVD during whole-body heat stress (16). These studies provided indirect 
evidence that bradykinin is associated with CAVD, but did not demonstrate that 
bradykinin caused CAVD. This limitation was acknowledged by Fox and Edholm (53), 
who suggested that the final proof or disproof of the bradykinin hypothesis would come 
when a means to specifically block the bradykinin mechanism was found. 
 In 2002, Kellogg et al. administered HOE-140, a bradykinin ß2 receptor 
antagonist, via intradermal microdialysis to directly assess the role of bradykinin in 
CAVD (112). These authors found that bradykinin ß2 receptor blockade did not attenuate 
or alter the threshold of CAVD during whole-body heat stress. In addition, exogenous 
administration of bradykinin at bradykinin ß2 receptor blocked sites did not result in 
vasodilation, confirming the absence of ß1 receptors. From this observation it was 
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concluded that bradykinin formation from sweat gland activation is not responsible for 
CAVD. 
Cholinergic Co-transmission Theory 
Previous work by Roddie et al. showed that cutaneous vasodilation in response to 
heat stress contains a cholinergic component (175, 176). Infusions of intra-arterial 
atropine, a muscarinic antagonist, abolished sweating but only delayed the onset of 
CAVD and/or attenuated the magnitude of dilation, depending on the timing of atropine 
administration. Specifically, administration during hyperthermia did not attenuate CAVD 
but atropine administration prior to hyperthermia reduced the overall cutaneous 
vasodilation. These authors concluded that sudomotor activity is almost entirely mediated 
by cholinergic mechanisms whereas cholinergic mechanisms contribute but are not the 
primary mediators of CAVD.  
An alternative to the bradykinin hypothesis was that CAVD is dependent on a co-
transmitter system. Hokfelt et al. suggested that a single neuron was responsible for both 
sudomotor and CAVD responses to whole body heating (78). This co-transmitter system 
explained the observation that atropine abolished sweating but did not affect CAVD to a 
large extent. In 1995, Kellogg et al. provided the most convincing evidence of the co-
transmitter theory (114) (Fig 2.3). Intradermal injection of botulinum toxin A (which 
blocks presynaptic cholinergic neurotransmitter release) as well as administration of 
atropine via iontophoresis during whole body heating led to two key findings. First, 
atropine administration abolished sweating and delayed the onset of cutaneous 
vasodilation but did not attenuate it. This confirmed the contribution of acetylcholine to 
sweating and minor contribution to cutaneous vasodilation. Second, botulinum toxin A 
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abolished both sweating and cutaneous active vasodilation during whole body heat stress, 
but not vasodilation to directly applied heat. This confirmed the release of an unknown 
neurotransmitter(s) from the cholinergic nerve terminal is the primary mediator of 
CAVD. 
In a study by Crandall et al. (38), skin blood flow was found to decrease via active 
vasodilator withdrawal but sweat rate was found to increase when subjects performed 
isometric handgrip exercise during moderate hyperthermia. Follow up work (39) 
determined that the observed active vasodilator withdrawal was likely mediated by a 
metaboreflex, as skin blood flow in the exercised limb continued to decrease at the 
cessation of exercise and after the limb was occluded to trap metabolites. These findings 
suggested independent cholinergic nerve control of sweating and CAVD, or dual nerve 
theory. Interestingly, more recent work by McCord and Minson (146) demonstrated a 
non-neural mechanism may be responsible to for the previously observed reductions in 
skin blood flow during isometric handgrip exercise during hyperthermia. They found that 
this response could only occur when skin blood flow was significantly elevated prior to 
isometric handgrip exercise and was likely the result of myogenic autoregulation from 
increased perfusion pressures. These authors concluded that the separation of skin blood 
flow and sweating during isometric handgrip exercise during hyperthermia is not due to 
active vasodilator withdrawal. While these findings are hard to interpret, it is likely that 
there are not independent cholinergic nerves controlling skin blood flow and sudomotor 
activity. 
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Figure 2.3. From Kellogg (114). (Right) The effect of botulinum toxin on cutaneous active 
vasodilation (CVC) and sweating (Relative humidity) during whole body heating and local 
warming. Open circles are untreated and closed circles are botulinum treated sites. (Left) The effect 
of atropine administration on cutaneous active vasodilation (CVC) and sweating (Relative 
humidity) during whole body heating and local warming. Open circles are untreated and closed 
circles are atropine treated sites. 
 
 
The data from Kellogg et al., combined with the historic work of others, have 
established our current model of cutaneous active vasodilation: the cholinergic co-
transmission theory. The exact identification of the unknown neurotransmitter(s) and the 
pathways involved in active vasodilation, have been targets of much research and debate. 
It should be noted that the aforementioned seminal work done by Kellogg et al. is now 
over 20 years old. Furthermore, the current understanding of the co-transmitter theory of 
CAVD is based on observations made in a limited sample size (N=6). To date, no one has 
corroborated these findings or expanded them to include different thermal loading 
modalities (e.g. exercise vs. passive whole-body heating). This is problematic, because 
 23 
more recent research has suggested that there may be mechanistic differences in the skin 
blood flow responses to hyperthermic challenge that are dependent on how thermal 
loading is accomplished (see nitric oxide section below). In light of these observations, it 
is conceivable that CAVD may have different transduction pathways (e.g. different 
nerves). Therefore, we submit that the co-transmission theory of active vasodilation 
needs to be confirmed and expanded to include exercise heat loading. 
 
Vasodilators Involved in CAVD 
Multiple vasodilator pathways have been identified as having a role in CAVD. 
The synergistic nature of these pathways have made CAVD difficult to study. In vivo 
mechanistic studies have used pharmacological agents to inhibit or stimulate receptors 
such that our current understanding has been limited to the involvement of specific 
receptors and vasodilator pathways. Less is known about the particular vasodilator 
substances. 
Nitric Oxide 
Dietz et al. conducted the first study in humans to determine the role of NO in 
active vasodilation (45). In this study, intra-arterial infusions of the NO synthase inhibitor 
NG-monomethyl-L-arginine (L-NMMA) into the brachial artery during whole-body 
heating failed to attenuate a rise in forearm blood flow. It was concluded that NO was not 
involved in reflex vasodilation. Conversely, subsequent studies in humans have 
demonstrated that NO does in fact contribute to CAVD. In these studies, pharmacological 
blockade of NO synthase by either NG-nitro-L-arginine-methyl ester (L-NAME) via 
intradermal microdialysis or L-NMMA via intra-arterial infusion (188, 189) attenuated 
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cutaneous active vasodilation by approximately 30% in young healthy individuals during 
whole-body heating. Despite the observed attenuation of CAVD following NOS 
blockade, the precise role that NO played in CAVD was still unknown. 
Previous research using the rabbit ear model had suggested that NO played a 
“permissive” role but was not an effector of active vasodilation (49, 50). To address this 
in humans, Crandall and MacLean (37) measured interstitial NO breakdown products 
during whole-body heating and found no measurable increase. This suggested that NO 
was indeed a permissive factor of CAVD; however, later work by Kellogg et al. (116) 
directly measuring NO using an amperometric probe found that bioavailable NO 
concentrations increased during heat stress. From this it was suggested that NO could be 
an effector of CAVD. To clarify these discordant findings, Wilkins et al. (218) 
administered L-NAME to block endogenous NO production while simultaneously 
delivering a low dose of sodium nitroprusside. The results from this study showed that 
NOS blockade attenuated CAVD and exogenous delivery of NO only partially restored 
active vasodilation (that is, NO plays a synergistic role in CAVD). These findings lend 
support to our current understanding that NO is a direct effector and not a permissive 
factor of CAVD in humans.  
 More recent evidence suggests that neuronal nitric oxide (nNOS) is the primary 
NOS isozyme that contributes to the NO component of CAVD during whole body heat 
stress. Administration of the nNOS inhibitor, 7-nitrioindazole (7-NI), via intradermal 
microdialysis significantly attenuated skin blood flow increases during whole-body 
heating, but had no effect on skin blood flow increases induced by local heating (Fig 2.4) 
(117). This finding, in conjunction with other work by Kellogg et al., determined that 
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nNOS contributes to the NO component of CAVD and endothelial nitric oxide synthase 
(eNOS) contributes to the NO component of vasodilation during local heating (117, 118, 
120).  
   
Figure 2.4. From Kellogg (117). The effect of nNOS inhibition with 7-NI on cutaneous active 
vasodilation. Open circles are untreated and closed circles are 7-NI treated sites. 
 
 
Interestingly, work done by McNamara et al. has indicated that the eNOS isozyme 
contributes to CAVD during sustained dynamic exercise (148). These conflicting 
findings between active and passive heat stress highlight the possibility that the 
mechanisms of CAVD may vary depending on the source of the heat stress (dynamic 
exercise versus passive heating). These conflicting findings may also be the result of the 
posture in which subjects are heated as subjects were supine during passive heating and 
subjects were seated during exercise. McNamara et al., suggested that these differences 
could be due to differences in active vasodilator nerve firing rates (secondary to different 
afferent input) or due to increases in circumferential strain, which has been associated 
with eNOS activation (148). It had previously been demonstrated that an increase in shear 
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The suit and garment covered the entire body with the
exception of the head and the forearm from which LDF
measurements were made. The hands and feet were also
uncovered.
Internal temperature (Tor) was monitored with a
thermocouple placed in the sublingual sulcus. Subjects
were instructed not to speak during studies so as not to
interfere with this measurement. T sk was recorded as the
weighted electrical average from six thermocouples taped
on the skin surface (Rowell et al. 1969; Johnson & Park,
1981).
After arriving in the laboratory on the morning of the
study, two intradermal microdialysis probes were placed
on the ventral surface of one forearm. Subjects were
prepared for the specific protocol with instrumentation
as outlined above. Finally, subjects were placed in a supine
position for data collection.
Data collection began with a 5–10 min normothermic
control period during which T sk was maintained at
a normothermic level and all microdialysis sites were
perfused with Ringer solution at 2 µl min−1. After this
period, the perfusates at both microdialysis sites were
changed to 5% DMSO in Ringer solution. Perfusion
was maintained at 2 µl min−1 for 30–35 min. Following
this period, the perfusate of one microdialysis site was
changed to 7-NI (2 mm) dissolved in 5% DMSO and
Ringer solution which served as the treated experimental
site. Perfusion at a second microdialysis site was continued
with 5% DMSO in Ringer solution which served as the
Figure 1. Protocol 1. Example of nNOS antagonism and whole-body heat stress
Two microdialysis sites were used. After an initial normothermic control period when both microdialysis sites were
perfused with Ringer solution, both perfusates were changed to 5% DMSO in Ringer solution. Perfusate at one
microdialysis site was then changed to 2 mM solution of 7-NI in 5% DMSO in Ringer solution while 5% DMSO in
Ringer solution was maintained at the other site that served as an untreated control. After 30–35 min of perfusion
with the 7-NI, skin temperature (T sk) was decreased to induce whole-body cold stress for 3 min. T sk was then
increased to induce whole-body heat stress for 35–50 min. Finally, subjects were cooled to normothermia and the
perfusates at both sites changed to 56 mM nitroprusside to cause maximal vasodilatation.
untreated control site for any unanticipated effects of
DMSO. Perfusion rates at both sites were maintained at
2 µl min−1 throughout subsequent periods of cold and
heat stress. After perfusing for 30–35 min to allow for
the antagonist to enter the intradermal space, T sk was
decreased to induce cold stress for 3 min after which T sk
was returned to a normothermic level. T sk was then raised
to 38–39◦C and maintained at that level for 35–50 min
to induce heat stress and thus activate the vasodilator
system. Whole-body heating was maintained until Tor had
increased by approximately 1◦C and SkBF had stabilized
at an elevated level. After heat stress, subjects were
cooled to normothermic levels. All microdialysis sites were
then perfused with 56 mm nitroprusside (SNP) to effect
maximal vasodilatation by an endothelium-independent
mechanism at each site (Kreidstein et al. 1992; Kellogg
et al. 2005). SNP perfusion was maintained for 30–40 min
until a clear plateau in LDF had been achieved for data
normalization. The protocol is summarized in Fig. 1.
Data are presented as group means ± s.e.m. For data
analysis, CVC was indexed as LDF (in mV) divided
by MAP (in mmHg). CVC data were normalized to
their respective maxima as elicited by SNP at each site.
This normalization allowed for comparisons between
7-NI-treated and untreated control sites within and
between subjects. The vasomotor and NO responses to
heat stress were analysed by comparing the internal
temperature thresholds for the initial increases in
CVC during whole-body heating at the different
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stress does not account for the rise in NO-dependent vasodilation in the skin (226). More 
recent work by Fujii et al. corroborated the findings by McNamara et al. (55). In their 
study, intradermal administration of the eNOS inhibitor, LNAA, attenuated cutaneous 
vascular conductance (CVC) in young healthy adults during two 30-minute bouts of 
cycling in the heat. It had previously been assumed that the mechanisms of CAVD were 
the same between exercise and passive heating. More recent research is suggesting that 
this assumption is incorrect. More work needs to be done to further dissect the underlying 
mechanistic differences between exercise and passive heating. 
  Regardless of the NOS isozyme, NO is a significant contributor to CAVD in both 
passive and active heat stress models. More importantly, the NO pathway can be 
activated by a number of receptors that have been implicated in CAVD; plus, NO 
blockade does not account for the entire response. This indicates the presence of other 
vasodilator pathways that work in concert with and/or compliment the NO pathway. 
Vasoactive Intestinal Polypeptide 
Vasoactive intestinal polypeptide (VIP) is a vasoactive peptide hormone that was 
first suggested to be the unknown co-transmitter involved in CAVD. This submission 
originated from Hokfelt et al. whose study of the cat paw led to the discovery of an 
atropine resistant co-transmitter mechanism that released both ACh and VIP (78). 
Additional immunohistochemical studies have indicated that VIP is co-localized with 
acetylcholine in nerves associated with both sudomotor and vasomotor activity in humans 
(71, 210). In light of the observed co-localization of VIP and ACh, it was hypothesized 
that a single branch of neurons could be the effectors for both sweating and active 
vasodilation; however, direct evidence of a role for VIP in CAVD is lacking.  
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 The first experimental data testing the role of VIP in CAVD came from the study 
of cystic fibrosis (CF) patients, who have minimal levels of VIP in cutaneous nerves (73). 
Savage et al. (183) observed that CF patients maintained a normal CAVD response 
during heat stress which indicates that VIP is not involved in CAVD. Independent 
follow-up studies in CF patients by Kellogg et al. (107) and Wilkins et al. (219) tested 
whether enhanced ACh release or augmented NO production, respectively, were possible 
compensatory mechanisms of reduced VIP levels in CF patients. In both studies, no 
difference was found between control and CF subjects, arguing against the possibility of 
redundant mechanisms in the CAVD of CF patients (107, 219). 
 Pharmacological interventions to determine the effect of VIP on CAVD in healthy 
humans have also yielded mixed results. Bennet et al. delivered VIP10-28 to the skin (via 
intradermal microdialysis) to inhibit the VIP receptors, VPAC1 and VPAC2 (7). It was 
reported that VIP10-28 delivery attenuated the increase in skin blood flow during heat 
stress, indicating a role for VIP in CAVD. This finding was not confirmed in a 
subsequent study using VIP10-28 (220). Confounding both studies were the observations 
that in some subjects, concentrations of the VIP antagonist VIP10-28 also caused 
vasodilation, challenging the interpretation of the findings. These results were made even 
more unclear with the observation that VIP10-28 could augment the vasodilator response to 
exogenous VIP administration (via intradermal microdialysis) (217, 220). It was also 
demonstrated that the majority of vasodilation to VIP in the skin is through NO-
dependent pathways. This suggests that even if VIP is an involved co-transmitter, it does 
not explain the full expression of CAVD. 
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Histamine 
Histamine is another transmitter that has been implicated in CAVD. In a study by 
Wong et al., delivery of the H1 receptor antagonist pyrilamine and the H2 receptor 
antagonist cimetidine via microdialysis have indicated that only H1 receptors play a 
functional role in CAVD (227). Additionally, simultaneous administration of the NOS 
antagonist, L-NAME, with pyrilamine did not cause a further attenuation in CAVD (Fig 
2.5), suggesting that a portion of NO-mediated CAVD can be explained by H1 receptor 
activation. Lastly, exogenous VIP administration has been shown to have an H1 receptor 
component (217). Consideration of the aforementioned studies have led to the hypothesis 
that VIP release from the sympathetic cholinergic vasodilator nerves may cause some 
degree of H1 receptor activation (217, 227). 
 
Figure 2.5. From Wong (227). Group mean values from plateau of skin blood flow (CVC) during 
whole body heating at control treated, Pyrilamine treated, L-NAME treated, and L-
NAME+Pyrilamine treated sites. *P<0.05 versus control site; †P<0.05 versus Pyrilamine site. 
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Neurokinin Receptor-mediated Vasodilation 
Substance P is a neurokinin localized in the skin (70, 87, 152) that causes a 
partially NO-mediated vasodilation (129, 225). In a study by Wong et al., repeated 
infusions of substance P to desensitize neurokinin-1 receptors (NK1) (225) attenuated 
CAVD by approximately 30% (224) (Fig 2.6). Interestingly, the addition of the NOS 
inhibitor L-NAME along with NK1 desensitization attenuated CAVD by approximately 
80% (224). Taken together, these data suggest that NK1 receptor activation and NO 
contribute to CAVD in a largely independent fashion. Despite the aforementioned 
research, identification of a precise role for substance P in CAVD has been difficult for 
two reasons. First, it is unknown if substance P is what activates NK1 receptors. Other 
peptides from the kinin family such as neurokinin A and neurokinin B could also be 
responsible for receptor activation during active vasodilation, although the NK1 receptor 
has the highest affinity for substance P. Second, substance P has not been localized in 
active vasodilator nerves. Substance P is mainly found in sensory nerves and endothelial 
cells of the skin (70, 87, 152) making it unclear how sympathetic vasodilator nerves 
effect substance P release. Previous work by Charkoudian et al. found that both acute (to 
stimulate local sensory nerves) and chronic (to desensitize local sensory nerves) 
application of capsaicin to the skin did not affect CAVD in response to whole body 
heating, suggesting that substance P found in sensory neurons is not involved in active 
vasodilation (29). To date, the NK1 receptor agonist and its origin of release remain 
unknown. 
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Figure 2.6. From Wong and Minson (224). Group mean values from plateau of skin blood flow 
(CVC) during whole body heating at control treated, Substance P treated, L-NAME treated, and L-
NAME+Substance P treated sites. *P<0.05 versus control site; •P<0.05 versus Substance P site; 
#P<0.05 versus L-NAME site. 
 
TRPV1 Receptors 
As mentioned above, data from Charkoudian et al. suggest that sensory neurons 
are not involved in active vasodilation (29). More recent evidence from Wong and Fieger 
suggests that sensory neurons may actually play a role in CAVD (223). In this study, the 
role of TRPV1 channels in CAVD was studied. TRPV1 channels are predominantly 
found on sensory neurons and to a lesser extent on endothelial cells in skin. 
Pharmacological blockade of TRPV1 channels, by Wong and Fieger, using capsazepine 
delivered via microdialysis attenuated CAVD by approximately 25%. To further 
determine the role of TRPV1 in CAVD, the Wong also administered the NOS antagonist 
L-NAME with and without capsazepine (222). It was shown that there was no difference 
between NOS blockade and NOS + TRPV1 blockade, suggesting that TRPV1 channel 
activation may contribute to the NO-mediated component of CAVD. From these data, the 
author concluded that cutaneous sensory nerves contribute to CAVD; however, it is 
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unknown if TRPV1 channel activation on sensory neurons or endothelial cells is 
responsible for the TRPV1 component of CAVD. The aforementioned study by 
Charkoudian et al. suggests that it is endothelial TRPV1 channels that contribute to 
CAVD. This would also explain how TRPV1 channel activation contributes to the NO-
mediated portion of CAVD. 
Prostaglandins 
 A study by McCord et al. identified the prostanoid pathway as contributing to 
CAVD (145). In this study the authors inhibited the COX pathway using ketorolac 
delivered via intradermal microdialysis. COX blockade attenuated vasodilation by 
approximately 16% suggesting that prostanoids are involved in CAVD. Simultaneous 
NOS inhibition attenuated CAVD to a larger extent than independent NOS and COX 
inhibition, suggesting that COX mediates vasodilation independently of NO. A more 
recent study testing the effects of chronic aspirin therapy (COX inhibitor) demonstrated a 
blunted active vasodilator response to whole-body heating and subsequently confirmed 
the COX pathways involvement in CAVD (82). 
Calcium-Activated Potassium Channels (Kca) and Endothelial Derived 
Hyperpolarizing Factors (EDHF) 
Brunt et al. sought to determine the role that KCa channels and EDHFs contribute 
to active vasodilation (22). Use of tetraethylamonium (TEA), a KCa channel blocker and 
therefore an EDHF antagonist, with and without L-NAME highlighted a complicated role 
for EDHFs in CAVD. These authors found that EDHFs do not contribute to CAVD; 
however, simultaneous NOS inhibition augmented CAVD. When barium chloride, a 
KATP and Kir channel blocker, was administered with both TEA and L-NAME, the 
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response was reduced to a level similar to L-NAME alone. These data suggest that EDHF 
is not obligatory to CAVD and that a complex interplay exists between the EDHF, NO, 
Kir, and KATP pathways. 
Neurotransmitter(s) 
Neural control of the cutaneous vasculature, and more specifically CAVD, is of 
extreme importance to temperature regulation in humans. The development of new 
techniques and use of new pharmacological agents has introduced new insights and raised 
new questions about CAVD. Yet old questions remain unanswered. For instance, it is still 
unknown what substance(s) are co-transmitted alongside ACh from CAVD nerves. 
Pharmacological blockade of downstream receptors has given insights on what these 
substances might be but this is far from definitive evidence; since most pharmacological 
agents used to antagonize receptors and pathways likely have numerous physiological 
effects that are unknown to the researcher. Based on the mechanistic research described 
above, it is currently thought that VIP, histamine, and substance P may be substances that 
are co-transmitted by CAVD nerves or released by other cell types in response to CAVD 
nerve activation.  
As previously stated, it is known that VIP is co-localized with acetylcholine in 
nerves associated with both sudomotor and vasomotor activity in humans (71, 210); it is 
also known that exogenous VIP administration has been shown to have an H1 receptor 
component (217). Taken together, VIP release from the sympathetic cholinergic 
vasodilator nerves may cause some degree of H1 receptor activation through secondary 
release of histamine from mast cells in tissue (Figure 2.7) (217, 227). Co-transmission of 
VIP could also have direct effects on the cutaneous vasculature. However, 
 33 
pharmacological interventions to determine the effect of VIP on CAVD in healthy 
humans have yielded mixed results and the role of VIP in CAVD is inexact. Substance P 
has also been indirectly implicated as being responsible for approximately 30% of the 
CAVD response (224) (Fig 2.6), but Substance P has not been localized in active 
vasodilator nerves. Substance P is mainly found in sensory nerves and endothelial cells of 
the skin (70, 87, 152) making it unclear how sympathetic vasodilator nerves effect 
Substance P release. What is clear is that a substance(s) is co-transmitted alongside 
acetylcholine from CAVD nerves. Currently it is unknown what this substance(s) is and 
if its mechanisms of action are primary or secondary in nature to the vasodilator 
response. 
Summary 
The studies discussed above on the mechanisms of CAVD have uncovered a 
highly complex system that involves the activation of multiple receptors and vasodilator 
pathways in a synergistic and sometimes redundant manner (Fig 2.7). It has become clear 
that CAVD is not just mediated by a single neurotransmitter such as ACh but is likely 
mediated by the co-transmission of numerous transmitters from cholinergic nerves. It is 
also conceivable that numerous types of sympathetic cholinergic nerves exist that 
innervate different organelles within the dermis of the skin. While our understanding 
remains murky at best, we do know different vasodilators are involved at different times 
(e.g. ACh) and some contributors may be secondary to the neurotransmitter released. 
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Figure 2.7. Summary of known and unknown mechanisms of cutaneous vasodilation. 
Acetylcholine (ACh) is released from sympathetic cholinergic vasodilator nerves and is responsible 
for sweating as well as the early rise in skin blood flow from CAVD. Possible co-transmitters 
include vasoactive intestinal peptide (VIP) as well as other unidentified substance(s). VIP will bind 
to vasoactive intestinal peptide receptor 1 and 2 (VPAC 1 and 2) to cause vasodilation. VIP may 
also cause mast cell degranulation and histamine release which may account for histamine receptor 
(H1) activation during CAVD. Lastly, activation of both neurokinin-1 receptors and transient 
receptor potential vanilloid receptor 1 (TRPV-1) have been implicated in CAVD. Within the 
endothelium, neuronal nitric oxide synthase (nNOS) and the cycloogenase (COX) pathway are 
thought to produce the nitric oxide and prostacyclin during CAVD. 
 
 
Modifiers of CAVD 
CAVD is the end result of a highly integrative process that relies on input from 
numerous signals. Many factors can modify the CAVD system. The final section of this 
chapter will briefly focus on acute and chronic modulators of CAVD, as well as CAVD 
in special populations. Johnson et al. published a detailed discussion of CAVD 
modulators (95). 
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Whole-Body Heating and Skin Temperature 
It has been shown that skin temperature affects the internal temperature 
equilibrium point for active vasodilation and sweating (8, 96, 167, 168). At high skin 
temperatures there is a leftward shift (Fig 2.8) in the equilibrium point of CAVD 
resulting in an earlier onset of sweating and active vasodilation, as well as a greater level 
of skin blood flow and sweating at any internal temperature above the equilibrium point 
(96, 167, 168). The independent study of skin temperature and internal temperature on 
CAVD has been difficult because raising internal temperature typically involves raising 
skin temperature or activation of other reflex responses, such as those serving to maintain 
blood pressure during exercise.  
 
Figure 2.8. A schematic showing the relationship between skin blood flow and internal temperature 
as well as the internal temperature equilibrium point for active vasodilation. Factors that can shift 
the relationship left and right are listed. 
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Acute Modifiers: Circadian Rhythm 
It is well known that there is a circadian rhythm in resting internal temperature in 
humans. This rhythm follows endogenous heat production such that internal temperature 
is lower in the morning and higher in the evening (4, 133). Cutaneous vascular responses 
to heat stress also show a circadian rhythm in the balance point for cutaneous vascular 
responses to hyperthermia (2, 200, 203, 214). For example, during passive heat stress the 
internal temperature equilibrium point shift to higher temperatures in the evening (Fig 
2.8) and lower temperatures in the morning (2). Additionally, the gain of this response 
(internal temperature vs. skin blood flow) is lower in the morning than in the evening. A 
study by Aoki et al. using bretylium, administered via intradermal microdialysis, to block 
noradrenergic vasoconstriction demonstrated that the diurnal changes in reflex control of 
skin blood flow during whole body heating involves both the vasoconstrictor and 
vasodilator systems (3). Specifically, these authors found that the internal temperature 
equilibrium point for cutaneous vasodilation was higher in the evening at both control 
and bretylium treated sites, suggesting the shift in the balance point is dependent on the 
active vasodilator system. Furthermore, the gain of the response (internal temperature vs. 
skin blood flow) was reduced in the morning. Lastly, the gain was significantly lower at 
control sites when compared to bretylium treated sites, suggesting the sensitivity of 
cutaneous vasodilation is dependent on the vasoconstrictor system.  
Acute Modifiers: Postural Influences 
During orthostasis (upright posture), arterial baroreceptor activation results in an 
increase in total peripheral resistance (via peripheral vasoconstriction) to maintain an 
adequate perfusion pressure to the brain. This reflex vasoconstriction is mediated in part 
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by the cutaneous vasculature in both normothermic and hyperthermic conditions (36, 
111). In prior work by Kellogg et al., they blocked adrenergic vasoconstrictor activity, 
using bretylium iontophoresis, and measured skin blood flow responses at breylium 
treated and control sites to -40 mmHg lower body negative pressure (LBNP) in both 
normothermic and hyperthermic conditions (111). These authors found that reductions in 
skin blood flow following LBNP during hyperthermia were due to active vasodilator 
withdrawal, whereas during normothermia, reductions in skin blood flow were due to 
enhanced vasoconstrictor activity. To determine which baroreceptor population was 
mediating this active vasodilator withdrawal, Crandall et al. used external neck pressure 
to unload carotid baroreceptors and low levels of LBNP to unload cardiopulmonary 
baroreceptors independently of each other (36). Again, skin blood flow responses were 
measured at bretylium treated and control sites and it was concluded that neither 
cardiopulmonary or carotid baroreceptor unloading could account for the attenuated 
active dilator response during orthostasis (36).  
To date, the mechanisms of CAVD have principally only been explored in the 
supine position during passive whole-body heat loading. Mechanistic differences 
observed (eNOS vs. nNOS) during different thermal loading modalities may actually be 
due to differences in posture. We submit that, postural influences must be studied 
independently of differential thermal loading modalities to confirm the variable 
contribution of eNOS and nNOS during exercise and passive whole-body heat loading, 
respectively. 
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Acute Modifiers: Dynamic Exercise 
The onset of acute dynamic exercise involves a reduction in skin blood flow due 
to increased cutaneous sympathetic vasoconstrictor outflow (10, 11, 229). As previously 
mentioned, dynamic exercise generates a thermal load that can initiate CAVD similar to 
passive heat stress, although perhaps through slightly different mechanisms. Probably the 
most notable modification between passive and exercise-induced heat stress is the 
rightward shift in the internal temperature equilibrium point (Fig 2.8) for active 
vasodilation (97, 110, 125, 204). The magnitude of this shift is dependent on exercise 
intensity, with greater shifts occurring at higher intensity exercises (206). Once internal 
temperature has surpassed the balance point during exercise, skin blood flow rises 
linearly with increasing internal temperature until an internal temperature of 
approximately 38°C is reached. At this point, skin blood flow plateaus at approximately 
50% of max and any further increase in internal temperature does not result in a further 
increase in skin blood flow(17, 62, 98, 108, 125, 174). This plateau in skin blood flow is 
likely a limit imposed by competition for cardiac output between active muscle and skin 
blood flow (98). 
 Endurance exercise often results in dehydration which is associated with 
hyperosmolality, which leads to decreased skin blood flow and sweating responses to 
hyperthermia, even in the absence of hypovolemia (51, 157, 184, 185, 190). Specifically, 
Nadel et al. showed that individuals dehydrated by 3% body weight experienced 
rightward shifts in their internal temperature equilibrium point for CAVD (157). 
Conversely, hyperhydration does not seem to alter internal temperature equilibrium point 
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or modify the gain of the thermoregulatory responses when compared to euhydrated 
controls (136, 137, 157).  
Chronic Modifiers: Exercise Training/Heat Acclimation 
Both exercise training and heat acclimation have been shown to improve 
thermoregulatory responses to heat stress (47, 160, 174). This occurs by decreasing the 
internal temperature equilibrium point for active vasodilation and sweating (Fig 2.8) (47, 
174). A component of exercise training is the repeated heat stress inherent with exercise 
and therefore some level of heat acclimation occurs with chronic exercise training (61). 
Because of the relationship with exercise and thermal loading, exercise training and heat 
acclimation are inextricably linked. Exercise in a hot environment has demonstrated 
larger shifts in balance point than just exercise alone (174). In the classic study by 
Roberts et al., 10 days of exercise in thermoneutral conditions shifted the equilibrium 
point for active vasodilation and sweating towards lower internal temperatures (174). 
When the same protocol was performed in a hot environment, the internal temperature 
equilibrium point shifted to a greater extent than just exercise alone. This is likely due to 
the increased thermal load associated with each training bout in the heat. The 
thermoregulatory benefits of exercise and therefore heat acclimation have been shown in 
both young and old individuals (207). 
Chronic Modifiers: Sex Steroids 
Sex hormones fluctuate with the menstrual cycle such that progesterone and 
estrogen are elevated during the midluteal phase and low during the early follicular 
phase. These sex hormones have been shown to alter internal temperature as well as 
thermoregulatory control of skin blood flow and sweating (75, 77, 131, 171, 200, 201, 
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205). For example, core temperature is reduced during the early follicular phase and is 
elevated during the midluteal phase when estrogen and progesterone are high. These 
fluctuations in internal temperature are also paralleled by fluctuations in the internal 
temperature equilibrium point for both active vasodilation and sweating. For instance, 
there is a leftward shift in the internal temperature equilibrium point for active 
vasodilation during the follicular phase and a rightward shift during the mid-luteal phase 
(Fig 2.8) (27, 75, 77, 149, 171, 200, 202, 205). These shifts in internal temperature and 
the balance point also occur with oral contraceptives that contain estrogens and 
progestins.  
Interestingly, estrogen replacement therapy in women causes a decrease in 
equilibrium for CAVD and the addition of progesterone reverses this trend (18, 205). 
From these observations, it was concluded that estrogen seems to decrease internal 
temperature and thermoregulatory equilibrium points and progesterone promotes 
increases in body temperature.  
Modifiers - Special Populations 
Aging - The attenuated thermoregulatory responses to heat stress in aging 
populations are well documented (79, 83, 85, 86, 124, 128, 144, 154, 182). In particular, 
reductions in cutaneous active vasodilation are observed in the elderly during body 
heating and exercise (128, 170) and are associated with changes in the vascular 
responsiveness of the skin itself (79, 85, 86). Research by Holowatz et al. demonstrated 
that the decreasing vascular responsiveness of the skin is due in part to an attenuated NO-
mediated vasodilation that is a result of decreased NO-bioavailability (79, 85, 86). 
Interestingly, these authors also found that older individuals rely more heavily on NO to 
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augment skin blood flow in response to hyperthermia (79); suggesting that aging may be 
affecting other vasoactive pathways involved in CAVD. Continued research has 
demonstrated that decreased NO bioavailability in aging populations is due to NO 
quenching via oxidative stress (85, 86) and NOS uncoupling via elevated arginase 
activity or reduced L-arginine levels, and reduced active tetrahydrobiopterin (BH4) levels 
(196, 197).  
Hypertension & Type II Diabetes - In some but not all studies, individuals with 
essential hypertension have been shown to have a blunted active vasodilator response 
during both exercise and passive heating (80, 81, 113, 123, 126, 127). Work by Holowatz 
et al. showed that arginase inhibition (81) and antioxidant administration (80) both 
augmented active vasodilator responses in hypertensives through NO-dependent and 
independent mechanisms. In addition to the aforementioned mechanisms, maximal 
forearm skin blood flow has also been shown to be decreased in hypertensive subjects 
(24), suggesting that structural changes in the cutaneous vasculature are also occurring. 
 To date there are no studies that have directly addressed CAVD and type 1 
diabetes. However, type 1 diabetes has been shown to negatively affect heat loss at high 
intensity exercise but not during more moderate bouts of exercise (26, 147, 199). 
Conversely, type 2 diabetics have been shown to have impaired active vasodilator 
responses (194, 216). These impairments manifest as a reduced magnitude of cutaneous 
vasodilation due to decreased responsiveness to NO (194) as well as a rightward shift in 
the internal temperature equilibrium point for active vasodilation (Fig 2.8) (216).  
Heart Failure - Heart failure patients have impaired thermoregulatory responses 
to heat stress (42, 65). In a study by Cui et al., it was shown that the active vasodilator 
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response to whole body heating was reduced in individuals with heart failure (42). 
Similar to hypertensive individuals, maximal forearm skin vasodilation is impaired in 
heart failure patients, suggesting that cutaneous vascular remodeling contributes to the 
impaired active vasodilation (42). Subsequent work by Green et al. sought to determine if 
the NO-dependent component of CAVD could be attenuated and also contribute to the 
reduction in the cutaneous active vasodilator response (65). These authors determined 
that the NO-dependent component of CAVD was attenuated in heart failure patients. 
 
Conclusions 
The skin is the primary site where thermal interaction occurs between the human body 
and the environment. Modulation of skin blood flow allows humans to increase or 
decrease the convective heat transfer from internal tissues to the periphery where it can 
then engage in heat loss or heat retention with the environment. Therefore, neural control 
of the cutaneous vasculature, and more specifically CAVD, is of extreme importance to 
temperature regulation in humans. As has already been mentioned, the complexity and 
redundancy of this system has made its study difficult; however, the development of new 
techniques and use of new pharmacological agents has introduced new insights and raised 
new questions about CAVD. For instance, the potential mechanistic differences to CAVD 
during passive vs. active heating has changed the previously held notion that CAVD is 
mechanistically the same no matter the source of heat production. There are also old 
questions that have yet to be answered. Such as what vasodilator substance(s) mediate 
cutaneous active vasodilation in humans. To say we have only scratched the surface is an 
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understatement and continued research with new investigators and new methodologies is 
warranted. 
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CHAPTER III 
METHODOLOGY 
 
Outline 
This dissertation sought to interrogate cutaneous active vasodilation (CAVD) in 
response to varying thermal loading modalities and postures using the techniques 
described in this chapter. Two studies were conducted in young, healthy, recreationally 
active subjects. Subjects were assigned to participate in one of the following study 
protocols. 
Protocol 1: Postural Influences on the Nitric Oxide Component of CAVD 
Protocol 1 (Figure 3.1A) was designed to determine the contribution of neuronal 
nitric oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) isozymes to 
cutaneous vasodilation during passive whole-body heat loading in the supine and seated 
positions. Some subjects completed a second study day in the alternative posture (i.e., 
Study Day 1 = seated and Study Day 2 = supine or Study Day 1 = supine and Study Day 
2 = seated). The specific methodology and results of this study are detailed in Chapter IV. 
Protocol 2: Thermal Loading Modalities and CAVD Nerve Activation 
Protocol 2 (Figure 3.1B) was designed to determine the extent to which 
cholinergic nerve activation mediates CAVD during exercise heat loading and passive 
whole-body heat loading by comparing skin blood flow responses at cholinergic nerve 
blocked and unblocked sites using a crossover study design. The specific methodology 
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and results of cholinergic nerve blockade on CAVD during exercise heat loading and 
passive whole-body heat loading are detailed in Chapter V.  
Secondarily, this study sought to identify unknown vasoactive substances 
associated with CAVD. The specific methodology and the current status of the 
identification of unknown vasoactive substances associated with CAVD is also discussed 
in Chapter V. 
 
  
Figure 3.1. A schematic of Protocol 1 (A) and Protocol 2 (B).  (A) Subjects were randomly 
assigned a posture for passive whole-body heat loading (N=16) and a subset of subjects completed 
a second study day in the alternate posture (N=4).  X’s represent enzyme blockade.  (B) Subjects 
were randomly assigned an initial heating condition (N=8) and completed a second study day in the 
alternate heating condition 1-4 weeks later. 
 
 
Human Subjects 
All protocols in human subjects were approved by the Institutional Review Board 
at the University of Oregon (IRB #12102010.027, see Appendix page (128) for informed 
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consent documents). All subjects gave oral and written consent prior to participation in 
accordance with the Declaration of Helsinki. 
33 individuals were assessed for qualification in this dissertation project. Subject 
inclusion criteria included age 18-30 years, recreationally-active (<150 minutes of intense 
exercise a week), no cigarette smoking, not taking prescription medications with the 
exception of hormonal contraceptives, not currently pregnant or breast-feeding, no 
history of allergic reactions to any drugs similar to those used in protocols 1 and 2, and 
no history of cardiovascular, metabolic, or other chronic diseases. Of these 33 
individuals, sixteen (8 men, 8 women) individuals enrolled in Protocol 1 and eight (3 
men, 5 women) individuals enrolled in Protocol 2. Subject demographics for both 
protocols are presented in Table 3.1. 
 
Table 3.1. Demographics of subjects who completed Protocol 1 or Protocol 2. Data are 
mean ± S.E. 
 Protocol 1 (N=16) Protocol 2 (N=8) 
# of women 8 5 
Age (yrs) 23 ± 0.7 22 ± 1.1 
Height (cm) 172 ± 3 173 ± 4 
Weight (kg) 69 ± 5 68 ± 2 
BMI (kg/m2) 23.4 ± 1.6 22.7 ± 0.6 
 
Prior to thermal loading study days, subjects abstained from food for 4 hours, 
alcohol and caffeine for 12 hours, and exercise and over-the-counter medications for 24 
hours.  All female subjects had a negative pregnancy test on the morning of each study 
day.  For Protocol 1, women were studied during the low hormone phase of their 
menstrual cycle.  Women taking hormonal contraceptives (N=6) were studied during the 
placebo phase and those naturally menstruating (N=2) were studied during the early 
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follicular phase of menstruation (self-reported).  For Protocol 2, women taking hormonal 
contraceptives (N=4) were studied during the placebo phase and those naturally 
menstruating (N=1) were studied during the early follicular phase of menstruation (self-
reported).  In order to study females under consistent hormone levels for Protocol 2, 
females returned one full cycle later (i.e. 3-4 weeks apart) for their second study day visit.  
In Protocol 1, the single female that completed passive whole-body heating in both 
postures, returned 8 days after her first study day visit for her second visit. 
 
Thermal Loading Study Days 
As discussed in Chapter II, differences in thermal loading and/or posture, may 
result in an increased SkBF response by different mechanistic means. To explore these 
potential differences, this dissertation utilized both exercise heat loading and passive 
whole-body heat loading modalities to study the mechanisms and transducers of CAVD 
in young, healthy, recreationally active individuals.   
General Instrumentation 
Regardless of protocol or thermal loading modality, subjects reported to the 
Human Cardiovascular Control Laboratory in Esslinger Hall on the University of Oregon 
campus for their thermal loading study days. Upon arrival, subjects provided a urine 
sample to confirm euhydration via urine specific gravity <1.02 (Analog Regractometer; 
Atago, Tokyo, Japan). If urine specific gravity was >1.02, subjects drank 5 ml/kg of 
water prior to study. Dry nude body weight was measured before and after thermal 
loading to calculate mean whole body sweat rate. Subjects were instrumented with a 
sterile rectal thermistor probe (YSI Series 400; Yellow Spring Instruments, Yellow 
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Springs, OH) inserted approximately 10 cm past the anal sphincter to monitor internal 
temperature (Tc).   
Skin surface thermistors (MSR145WD, MSR Electronics GmBH, Seuzach, 
Switzerland) were applied to standard locations on the chest, forearm, calf, and quadricep 
to continuously measure skin temperatures. Mean skin temperature (Tsk) was calculated 
using the 4-site weighting method previously developed by Ramanathan (172):  
Tsk = 0.3(tchest + tarm) + 0.2(tthigh + tcalf)          (1) 
Where  
tchest = skin temperature measured at the chest,  
tarm = skin temperature measured at the forearm,  
tthigh = skin temperature measured at the quadricep, and  
tcalf = skin temperature measured at the calf. 
 
Mean body temperature (Tb) was calculated using the internal temperature and mean skin 
temperature weighting method described by Gagge and Gonzalez (57): 
Tb = 0.8(Tc) + 0.2(Tsk)          (2) 
 
Heart rate and ventilatory frequency were monitored using a 3-lead 
electrocardiogram (CardioCap; Datex Ohmeda, Louisville, CO).  Baseline blood pressure 
was measured in triplicate following 20 minutes of rest and periodically throughout the 
studies via brachial oscillation (Datascope Accutorr Plus, Duluth, GA) and auscultation 
as described below.   
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Exercise Heat Loading 
Exercise heat loading was accomplished by having subjects exercise on a 
stationary bicycle ergometer (Excalibur Sport, Lode, Groningen, Netherlands) at a 
constant workload that corresponded to 60% of their VO2peak (VO2peak test methodology) 
for 60 minutes (Figure 3.2.).  This relative workload was based on McNamara et al. 
(148). During the first approximate 10 minutes of the 60-minute exercise interval, 
subjects were attached to a breath-by-breath metabolic measurement system 
(Parvomedics, Sandy, UT) to ensure they were exercising at 60% of their VO2peak. 
Pulmonary gas exchange was then “spot” checked approximately every 20 minutes for 
the duration of exercise. During exercise heat loading study days, blood pressure in the 
brachial artery was measured using the auscultatory method (mercury 
sphygmomanometer and stethoscope) due to inaccuracy of oscillometric recorders during 
physical activity (164). 
 
Figure 3.2. Representative temperature response to 60 minutes of exercise heat loading from one 
subject. Filled circles represent mean body temperature and filled triangles represent internal 
temperature (Left Y axis).  Open circles represent mean skin temperature (Right Y axis). 
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Passive Whole-Body Heat Loading 
Passive whole-body heat loading was accomplished by having subjects wear a 
two-piece nylon water-perfused suit (Med-Eng Systems, Ottawa, Canada), which covered 
all skin surfaces except the experimental arm, face, hands, and feet. In addition, subjects 
wore a water-impermeable plastic garment over the suit to mitigate evaporative heat loss. 
During thermal loading, mean skin temperature was maintained at approximately 39 °C 
for 60 minutes using a heated circulating water bath (HT CIRC 7L AD, Polyscience, 
Niles, Illinois) to perfuse hot water (50°C) through the suit (Figure 3.3).  This water 
temperature was based on previous work from our lab and has been previously shown to 
raise internal temperature 0.7-1.0°C above baseline in approximately 60 minutes (22, 
218, 224). During passive whole-body heat loading studies, blood pressure in the brachial 
artery was measured using the oscillometric method. 
 
Figure 3.3. Representative temperature response to 60 minutes of passive whole-body heat loading 
from one subject. Filled circles represent mean body temperature, filled triangles represent internal 
temperature, and open circles represent mean skin temperature. 
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VO2peak Test  
VO2peak was assessed using a graded cycling protocol on a stationary bicycle 
ergometer. The graded cycling protocol involved a 5-minute warm-up at 100 watts 
followed by 20 or 25 watt (Female and Male increases, respectively) increases in work 
load every minute until volitional fatigue.  Heart rate was monitored via telemetry (Model 
RS400, Polar Electro, Lake Success, NY) and ratings of perceived exertion were noted at 
every work stage.  VO2peak was then validated by having subjects cycle at a supramaximal 
workload (115% VO2peak) to ensure their VO2 did not rise above their previously 
determined plateau. 
 
Cutaneous Microvascular Assessment During Thermal Loading 
 As discussed in Chapter II, human temperature regulation is modulated through 
cutaneous vasomotor adjustments, sweating, and thermogenesis (shivering). The 
expansion of the thermal gradient from the core to the periphery via skin blood flow is 
critical to increasing heat dissipation during exercise heat loading or passive whole-body 
heat loading.  The majority of recent research has used remote pharmacological 
interventions and local cutaneous microvascular imaging to study skin blood flow 
responses to hyperthermic challenge in humans.  In this dissertation, intradermal 
microdialysis and laser-Doppler flowmetry were used to interrogate the CAVD system in 
humans during thermal loading.  
Intradermal Microdialysis 
 Intradermal microdialysis, or skin microdialysis, consists of the placement of thin 
hollow fibers with tubular dialysis membranes into the dermis that are then perfused at a 
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low speed with perfusate.  The presence of the dialysis membrane allows for the flow of 
tiny molecules between the perfusate inside the membrane and the interstitial space 
immediately surrounding the membrane (approximately 1 cm in diameter around the 
membrane). In this manner, intradermal microdialysis can facilitate the local delivery of 
substances to a small area of skin and the recovery of substances released from the same 
area of skin (Figure 3.4).  Since intradermal microdialysis is relatively noninvasive and is 
well tolerated by human volunteers, it has been broadly used in the modeling of 
microvascular function (35, 84), drug discovery/ pharmacokinetics (21, 134, 161), and 
the study of normal/abnormal skin function (34, 150, 191) in vivo.   
Human thermal physiology research also has employed this technique to 
“pharmaco-dissect” the vasodilator mechanisms of the SkBF response to hyperthermic 
challenge (4, 22, 117, 145, 148, 218–220, 222–225, 227). This is most commonly 
accomplished by delivering pharmacological agents dissolved in a vehicle (perfusate is 
most commonly Lactated Ringer’s solution) to antagonize components of vasodilator 
pathways while simultaneously quantifying SkBF via laser-Doppler flowmetry in the 
volar forearm (Figure 3.4). 
 
Figure 3.4. A schematic of the intradermal microdialysis technique used in conjunction with Laser-
Doppler flowmetry and local thermal hyperemia. 
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Placement of microdialysis fibers in the dermis was performed using an aseptic 
technique.  Linear microdialysis fibers (CMA 31 linear microdialysis, 10 mm membrane, 
55Kda or 2000Kda CO; Harvard Bioscience, Holliston, MA) were placed in the dermal 
layer of the volar forearm of either the nondominant or dominant arm (randomized by 
subject), although other sites have been used to study regional variations in skin 
responses (64, 198).  The volar forearm was chosen because most of the aforementioned 
thermal physiology research was conducted in the forearm and the volar surface is 
typically less sun damaged.  Prior to fiber placement, a tourniquet was used to identify 
superficial veins to be avoided during placement and to also identify additional sites a 
minimum of 5 cm apart in cases where multiple fibers were to be placed.  This ensured 
that fibers were placed in the microvasculature and prevented the interaction of 
pharmacological agents between fiber sites.  Fibers were placed by first introducing a 25-
gauge or 23-gauge needle approximately 1 mm below the surface of the skin, with entry 
and exit points 2-3 cm apart.  Fibers were threaded through the lumen of the needle and 
the needle was removed leaving the dialysis membrane of the fiber centered between the 
needle entry and exit points (Figure 3.5).   
A period of approximately ninety minutes was allowed to let needle insertion trauma 
and the resulting transient rise in skin blood flow resolve. Resolution of the skin blood 
flow rise was determined by the observed reduction and subsequent plateau of skin blood 
flow values. To maintain patency of the dialysis membrane during this time, fibers were 
perfused with Lactated Ringer’s solution at a rate of 2.0 ul/min (CMA 102 Syringe 
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Pump; CMA Microdialysis AB, Solna, Sweden) until the start of study drug infusions or 
perfusate recovery. 
 
 
Figure 3.5. Three intradermal microdialysis fibers in the volar forearm with laser-Doppler 
flowmeters and local heating units removed.  Photo by Michael Francisco. 
 
Laser-Doppler Flowmetry 
Most recent mechanistic studies of the SkBF response to hyperthermic challenge 
have quantified SkBF using laser-Doppler flowmeters. Laser-Doppler flowmeters, or 
probes, sit flush with and perpendicular to the skin surface (Figure 3.4) and can be 
mounted by themselves or seated in the center of local heating units on the skin surface 
(Figure 3.4 and Figure 3.6).   
Laser-Doppler flowmetry is based on measuring the Doppler shift generated by 
the movement of red blood cells to the illuminating coherent light (139). Probes emit a 
beam of infrared light which penetrates the dermis and reflects off the dermal tissue and 
red blood cells; the reflected light is received by collecting fibers in the probe. 
Backscattered light carries information about red blood cell velocity (light frequency 
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shift) and concentration (fraction of total photons that are frequency shifted) (139). Red 
blood cell flux is then calculated as the product of red blood cell concentration and 
velocity.   
In this dissertation, local heating units (SH02 Skin Heater/Temperature Monitor; 
Moor Instruments, Axminster, UK) were placed on the skin surface and integrated blunt 
needle laser-Doppler probes (MP12-V2, Moor Instruments) were seated in the local 
heating units to assess SkBF in real time (Figure 3.4 and Figure 3.6). Laser-Doppler 
probes were connected to a laser-Doppler server unit with three additional satellite units 
(moorLAB, Moor Instruments) allowing up to four laser-Doppler flowmeters to be used 
simultaneously.   
Because blood vessel density across the skin is not uniform, red blood cell flux 
values are dependent on probe placement. To make inter-site and inter-subject 
comparisons using this technique, it is common to normalize site flux measures to a site’s 
maximal flux. In the skin, maximal flux is achieved by locally heating the skin to >43°C 
and microdialysis infusion of the endothelium-independent nitric oxide donor, sodium 
nitroprusside. We achieved maximal flux at each site by using a combination of local 
heating to 44°C and microdialysis infusion of 56 mM sodium nitroprusside. Additionally, 
to account for changes in blood pressure, data were converted to cutaneous vascular 
conductance (CVC = flux / mean arterial pressure) and presented as a percentage of 
maximal CVC. By accounting for blood pressure and normalizing site flux measures to 
site maximal flux, the percent of maximal CVC values provide a strong indicator of a 
site’s blood vessel tone and inter-site/inter-subject comparisons can be made. 
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Figure 3.6. A laser-Doppler probe seated in a local heating unit positioned on the skin surface 
directly over a microdialysis fiber. Photo by Michael Francisco. 
 
Pharmacological Interventions 
 Pharmacological agents in this dissertation were delivered via intradermal 
microdialysis or intradermal injection.  Protocol 1 assessed the effects of posture on the 
NO component of CAVD. 4 microdialysis sites were randomly assigned to be perfused 
with:  
1) Lactated Ringer’s solution (sham site),  
2) 5 mM N-propyl-L-arginine (NPLA),  
3) 10mM N5-(1-iminoethyl)-L-ornithine dihydrocholoride (L-NIO), or  
4) 20mM N-nitro-L-arginine-methyl ester (L-NAME).   
NPLA is an L-arginine analog that is a highly selective antagonist of nNOS based on in 
vitro and in vivo studies (1, 230). In addition, NPLA has been previously used to inhibit 
nNOS in human skin (20, 119, 148, 192). L-NIO is an L-arginine analog that has been 
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used to selectively block eNOS in vitro and in vivo (9, 44, 66, 91, 92, 148). It has also 
been previously used to inhibit eNOS in human skin (148). L-NAME is an analog of L-
arginine, which non-specifically inhibits NO synthase and has been used extensively in 
human skin studies (23, 31, 56, 115, 129, 189, 197, 198, 225, 227).   
Independent assessment of the SkBF responses at control, non-specific NOS 
blockade, nNOS specific blockade, and eNOS specific blockade sites, allows 
investigation of the relative contribution of NOS isoforms to the NO mediated portion of 
CAVD.  Drug concentrations were selected as the minimum doses necessary for eliciting 
maximal inhibition based on previous skin studies (31, 148). 
 All drugs used were at the highest chemical purity available.  Drugs were diluted 
to the appropriate concentrations by the primary investigator with sterile Lactated 
Ringer’s solution.  After dilution and before administration, perfusates were filtered 
through a 0.2µm filter needle.  Investigational new drug approval was obtained through 
the U.S. Food & Drug Administration for the use of L-NIO and NPLA in these studies 
(IND# 141941; PI: Minson CT).  Investigational new drug approval for the use of L-
NAME was previously obtained. (IND# 124303; PI: Minson CT). 
 Protocol 2 assessed the SkBF responses to exercise and passive whole-body heat 
loading at cholinergic nerve blockade and control sites.  nerves in the skin were blocked 
via intradermal injection of botulinum toxin type A (BOTOX®, onabotulinumtoxin A). 
Botulinum toxin binds irreversibly to presynaptic cholinergic nerve terminals, where it 
interacts with the soluble N-ethylemaleimide-sensitive fusion protein attachment protein 
receptor complex, to inhibit neurotransmitter release (6). This allowed study of the 
contribution of CAVD nerves (discussed in chapter II) to the SkBF response during 
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exercise and passive whole-body heat loading modalities. This model was used to recover 
perfusate at control and BOTOX® treated sites in an attempt to identify potential 
unknown neurotransmitters being co-released from CAVD nerves.  
BOTOX® was procured as a lyophilized preparation (Allergan, Madison, NJ). 
Preparations were then reconstituted with preservative-free 0.9% Sodium Chloride 
Injection USP by the primary investigator and used within 24 hours of reconstitution. 
Standard insulin syringes (1/2 cc, 1/2”, 31G) were used for intradermal injections. 
Subjects received three injections of approximately 5 units BOTOX® into the dermis 
(approximately 2 mm from the surface), with injection sites no farther than 
approximately 1.5 cm away from each other (Figure 3.7). Each injection site had a ring of 
effect that was approximately 2 cm in diameter. The “ring of effect” was identified by the 
primary investigator and drawn onto the skin surface using a permanent marker and 
photographs were taken to aid in re-identification of BOTOX® treated sites on thermal 
loading study days (Figure 3.7). Subjects were instructed to re-mark the “ring of effect” 
each day after showering or bathing. Subjects waited a period of at least 1 week after 
BOTOX® administration before participating in their first thermal loading study day. 
 59 
 
Figure 3.7: The ring of effect and three marked BOTOX® sites post-intradermal injection in the 
volar forearm in one subject.  Photo by Michael Francisco. 
 
Local Thermal Hyperemia 
 In the current dissertation, local heating was used in both Protocol 1 and Protocol 
2 to test drug specificity (Figure 3.8) and the preservation of local vasodilator responses 
in cholinergic nerve blocked skin, respectively. Local skin heating and the resulting 
vasodilator response, known as “local thermal hyperemia”, is one of the most 
characterized thermo-vascular responses in humans. Traditionally, local heating involves 
heating the skin to 42 °C at a rate of 0.1 °C/sec and results in a biphasic vasodilator 
response consisting of an initial peak and secondary plateau (Figure 3.8). The initial peak 
is mediated by a sensory nerve axon reflex that is likely the result of the release of 
calcitonin gene-related peptide and Substance P onto the cutaneous microvasculature 
(153, 213). The secondary plateau phase is approximately 60% dependent on eNOS 
generation of NO and 40% dependent on endothelial-derived hyperpolarizing factors 
(EDHFs) (23, 153). 
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Our lab recently developed a new local heating protocol in which the skin is 
heated to 39°C at a rate of 0.1°C/sec (31). Heating to this temperature results in a 
biphasic vasodilator response similar to heating to 42°C; however, the magnitude of the 
SkBF response is less (eg. the secondary plateau is approximately 40-50% of maximum 
vs. approximately 90-95% of maximum) and NO is an even larger contributor to the 
secondary plateau phase (approximately 80% eNOS mediated) (31, 153). For this 
dissertation we chose local heating to 39°C because of the large eNOS mediated 
vasodilation in the response and its relevance to Protocol 1 (discussed in Chapter IV). 
 
Figure 3.8. A representative tracing from one subject during local heating (39°C) of the skin at four 
microdialysis sites receiving: 1) Lactated Ringer’s (control site), 2) 5mM N-propyl-L-arginine 
(NPLA), a neuronal nitric oxide synthase (nNOS) inhibitor, 3) 10mM N5-(1-iminoethyl)-L-
ornithine dihydrocholoride (L-NIO), a endothelial nitric oxide synthase (eNOS) inhibitor, or 4) N-
nitro-L-arginine-methyl ester (L-NAME), a non-specific nitric oxide synthase (NOS) inhibitor.  For 
clarity, X’s represent blockade of particular enzymes. Data are presented as a percentage of 
maximal cutaneous vascular conductance (% maximal), determined by infusion of 56 mM sodium 
nitroprusside and maximal heating to 44 °C.  
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Perfusate Recovery 
 The technique of microdialysis is commonly used in the sampling and collecting 
of small-molecular-weight substances from the interstitial space in vivo and ex vivo. For 
example, it is widely used in neuroscience to quantify neurotransmitters, peptides, and 
hormones in living animals and in the determination of neurotransmitter release from 
prepared tissues (30).  
This dissertation sought to identify unknown vasoactive substances associated 
with CAVD using intradermal microdialysis to recover dialysate from cholinergic nerve 
blockade and control sites in the dermis of the volar forearm of human subjects. Lactated 
Ringer’s was perfused at a rate of 2 ul/min (CMA 102 Syringe Pump; CMA 
Microdialysis AB, Solna, Sweden) through linear microdialysis fibers placed in the 
manner previously described. Dialysis membranes were polycarbonate-ether, 10 mm in 
length, and had either 55 Kda or 2000 Kda cutoffs (CMA 31 linear microdialysis, 10 mm 
membrane, 55 Kda or 2000 Kda CO; Harvard Bioscience, Holliston, MA).  A peristaltic 
pump (Reglo ICC Digital Peristaltic Pump, IMSATEC, Wertheim, Germany) was 
attached to the distal “receiving” end of the fibers to reduce the build-up of back pressure 
and prevent ultrafiltration in the probe and improve analyte recovery efficiency (Figure 
3.9).  Thirty minute baseline dialysate samples were obtained at BOTOX® treated and 
untreated sites prior to thermal loading.  Dialysate at BOTOX® treated and untreated 
sites was then collected for the entire duration (approximately 60 minutes) of exercise 
and passive whole-body heat loading.  Dialysate samples were collected in 0.5 ml sterile 
cryotubes and were immediately frozen at -80 °C for future analysis. 
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In principle, once a microdialysis probe is inserted (described above) into tissue 
and perfusion begins, substances outside of the dialysis membrane diffuse through the 
membrane along their concentration gradient. In this manner the interstitial concentration 
of the analyte to be recovered can affect the overall amount of analyte found in the 
recovered perfusate. Importantly, the concentration of analyte collected will only 
represent a fraction of the extracellular fluid concentration. The diffusion of substances 
into the dialysis fiber and therefore recovery efficiency, are most affected by perfusate 
flow rate and composition, dialysis membrane properties, and both analyte properties and 
tissue properties;  
Analyte recovery is inversely related to perfusate flow rate with near one hundred 
percent recovery efficiency at extremely low flow rates (approximately 0.1ul/min) and 
low recovery efficiency at high flow rates (100, 228).  While extremely low flow rates 
are ideal for analyte recovery, these rates do not allow for sufficient time or volume 
resolutions to be practical.  High flow rates produce considerable back pressure in the 
probe, resulting in ultrafiltration of the perfusate and reduced recovery efficiency (30). In 
addition, solutes contained in the perfusate may disturb the interstitial neurochemical 
milieu and alter basal levels of neurotransmitters. For example, high concentrations of 
calcium (2.4 vs. 1.2 mM) can result in stimulated neurotransmitter rather than basal 
neurotransmitter release (215). Lactated Ringer’s and synthetic cerebral spinal fluid are 
most commonly used in dialysate recovery studies. For these reasons, we chose to 
perfuse Lactated Ringer’s at a rate of 2 ul/min with the aid of a peristaltic pump. 
Analyte recovery is directly proportional to membrane surface area (100). Greater 
membrane surface areas aid in the recovery of high molecular weight and/or “sticky” 
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compounds.  Kendrick et al, observed a strong negative relationship between recovery 
efficiency and analytes with larger molecular weights or greater hydrophobic properties 
(“sticky”) (121, 122).  It is thought that differences in membrane material and cutoff size 
may also affect the recovery of large molecular weight and/or “sticky” analytes. 
However, differences by membrane material have only been shown in vitro; while no 
differences in recovery have been found in vivo (88). Because we were attempting to 
identify unknown substances, we chose to use fibers with 10 mm long membranes and 
larger cut-offs (55 Kda or 2000 Kda) to help aid in the recovery of any larger molecular 
weight and/or “sticky” analytes. 
Consideration of tissue properties in dialysate recovery studies is also warranted 
when designing a dialysate recovery experiment. Analyte diffusion in tissue is typically 
slower than in an aqueous solution and this due to reduced fluid volume and tissue 
tortuosity (increased diffusional path) (159). Diffusion in tissue can be further slowed by 
analyte binding to cell surface receptors along the diffusional path. Because of this, it 
should be noted that tissue characteristics such as fluid volume, tortuosity, hindrance, and 
rate of analyte clearance, affect diffusional resistance and can therefore affect recovery 
efficiency. These factors can be experimentally problematic because they can reduce the 
dialysate levels of the analyte below the sensitivity of analytical detection, and any 
procedure (e.g. fiber placement) or treatment that affect the physiology of the tissue and 
its characteristics can lead to changes in probe recovery efficiency (30). 
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Figure 3.9. A schematic of the intradermal microdialysis set-up used to collect dialysate from 
BOTOX® treated and untreated sites in the dermis of the volar forearm. 
 
Perfusate Analysis for Unknown Proteins 
 The Proteomics Shared Resource Facility at Oregon Health Sciences University 
was retained to run a shotgun proteomics analysis on the dialysate samples. Mass 
spectrometry-based proteomics has become an increasingly powerful tool that has 
allowed the detection and quantification of thousands of proteins. In particular, liquid 
chromatography-mass spectrometry (LC-MS) allows for a bottom-up approach that has 
been used extensively in the determination of proteins found in dialysates (14, 163, 165). 
The typical LC-MS work flow involves the digestion of proteins into peptides (via 
trypsin), peptide separation by LC, and ionization of peptide molecules before entering 
the MS where they can be detected or filtered based on their mass-to-charge values (165). 
 The general proteomic analysis workflow at Oregon Health Sciences University 
was provide and is as follows. The skin dialysate samples are ultra-filtrated using 10 kDa 
cutoff Amicon Ultra 0.5 ml ultrafiltration spin cartridges (Cat #UFC501024, Millipore-
Sigma) to remove higher molecular weight proteins. Since the amount of recovered 
protein was below the limit of accurate detection by a Pierce BCA protein assay (< 0.1 
µg/µl), the filtrate is divided into two equal portions, dried by vacuum centrifugation and 
Syringe pump
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Cryotube
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the entirety of each sample subsequently analyzed. One portion is analyzed by mass 
spectrometry without digestion, and the other portion was reduced using DTT, alkylated 
with iodoacetamide, and digested overnight with trypsin (0.9 µg per sample) in the 
presence of ProteaseMax™ detergent, as recommended by the manufacturer (ProMega 
Corporation).  Following trypsin digestion, samples are filtered (0.22 um) and again dried 
by vacuum centrifugation. 
 Both dried trypsin digested and non-digested samples are dissolved in 22 µl of 5% 
formic acid and each analyzed by liquid chromatography-mass spectrometry (LC-MS). 
20 µl of each sample is auto-injected and peptides separated using a Dionex NCS-
3500RS UltiMate RSLCnano UPLC system, and mass spectrometric analysis is 
performed using an Orbitrap Fusion Tribrid instrument with an EasySpray nano source 
(Thermo Scientific). Peptides are desalted using an Acclaim PepMap 100 μm x 2 cm 
NanoViper C18, 5 μm trap column on a switching valve. After 5 min of loading and 
washing, the trap column is switched on-line to a PepMap RSLC C18, 2 μm, 75 μm x 25 
cm EasySpray column (Thermo Scientific). Peptides are then separated using a 7.5–30% 
acetonitrile gradient over 60 min in a mobile phase containing 0.1% formic acid at a 300 
nl/min flow rate. Survey MS scans are collected using the instrument’s Orbitrap mass 
analyzer at a resolution of 120,000. Data-dependent MS/MS spectra were collected in the 
instrument’s ion trap using higher-energy dissociation (HCD) following quadrupole 
isolation. The dynamic exclusion feature of the instrument and its top speed mode 
areused to increase the number of unique peptides that were identified.  
 RAW instrument files are processed using Proteome Discoverer version 1.4 
(Thermo Scientific), SEQUEST HT software and a UniProt human database (Swiss 
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Bioinformatics Institute, Geneva, Switzerland). For trypsin digested samples, searches 
are configured with a static modification for alkylated cysteines (+57.021 Da), variable 
modifications for oxidation of methionine (+15.995 M residues), and trypsin specificity. 
Undigested samples are similarly searched, except without specifying cysteine alkylation 
and using no enzyme specification.  A parent ion tolerance of 10 ppm, fragment ion 
tolerance of 1.0 Da, monoisotopic masses, and for trypsin cleaved samples, a maximum 
of 2 missed cleavages are allowed.  Searches used a reversed sequence decoy strategy to 
control peptide false discovery using Percolator software (48, 102). Results are filtered to 
remove peptide identifications with q-scores > 0.05, to maintain false discovery rates 
below 5%. Differences in protein abundances across samples were estimated by 
comparison of numbers of assigned MS/MS spectra to each protein (135). 
 
Final Remarks 
This dissertation sought to interrogate the CAVD system in response to varying 
thermal loading modalities and postures using the techniques described in this Chapter. In 
Protocol 1, the contribution of nNOS and eNOS isozymes to cutaneous vasodilation 
during passive whole-body heat loading in the supine and seated positions was assessed. 
The specific methodology and results of this study are detailed below in Chapter IV. In 
Protocol 2, the extent to which cholinergic nerve activation mediates CAVD during 
exercise heat loading and passive whole-body heat loading was assessed. Identification of 
unknown vasoactive substances associated with CAVD was also attempted. The specific 
methodology and results of this study are detailed in Chapter V. 
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CHAPTER IV 
POSTURAL INFLUENCES ON THE NITRIC OXIDE 
COMPONENT OF CUTANEOUS ACTIVE VASODILATION 
 
Introduction 
In humans, the primary response to increasing internal temperature (Tc) is 
increased cutaneous blood flow along with sweating. These reflexes facilitate heat 
dissipation to the environment by expanding the thermal gradient between the core and 
the periphery of the body. Noradrenergic vasoconstrictor nerves as well as a cholinergic 
vasodilator system control skin blood flow in human non-glabrous skin. During heat 
stress, the initial rise in internal temperature causes an increase in skin blood flow that is 
mediated by vasoconstrictor withdrawal (46, 175); the magnitude of this initial response 
is dependent on environmental conditions (53). As internal temperature continues to rise, 
there is a marked increase in skin blood flow and sweating in non-glabrous skin that is 
the result of exceeding the internal temperature threshold for activation of the cutaneous 
active vasodilator system (CAVD) (94, 98, 176). In non-glabrous skin, CAVD can 
account for approximately 80-95% of the rise in skin blood flow that accompanies heat 
stress (98, 180).   
The robustness of the CAVD system to thermal challenge has made it the topic of 
much research. A number of vasodilator pathways have been identified as having a role 
in CAVD; yet the complexity of the mechanisms involved in this system make it difficult 
to understand. Nitric oxide (NO) has been shown to contribute approximately 30-45% to 
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CAVD in young healthy individuals during supine passive whole-body heating (79, 117, 
119, 148, 188, 189). Previous research suggests that neuronal nitric oxide (nNOS) is the 
primary NOS isozyme that contributes to the NO component of CAVD during supine 
whole-body heat stress (117). Administration of the nNOS inhibitor, 7-nitrioindazole (7-
NI), via intradermal microdialysis attenuated the skin blood flow response during passive 
whole-body heating, but had no effect on skin blood flow response to local heating (117). 
Further work by Kellogg et al., determined that nNOS contributes to the NO component 
of CAVD and endothelial nitric oxide synthase (eNOS) contributes to the NO component 
of vasodilation during local heating (117, 118, 120). 
Interestingly, a study conducted by McNamara et al. indicated that the eNOS 
rather than the nNOS isozyme contributes to CAVD during sustained dynamic exercise 
(148). It was suggested that these disparate findings may be due to differences in active 
vasodilator nerve firing rates or increases in cyclic circumferential vessel wall strain 
(which has been shown to increase eNOS activity (138)) that are unique to exercise but 
not to passive whole-body heat loading (148). Taken together, these studies highlight 
distinct mechanistic differences in CAVD that may be dependent on the thermal loading 
modality used (e.g. semi-recumbent dynamic exercise vs. supine passive whole-body heat 
loading). It should be noted that exercise and passive-whole body heat loading are largely 
different stimuli that result in similar thermoregulatory reflexes. The afferent signals they 
share in common and those that delineate them may impact the mechanisms and 
transducers of CAVD; yet these signals and their impact on CAVD are not well 
understood. For example, differences in the NOS isozyme contributions during upright 
exercise and supine whole-body passive heating may simply be due to differences in skin 
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temperature or posture affecting the mechanisms of cutaneous vasodilation secondary to 
differences in afferent input (e.g. orthostatic and skin temperature inputs to the 
hypothalamus). 
During orthostasis (upright posture), arterial baroreceptor activation results in an 
increase in heart rate and cardiac contractility and an increase in total peripheral 
resistance (via peripheral vasoconstriction and venoconstriction within the splanchnic 
circulation) to maintain mean arterial pressure or adequate perfusion pressure to the 
brain. This reflex vasoconstriction is mediated in part by the cutaneous vasculature in 
both normothermic and hyperthermic conditions (36, 111). Kellogg et al. blocked 
adrenergic vasoconstrictor activity, using bretylium iontophoresis and measured skin 
blood flow responses at bretylium treated and control sites to -40 mmHg lower body 
negative pressure (LBNP) in both normothermic and hyperthermic conditions (111). 
These authors found that reductions in skin blood flow following LBNP during 
hyperthermia were due to active vasodilator withdrawal, whereas during normothermia, 
reductions in skin blood flow were due to enhanced vasoconstrictor activity. This 
manifests as a rightward shift in the Tc-skin blood flow relationship (Chapter 2, Figure 
2.8).  
To determine which baroreceptor population is mediating the active vasodilator 
withdrawal, Crandall et al. used external neck pressure to unload carotid baroreceptors 
and low levels of LBNP to unload cardiopulmonary baroreceptors independently of each 
other (36). It was concluded that neither cardiopulmonary nor carotid baroreceptor 
unloading could account for the attenuated active dilator response during orthostasis (36). 
While it is unknown what modulates the rightward shift in the Tc-skin blood flow 
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relationship, it is well documented that baroreception and thermoregulatory reflexes 
produce an integrated cutaneous vascular response (41, 74). Thus, it is possible that 
posture (e.g. orthostasis and some variation in baroreception) is a requisite afferent input 
to change active vasodilator nerve behavior and result in variable NOS isozyme 
recruitment (148) To date, the NO component of CAVD has only been explored in the 
supine position during passive whole-body heat loading. The impact of posture on NO 
generation during CAVD is unknown.   
Therefore, the purpose of this study (Protocol 1) was to examine the effect of 
posture on the NO component of CAVD during passive whole-body thermal loading. We 
hypothesized that the NO component of CAVD during passive whole-body heat loading 
in the supine and seated positions would both be mediated by the nNOS isozyme. We 
also hypothesized that passive whole-body heat loading in the seated position would 
attenuate the overall skin blood flow response compared to the supine position; but would 
not change the relative contribution of NO to reflex cutaneous vasodilation. 
 
Methods 
 All protocols in human subjects were approved by the Institutional Review Board 
at the University of Oregon (IRB #12102010.027, see Appendix page (128) for informed 
consent documents). All subjects gave oral and written consent prior to participation in 
accordance with the Declaration of Helsinki. 
Subjects  
Sixteen young (18-30 years) recreationally-active (<150 minutes of intense 
exercise a week) individuals volunteered to participate in this study. All subjects were 
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non-smokers with no history of cardiovascular, metabolic, or other chronic diseases, not 
taking prescription medications with the exception of hormonal contraceptives, not 
currently pregnant or breast-feeding, and with no history of allergic reactions to any 
drugs used in this study. A summary of physical characteristics is listed in Table 4.1. 
General Study Design and Setup 
Subjects participated in a passive whole-body heat loading study in either the 
supine or seated position which was randomly assigned prior to participation. Figure 4.1 
illustrates the randomization of subjects by posture for the passive whole-body heat 
loading interval and study drug to a site on the forearm. Treatments (Control, NPLA, L-
NIO, L-Name) were randomly assigned to sites on the forearm and are described below.  
 
 
 
Figure 4.1.  Randomization of subjects to a posture and study drug to a site on the forearm. 
 
A subset of subjects (4 of the 16 subjects) completed thermal loading in both 
positions. For these individuals, thermal loading study sequences were randomized and a 
period of at least 1 week separated the two thermal loading treatments. The subset of four 
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subjects underwent the thermal loading paradigm in both the seated and supine positions. 
After their initial study day, the four subjects crossed over and underwent thermal loading 
using the alternative position. Figure 4.2 shows the thermal loading positions for the four 
crossover subjects. Study drugs were administered to the same forearm during each of the 
two study periods. Four naïve drug treatment sites were identified on the subjects’ 
forearms during the second study period, and drug treatment was again randomly 
assigned to a forearm site. 
 
Figure 4.2.  Two period crossover study design for four subjects undergoing passive whole-body 
heat loading in both the seated and supine positions. 
 
Prior to thermal loading study days, subjects abstained from food for 4 hours, 
alcohol and caffeine for 12 hours, and exercise and over-the-counter medications for 24 
hours. All female subjects had a negative pregnancy test on the morning of each study 
day. Women were studied during the low hormone phase of their menstrual cycle. 
Women taking hormonal contraceptives (N=6) were studied during the placebo phase and 
those naturally menstruating (N=2) were studied during the early follicular phase of 
menstruation (self-reported). The single female that completed passive whole-body 
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heating in both postures was unable to return one full cycle later; she returned 8 days 
after her first study day visit for her second visit. 
On thermal loading study days, subjects reported to the Human Cardiovascular 
Control Laboratory in Esslinger Hall on the University of Oregon campus. Upon arrival, 
subjects provided a urine sample to confirm euhydration via urine specific gravity <1.02 
(Analog Regractometer; Atago, Tokyo, Japan). If urine specific gravity was >1.02, 
subjects drank 5 ml/kg of water prior to study. Dry nude body weight was measured 
before and after thermal loading to calculate mean whole body sweat rate. Subjects were 
instrumented with a sterile rectal thermistor probe (YSI Series 400; Yellow Spring 
Instruments, Yellow Springs, OH) inserted approximately 10 cm past the anal sphincter 
to monitor internal temperature (Tc).   
Skin surface thermistors (MSR145WD, MSR Electronics GmBH, Seuzach, 
Switzerland) were applied to standard locations on the chest, forearm, calf, and quadricep 
to continuously measure skin temperatures. Mean skin temperature (Tsk) was calculated 
using the 4-site weighting method previously developed by Ramanathan (172):  
Tsk = 0.3(tchest + tarm) + 0.2(tthigh + tcalf)       (1) 
Where  
tchest = skin temperature measured at the chest,  
tarm = skin temperature measured at the forearm,  
tthigh = skin temperature measured at the quadricep, and  
tcalf = skin temperature measured at the calf. 
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Mean body temperature (Tb) was calculated using the internal temperature and mean skin 
temperature weighting method described by Gagge and Gonzalez. (57): 
Tb = 0.8(Tc) + 0.2(Tsk)       (2) 
 
Heart rate and ventilatory frequency were monitored using a 3-lead 
electrocardiogram (CardioCap; Datex Ohmeda, Louisville, CO). Baseline blood pressure 
was measured in triplicate following 20 minutes of rest and every 5 minutes throughout 
thermal loading via brachial oscillation (Datascope Accutorr Plus, Duluth, GA).   
Passive Whole-Body Heat Loading   
Passive whole-body thermal loading was accomplished by having subjects wear a 
two-piece nylon water-perfused suit (Med-Eng Systems, Ottawa, Canada), which covered 
all skin surfaces except the experimental arm, face, hands, and feet. In addition, subjects 
wore a water-impermeable plastic garment over the suit to mitigate evaporative heat loss. 
During thermal loading, mean skin temperature was maintained at approximately 39°C 
for 60 minutes using a heated circulating water bath (HT CIRC 7L AD, Polyscience, 
Niles, Illinois) to perfuse hot water (50°C) through the suit. This water temperature was 
based on previous work from our lab and has been shown to raise internal temperature 
0.7-1.0°C above baseline in approximately 60 minutes (22, 218, 224). 
NOS Blockade  
Intradermal microdialysis was used to deliver nitric oxide synthase antagonists 
prior to and throughout thermal loading. Under aseptic conditions, all subjects had four 
microdialysis fibers (CMA 31 linear microdialysis, 10 mm membrane, 55Kda CO; 
Harvard Bioscience, Holliston, MA) placed in the dermal layer of the skin of either the 
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dominant or nondominant volar forearm. Fibers were placed by first introducing a 25-
gauge needle approximately 1 mm below the surface of the skin, with entry and exit 
points 2-3 cm apart. Fibers were threaded through the lumen of the needle and the needle 
was removed leaving the dialysis membrane of the fiber centered between the needle 
entry and exit points. Fibers were at least 5 cm apart to prevent the interaction of 
pharmacological agents between sites. A period of approximately 90 minutes was 
allowed to let needle insertion trauma and the resulting transient rise in skin blood flow 
resolve. This was confirmed by observing a plateau in laser-Doppler (described below) 
flux values. To maintain patency of the dialysis membrane during this time, fibers were 
perfused with Lactated Ringer’s solution at a rate of 2.0 ul/min (CMA 102 Syringe 
Pump; CMA Microdialysis AB, Solna, Sweden) until the start of study drug infusions.   
Forty-five minutes prior to passive whole-body heat loading, microdialysis fibers 
were randomly assigned to be perfused at 2ul/min with 1) Lactated Ringer’s solution 
(sham site), 2) 5 mM N-propyl-L-arginine (NPLA), 3) 10mM N5-(1-iminoethyl)-L-
ornithine dihydrocholoride (L-NIO), or 4) N-nitro-L-arginine-methyl ester (L-NAME). 
NPLA is an L-arginine analog that is a highly selective antagonist of nNOS based on in 
vitro and in vivo studies (1, 230). In addition, NPLA has been previously used to inhibit 
nNOS in human skin (20, 119, 148, 192). L-NIO is an L-arginine analog that has been 
used to selectively block eNOS in vitro and in vivo (9, 44, 66, 91, 92, 148). It has also 
been used to inhibit eNOS in human skin (148). L-NAME is an analog of L-arginine, 
which non-specifically inhibits NO synthase and has been used extensively in human skin 
studies (23, 31, 56, 115, 129, 189, 197, 198, 225, 227).   
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All drugs used were at the highest chemical purity available and drug 
concentrations were selected as the minimum doses necessary for eliciting maximal 
inhibition based on previous skin studies (31, 148). Drugs were diluted to the appropriate 
concentrations by the primary investigator with sterile Lactated Ringer’s solution and 
were perfused for the entire duration of the study.   
Skin Blood Flow  
Skin blood flow at the four microdialysis sites was quantified throughout the 
study using laser-Doppler flowmetry. Local heating units (SH02 Skin 
Heater/Temperature Monitor; Moor Instruments, Axminster, UK) were placed on the skin 
surface directly above the previously placed microdialysis fibers and integrated blunt 
needle end laser-Doppler probes (MP12-V2, Moor Instruments) were seated in the local 
heating units to measure red blood cell flux, an index of skin blood flow. Laser-Doppler 
flux was continuously recorded during a 2-minute baseline period and throughout the 
approximate 60-minute thermal loading period at all 4 drug sites.  
After completion of passive whole-body thermal loading and when skin red blood 
cell flux had returned to baseline levels at all 4 sites, a local heating protocol was used to 
ensure that L-NIO effectively inhibited and NPLA had no effect on NO-dependent 
vasodilation independent of passive whole-body heat stress (31). Local heating results in 
a biphasic vasodilator response consisting of an initial peak and secondary plateau (17, 
34). The initial peak is mediated by a sensory nerve axon reflex that is likely the result of 
the release of calcitonin gene-related peptide and substance P onto the cutaneous 
microvasculature (153, 213). The secondary plateau, is approximately 40-50% of the 
maximum skin blood flow response and is approximately 80% eNOS mediated.  
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Briefly, the local heaters at all sites were set to 33°C and a five minute baseline 
was recorded. All sites were then locally heated to 39°C at a rate of 0.1°C/sec. Maximal 
laser-Doppler flux was then obtained at each site by locally heating the skin to 44°C as 
well as infusing 56 mM sodium nitroprusside at each site. Timing of a thermal loading 
study day is summarized in Figure 4.3. 
 
Figure 4.3. A representative tracing of skin blood flow at a control site throughout the thermal 
loading study day. 
 
Data Analysis  
Skin red blood cell flux (RBCflux) data were digitized and recorded to a 
computer using data acquisition software (Windaq; Dataq Instruments, Akron, OH). The 
RBCflux measurements at each site during the 2-minute baseline period were averaged. 
Starting at the beginning of thermal loading, RBCflux measurements were averaged over 
each sequential one-minute interval during the approximate 60-minute thermal loading 
period. The red blood cell flux values were converted to cutaneous vascular conductance 
(CVC) and expressed as a percent of maximum CVC (%CVCmax). %CVCmax was 
derived as follows:    
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%CVCmax = [CVC / CVCmax] x 100 , 
 
where MAP is mean arterial pressure and was calculated as  
MAP = !
"
(systolic blood pressure) + #
"
(diastolic blood pressure). 
Skin blood flow responses at each site associated with increases in internal 
temperature were characterized using the %CVCmax value immediately after each 0.1°C 
increase in internal temperature.  
Statistics of Hemodynamics and Skin Blood Flow Results  
Statistical analyses of hemodynamic and temperature data were conducted using 
SigmaPlot 11.0 (Systat Software, San Jose, CA). Because there were no discernable 
differences between men and women, data from the two groups were combined for 
analysis. Hemodynamic and temperature data before and at the end of thermal loading 
were compared using a 2-way repeated measures analysis of variance (Intervention vs. 
Time).  
Statistical analyses of skin blood flow data were conducted using SAS 9.4 (SAS, 
Cary, NC). %CVCmax (observed values and change from baseline values) as a function 
of temperature increase and at the maximal temperature increase common to both the 
seated and supine positions (0.7 °C). The primary analysis included the naïve study day 
of all 16 subjects (i.e., the second study day for the 4 cross-over subjects was excluded). 
%CVCmax in the seated and supine positions as internal temperature increased 
was compared using a mixed model repeated measures analysis variance. The analysis 
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included position (seated, supine), site on the forearm (Control, NPLA, L-NIO, L-
NAME), temperature increase (0.1° C increments from 0.1 to 0.7 °C), site-by-
temperature increase interaction, and position-by-site-by-temperature increase interaction 
as fixed effects. A first-order autoregressive covariance structure was used to model the 
correlations among temperature increases within site.   
%CVCmax in the seated and supine positions at 0.7 °C was compared using a 
mixed model repeated measures analysis of variance. The analysis included position, site 
on the forearm, and position-by-site interaction. A compound symmetry covariance 
structure was used to model the correlations among sites. 
%CVCmax differences were examined in detail at the maximum internal 
temperature increase common to both positions (0.7 °C). Because the %CVCmax results 
from the seated and supine passive heating intervals identify the same NO synthase 
isozyme (eNOS or nNOS) as contributing to CAVD, %CVCmax differences between the 
seated and supine positions were explored further by comparing the least squares mean 
(LS mean) differences both between sites within position and between sites across the 
seated and supine positions. 
In the subset of four crossover subjects, potential position effects of NO synthase 
isozyme (eNOS or nNOS) contributions to CAVD, were summarized and examined 
graphically.   at the maximum internal temperature common to both positions. Results 
from the crossover subjects were consistent with those from the main study. Due to the 
small sample size, no further analyses were conducted. . 
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Results 
Subject Demographics 
 Subject demographics are presented as means ± S.E. in Table 4.1. Eight women 
participated in this study. 
Table 4.1. Demographics and baseline characteristics of subjects who completed passive 
whole-body heat loading (N=16). Data are mean ± S.E. A subset of subjects completed 
whole-body heat loading in both postures (4 of the 16). 
 Supine (N=8) Seated (N=8) 
# of women 3 5 
Age (years) 23 ± 1 23 ± 1 
Height (cm) 170 ± 3 168 ± 3 
Weight (kg) 65 ± 7 58 ± 4 
BMI (kg/m2) 22 ± 2 20 ± 1 
cm, centimeters; kg, kilograms; BMI, body mass index. 
 
Hemodynamics and Thermal Loading 
 Group mean hemodynamic data for passive whole-body heat loading in the seated 
and supine positions are presented in Table 4.2 below. Baseline heart rate, systolic blood 
pressure, diastolic blood pressure, mean arterial pressure, and pulse pressure were similar 
for the two postures. Baseline internal temperature (Tc) and mean body temperature (Tb) 
were also not different between postures (Figure 4.4 and Table 4.2, respectively). Heart 
rate increased equally during passive whole-body heat loading in each position [P<0.001 
for each position; Seated: 54 ± 2 (baseline) vs. 102 ± 3 (end of thermal loading); Supine: 
53 ± 3 (baseline) vs. 104 ± 4 (end of thermal loading) beats min-1, respectively]. 
Similarly, systolic blood pressure and pulse pressure increased to a similar extent relative 
to baseline by the end of passive whole-body heat loading in the seated and supine 
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positions (Table 4.2). Diastolic blood pressure and mean arterial pressure remained 
unchanged from baseline. Both postures resulted in similar increases in internal 
temperature and mean body temperature during passive whole-body heat loading (Figure 
4.4 and Table 4.2, respectively). There were no hemodynamic or body temperature 
differences between the two postures during passive whole-body heating. Additionally, 
there were no differences between the two postures for the subset of individuals studied 
in both positions. 
Table 4.2. Group mean hemodynamic and mean body temperature data at baseline and 
end of thermal loading in the seated and supine positions (N=16) for naïve subject study 
days. Data are mean ± S.E. 
 HR 
(beats 
min-1) 
SBP 
(mmHg) 
DBP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
Tb (C°) 
Seated (N=8)       
Baseline 54 ± 2 113 ± 3 70 ± 3 85 ± 2 43 ± 3 36.2 ± 
0.1 
Thermal 
loading 
102 ± 
4* 
129 ± 4* 66 ± 2 87 ± 3 64 ± 4* 38.0 ± 
0.2* 
Supine (N=8)       
Baseline 53 ± 3 116 ± 4 71 ± 2 86 ± 2 45 ± 3 36.1 ± 
0.1 
Thermal 
loading 
101 ± 
3* 
130 ± 6* 68 ± 3 89 ± 4 61 ± 4* 38.2 ± 
0.2* 
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean 
arterial pressure; PP, pulse pressure; Tb, mean body temperature; S.E., standard error. *P 
< 0.05 vs. baseline.  
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Figure 4.4. Internal temperature during 60 minutes of passive whole-body heat loading in the seated 
(closed circles; N=8) and supine (open circles; N=8) positions. Data are mean ± S.E. *P < 0.05 vs. 
baseline (time 0). 
 
Skin Blood Flow 
 %CVCmax measurements associated with 0.1 °C internal temperature increases 
during passive whole-body thermal loading in the seated and supine positions at each 
treatment site are summarized in Figure 4.5 and Figure 4.6, respectively. Increases in 
%CVCmax elicited following a 0.7 °C increase in internal temperature at each site during 
thermal loading in both positions are summarized in Figure 4.7. Baseline skin blood flow 
values were not different by site or by posture (P>0.050). Skin blood flow responses to 
increasing internal temperature were similar for the two postures (position differences, P 
= 0.811; position-by-site-by-temperature increase interaction, P=0.184) but differed by 
drug site (site-by-temperature increase interaction, P = 0.008). 
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During thermal loading in the seated position, skin blood flow values at the 
control site were elevated relative to baseline starting at a 0.1 °C (P < 0.001) increase in 
internal temperature and reached 51 ± 5 %CVCmax by the end of thermal loading 
(Figure 4.5). In the supine position, skin blood flow values at the control site were 
elevated relative to baseline starting at a 0.1 °C (P < 0.050) increase in internal 
temperature and reached 50 ± 8 %CVCmax by the end of thermal loading (Figure 4.6) 
Increases in skin blood flow at the NPLA sites as internal temperature increased 
did not differ from the control sites during thermal loading for both the seated and supine 
positions (all P > 0.072). At the maximum thermal load (0.7 °C internal temperature 
increase) for the seated and supine positions, the NPLA sites reached 55 ± 5 and 41 ± 6 
%CVCmax, respectively, and there were no postural differences (position*site 
interaction, P = 0.275; Figure 4.7). 
At L-NAME sites, skin blood flow was significantly increased (P < 0.050) 
relative to baseline by internal temperature increases of 0.4 and 0.3 °C in the seated and 
supine positions, respectively. Attenuation of the skin blood flow response relative to the 
control sites was evident starting at a 0.2 °C increase in internal temperature for both the 
seated (P < 0.001) and supine (P = 0.013) positions (Figure 4.5 and Figure 4.6). At the 
end of thermal loading for the seated and supine positions, L-NAME sites had reached 16 
± 3 and 20 ± 7 %CVCmax, respectively and were significantly different from their 
Control sites (P < 0.001 and P < 0.001, respectively). There were no differences by 
posture (P = 0.635; Figure 4.7).   
Skin blood flow at L-NIO sites was increased relative to baseline starting at 0.3°C 
increase in internal temperature for the seated position and at 0.2°C for the supine 
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position (P < 0.050). Evidence of an attenuated response relative to the Control was 
present starting at a 0.2°C and a 0.3°C internal temperature increase for the seated and 
supine positions, respectively ( P < 0.050). By the end of thermal loading in the seated 
and supine positions (0.7°C increase in internal temperature), L-NIO sites had reached 27 
± 4 and 27 ± 5 %CVCmax, respectively, and were significantly different from their 
Control sites (P = 0.002 and P = 0.003, respectively) (Figure 4.7). The difference 
between the seated and supine L-NIO sites at a 0.7°C increase in internal temperature 
was not significant (P = 0.972). 
  
Figure 4.5. Seated Position. Percentage of maximal cutaneous vascular conductance (%CVCmax) 
at Control (Ringers; filled circles), nNOS blockade (NPLA; open circles), eNOS blockade (L-NIO; 
closed inverted triangles), and nonspecific NOS blockade (L-NAME; open triangles) sites is shown 
for each 0.1 °C increase in internal temperature from baseline during passive whole-body heat 
loading in the seated position (N=8). Data are mean ± S.E. *P < 0.05 for Control and NPLA sites 
vs. baseline. §P < 0.05 for L-NIO and L-NAME vs. Control.   
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Figure 4.6. Supine Position. Percentage of maximal cutaneous vascular conductance (%CVCmax) 
at Control (Ringers; filled circles), nNOS blockade (NPLA; open circles), eNOS blockade (L-NIO; 
closed inverted triangles), and nonspecific NOS blockade (L-NAME; open triangles) sites is shown 
for each 0.1 °C internal temperature increase from baseline during passive whole-body heat loading 
in the supine position (N=8). Data are mean ± S.E. *P < 0.05 Control and NPLA sites vs. baseline 
(the solid line represents Control and NPLA; the dotted line represents Control). §P < 0.05 for L-
NIO and L-NAME vs. Control (the solid line represents L-NAME and L-NIO; the dotted line 
represents L-NAME). 
 
Figure 4.7. Percentage of maximal cutaneous vascular conductance (%CVCmax) at Control 
(Ringers), nNOS blockade (NPLA), eNOS blockade (L-NIO), and nonspecific NOS blockade (L-
NAME) sites at a 0.7C° increase in internal temperature during passive whole-body heat loading in 
the seated (black bars; N=8) and supine (gray bars; N=8) positions. Data are mean ± S.E. There 
were no differences in posture. *P < 0.05 vs. Control site in the same posture. L-NIO and L-NAME 
were not different. 
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Discussion 
This study investigated the effect of posture on the NO component of CAVD 
during passive whole-body heat loading. The main findings of the current study are 1) the 
NO component of CAVD during thermal loading in the seated and supine positions is 
eNOS rather than nNOS mediated and 2) differences in posture did not change the overall 
skin blood flow response or the relative contribution of NO to reflex cutaneous 
vasodilation. The finding that eNOS mediates the NO component of CAVD during 
thermal loading in the seated positions is contrary to our hypothesis which supposed the 
nNOS isozyme mediated the NO component of CAVD during passive whole-body heat 
loading. The finding that posture did not affect the overall skin blood flow response is 
also contrary to our hypothesis which supposed that the skin blood flow response in the 
seated position would be blunted when compared to the supine position. These 
suppositions were based on the observations that pharmacological blockade of nNOS 
(117, 118, 120) attenuated the entire NO component of CAVD and that orthostasis results 
in a rightward shift in the Tc-skin blood flow relationship via active vasodilator 
withdrawal during hyperthermia (111). 
nNOS vs. eNOS 
Nitric oxide (NO) has been shown to contribute approximately 30% to CAVD in 
young healthy individuals during supine passive whole-body heating (79, 117, 119, 148, 
188, 189). Previous research suggested that neuronal nitric oxide (nNOS) is the primary 
NOS isozyme that contributes to the NO component of CAVD during supine whole body 
heat stress (117). These findings, in conjunction with other work by Kellogg et al., 
determined that nNOS contributes to the NO component of CAVD and endothelial nitric 
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oxide synthase (eNOS) contributes to the NO component of vasodilation during local 
heating (117, 118, 120). A study conducted by McNamara et al. indicated that the eNOS 
rather than the nNOS isozyme contributes to CAVD during sustained dynamic exercise 
(148). More recent work by Fujii et al. corroborated the findings by McNamara et al (55). 
In their study, intradermal administration of the eNOS inhibitor, LNAA, attenuated CVC 
in young healthy adults during two 30-minute bouts of cycling in the heat. McNamara et 
al., suggested that these differences in NOS isozyme contribution could be due to 
variable active vasodilator nerve activation (secondary to different afferent input) or due 
to increases in circumferential strain, which has been associated with eNOS activation 
(148). While these findings currently reflect differences between exercise and passive 
heating, it is possible that differences in the afferent inputs due to skin temperature or 
posture (e.g. orthostasis), rather than exercise, may alter the mechanisms of reflex skin 
vasodilation.   
In the present study, no differences in the skin blood flow responses during 
passive whole-body heat loading were found when posture was varied (Figure 4.5, 4.6, 
and 4.7). Furthermore, our data suggest NO directly contributes approximately 60% to 
the increase in skin blood flow during whole body passive heating regardless of posture, 
which is higher than what most other studies that have shown (i.e., 30-45%) (79, 117, 
119, 148, 188, 189) but is within previously reported ranges (22). In conflict with the 
findings of others (117, 118, 120, 148), our data suggest that eNOS rather than nNOS is 
the primary isoform involved in reflex cutaneous vasodilation during passive heating 
(Figure 4.7). There are at least two possible explanations for these conflicting findings. 
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First, it is possible that NO generation in the cutaneous vasculature during thermal 
stress involves both nNOS and eNOS isoforms. It is possible that nNOS is a minor 
contributor to the initial cutaneous vasodilation whereas eNOS is the primary NO 
mediator and is responsible for sustained cutaneous vasodilation. In support of this, ACh 
has been shown to contribute to the onset of cutaneous vasodilation but is not the primary 
mediator of cutaneous vasodilation (114, 175, 176). This is notable because the nNOS 
isozyme is found at nerve terminals and is involved in the modulation of ACh release 
from cholinergic neurons (173). While not reported and not analyzed statistically, the 
present study observed what appears to be a roughly 3-5 minute delay in the skin blood 
flow rise at nNOS blocked sites relative to control sites as a function of time into heating. 
This is illustrated in Figure 4.8 which shows %CVCmax as a function of time post start 
of thermal loading in the seated position. Results for the supine position showed a similar 
delay. Therefore, it is possible that nNOS activation contributes to the initial rise in skin 
blood flow via modulation of ACh release from active vasodilator nerves. 
 
Figure 4.8.The increase in percentage of maximal cutaneous vascular conductance (%CVCmax) at 
Control (Ringers; filled circles), nNOS blockade (NPLA; open circles), eNOS blockade (L-NIO; 
closed inverted triangles), and nonspecific NOS blockade (L-NAME; open triangles) sites is shown 
over time into passive whole-body heat loading in the seated position (N=8). Data are mean ± S.E.  
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How eNOS mediates sustained cutaneous vasodilation in this paradigm is less 
clear. One possibility is that eNOS could be directly activated by temperature increases 
from blood; however, studies with isolated NOS isoforms have shown that eNOS activity 
is unaltered by physiological (5-45°C) temperatures alone (212). Another possibility is 
that temperature is mediating processes secondary to eNOS activation. For example, 
temperature-dependent ATP release from human erythrocytes has been previously 
demonstrated (103); and ATP is a modest endothelial-dependent vasodilator that is 
capable of activating eNOS (40, 209). Transient potential villanoid receptor 4 channels 
(TRPV4) found on the endothelium can also activate eNOS through a temperature-
dependent mechanism (67, 195). Because heat is convectively carried to the periphery by 
blood, it is conceivable that ATP release from erythrocytes and temperature-dependent 
TRPV4 activation may represent primary mediators of initial and sustained eNOS 
activation during heat stress. This activation may then be modulated with other stimuli 
such as the increased blood flow itself (and presumably shear stress) (138) although shear 
stress does not appear to result in NO-dependent vasodilation in the skin (226). 
Second, it is possible that use of pharmacological agents in the present study, and 
other studies conducted in humans have led to misinterpretations of the underlying 
physiological processes involved in CAVD. Studies in humans are limited to using 
pharmacological agents that can be safely administered, and more specific blockers are 
often times unsuitable for humans. For example, diphenyleneiodonium chloride is a 
potent eNOS inhibitor (half maximal inhibitory concentration (IC50) = 180 nM) when 
compared to L-NIO (IC50 = 500 nM) but has only been used in rats and is not FDA 
approved for human use due to its carcinogenic and teratogenic properties.  
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Additionally, we are not able to determine exactly which pathways are being 
affected by our interventions. Most NOS antagonists effect all the NOS isozymes to a 
varying degree and their relative specificity can be heavily dose specific. Because these 
drugs are being administered intradermally via microdialysis, it is not possible to determine 
the exact concentration of drug once it reaches the interstitium. This is further cofounded 
by the over generalization of drug specificity claims by drug manufacturers. Some vendors 
advertise L-NIO as an eNOS specific antagonist while others advertise it as a nonspecific 
NOS antagonist. This is best illustrated by the manufacturer SigmaAldrich, which changed 
their L-NIO description from eNOS specific to NOS nonspecific midway through the 
present study, then changed the description back to eNOS specific during the writing of 
this dissertation. SigmaAldrich currently advertises L-NIO as 5 times more potent as an 
inhibitor of eNOS than L-NAME despite them both having an IC50 = 500nM. In an attempt 
to circumnavigate these issues during pilot work, we used L-NIO and NPLA purchased 
from SigmaAldrich, Cayman Chemical, and TOCRIS; however, we observed no 
differences in the skin blood flow responses by drug vendor.  
It should be noted the present study utilized the same drugs and concentrations as 
used by McNamara et al. (148) and found the eNOS isozyme is the primary mediator of 
the NO component of CAVD during passive whole-body heating, which is in agreement 
with what they found during exercise but is in conflict with what they found during 
passive whole-body heating.  
Conclusion, Perspectives, and Bridge 
In this study, we found that eNOS rather than nNOS, is the primary NOS isoform 
responsible for the NO component of CAVD during passive whole-body thermal loading, 
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regardless of posture. This finding is in contrast to previous data demonstrating nNOS the 
primary mediator of the NO component of CAVD during passive whole body heat stress. 
While still unclear, we believe that nNOS may modulate the initial rise in skin blood flow 
and eNOS may be the primary contributor to sustained NO-mediated vasodilation during 
passive whole body heat stress. We submit that the differences in the present study may 
be due to pharmacological interactions unknown to the researcher. What is clear 
however, is the need to open a fieldwide dialogue about the use of pharmacological 
agents in the determination of mechanistic pathways in vivo, their interpretation, and the 
re-evaluation of what we know about the CAVD system.   
While we sought to determine if posture could explain mechanistic differences in 
the NO component of CAVD between exercise and passive whole body heating in the 
present study, our understanding of the CAVD system during exercise and passive 
heating is murky at best. In the next chapter, we sought to confirm the cholinergic co-
transmitter theory of CAVD during whole body passive heating and determine if exercise 
alters cholinergic co-transmission behavior or results in the recruitment of different 
nerves entirely. 
 
 
 
 
 
 
 
 92 
CHAPTER V 
THERMAL LOADING MODALITIES AND CUTANEOUS 
ACTIVE VASODILATOR NERVE ACTIVATION 
 
Introduction 
The cutaneous vasculature plays a key role in thermal balance. Skin blood flow 
(SkBF) modulates convective heat transfer between the body core and the skin surface. 
At rest, the skin receives approximately 5-10% of cardiac output; yet when maximally 
dilated, such as during whole body heating, the skin is estimated to receive up to 
approximately 6-8 L/min, accounting for 50-70% of cardiac output (98, 154, 178, 179, 
181). Cutaneous vasomotor adjustments in non-glabrous skin are modulated by 
noradrenergic and cholinergic sympathetic nerves. These nerves innervate arterioles that 
feed papillary loops in the cutaneous superficial plexus and are critical to heat dissipation 
or retention; papillary loops provide a large surface area and also demarcate the thermal 
interface between the human body and the environment (15).   
During hyperthermic challenge, the initial rise in internal temperature causes an 
increase in skin blood flow that is mediated by noradrenergic vasoconstrictor withdrawal 
(46, 175). As internal temperature continues to rise, further increases in skin blood flow 
are mediated by the engagement of the cholinergic vasodilator nerves. This is known as 
cutaneous active vasodilation (CAVD). CAVD has been the focus of much research and 
is responsible for approximately 80-95% of the rise in skin blood flow that accompanies 
heat stress (98, 180). 
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Previous work by Roddie et al. was the first to show that cutaneous vasodilation 
in response to heat stress contains a cholinergic component (175, 176). Infusion of intra-
arterial atropine, a muscarinic antagonist, abolished sweating but only delayed the onset 
of cutaneous vasodilation and/or attenuated the magnitude of dilation, depending on the 
timing of atropine administration. These authors concluded that sudomotor activity is 
almost entirely mediated by cholinergic mechanisms whereas acetylcholine (ACh) 
contributes but is not the primary mediator of CAVD.   
A seminal study by Kellogg et al. expanded the findings of Roddie et al. and 
established the co-transmitter theory of CAVD (114). In this study, intradermal injection 
of botulinum toxin A (BOTOX®, which blocks presynaptic cholinergic neurotransmitter 
release) as well as administration of atropine via iontophoresis during passive whole-
body heat loading in six individuals led to two key findings. First, atropine administration 
abolished sweating and delayed the onset of cutaneous vasodilation but did not attenuate 
it. This confirmed the contribution of ACh to sweating and a minor contribution to 
cutaneous vasodilation. Second, BOTOX® abolished both sweating and cutaneous active 
vasodilation during whole body heat stress, but not vasodilation to directly applied heat. 
This suggested the release of an unknown neurotransmitter(s) from the cholinergic nerve 
terminals is the primary mediator of CAVD.  
Immunohistochemical detection studies have identified vasoactive intestinal 
peptide (VIP) (7, 183, 217, 220) and calcitonin gene related peptide in active vasodilator 
nerves (71, 187, 210); and Substance P (183, 224) and histamine (227) have been found 
in dermal sensory nerves, endothelial cells, and/or mast cells (70, 87, 152). The 
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localization of these substances in the dermis make them likely co-transmitter(s) 
however, definitive proof of co-transmission during hyperthermic challenge is lacking.  
Identification of the unknown neurotransmitters is further confounded by the 
observation that different thermal loading modalities result in different mechanisms of 
NO mediated cutaneous vasodilation. Specifically, blockade of endothelial nitric oxide 
synthase (eNOS) was found to block the NO component of CAVD during exercise heat 
loading whereas neuronal nitric oxide synthase (nNOS) blockade was found to block the 
NO component of CAVD during passive whole-body heat loading (117, 148). These 
findings demonstrate variable roles for eNOS and nNOS that are dependent on the 
thermal loading modality employed. It was suggested that these differences could be due 
to differential active vasodilator nerve firing rates (secondary to different afferent input) 
resulting in the release of vasoactive substances unique to the mode of thermal loading. 
These findings highlight the possibility that CAVD nerve transduction may vary 
depending on the source of the heat stress (exercise heat loading vs. passive whole-body 
heat loading). This is problematic because it had previously been assumed that the 
mechanisms and transducers of CAVD were the same regardless of how thermal loading 
was accomplished. It is possible that differences in thermal loading modalities and the 
accompanying inputs that modulate active vasodilator outflow (e.g. motor commands, 
skin temperature, metaboreflexes etc.), may alter cholinergic co-transmission behavior 
(142) or result in the recruitment of different nerves entirely.  
There has been no further research on vasodilator nerve activation in 
approximately the last 10 years and the current model of the cholinergic co-transmission 
theory of CAVD is largely based on a singular study that is now 25 years old. The 
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findings by Kellogg et al. have not been independently corroborated and the current 
model of co-transmission is based on observations in six individuals (114). Second, it is 
unknown if the cholinergic co-transmitter theory of CAVD applies to other thermal 
loading modalities such as exercise heat loading. It is conceivable that exercise may alter 
cholinergic nerve transduction or achieve cutaneous vasodilation by an entirely different 
mechanism. Therefore, this study sought to confirm the cholinergic co-transmitter theory 
of CAVD during passive whole-body heat loading and expand these findings to exercise 
heat loading using a cross-over study design. It was hypothesized that the same 
cholinergic nerves are responsible for CAVD during exercise and passive whole-body 
heat loading. 
 Secondarily, this study sought to identify the vasoactive substances co-
transmitted with ACh from active vasodilator nerves in the skin using shotgun 
proteomics. By taking an agnostic approach to determine potential neurotransmitter(s) 
involved in CAVD, we hoped to not only identify the unknown co-transmitter(s) but to 
also determine if different thermal loading modalities could result in the variable co-
transmission of these substances. 
 
Methods 
 All protocols in human subjects were approved by the Institutional Review Board 
at the University of Oregon (IRB #12102010.027, see Appendix page (128) for informed 
consent documents). All subjects gave oral and written consent prior to participation in 
accordance with the Declaration of Helsinki. 
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Subjects 
Eight young (18-30 years) recreationally-active (<150 minutes of intense exercise 
a week) individuals volunteered to participate in this study. All subjects were non-
smokers with no history of cardiovascular, metabolic, or other chronic diseases, not 
taking prescription medications with the exception of hormonal contraceptives, not 
currently pregnant or breast-feeding, and had no history of allergic reactions to any drugs 
used in this study. A summary of physical characteristics is listed in Table 5.1. 
Aerobic Fitness Testing  
Upon enrollment in the study and prior to thermal loading study days, each 
subject reported to the Evonuk Environmental Physiology Core in Esslinger Hall on the 
University of Oregon campus to complete a VO2peak test. VO2peak was assessed using a 
graded cycling protocol on a stationary bicycle ergometer (Excalibur Sport, Lode, 
Groningen, Netherlands). The graded cycling protocol involved a 5-minute warm-up at 
100 watts followed by 20 or 25 watt (Female and Male increases, respectively) increases 
in work load every minute until volitional fatigue. Subjects were attached to a breath-by-
breath metabolic measurement system (Parvomedics, Sandy, UT) to measure oxygen 
uptake. Heart rate was monitored via telemetry (Model RS400, Polar Electro, Lake 
Success, NY) and ratings of perceived exertion were noted at every work stage. VO2peak 
was then validated by having subjects cycle at a supramaximal workload (115% VO2peak) 
to ensure their VO2 did not rise above their previously determined plateau.   
Cholinergic Nerve Blockade  
Cholinergic nerve blockade was achieved through intradermal botulinum toxin 
type A (BOTOX®) administration.  After VO2peak testing and prior to thermal loading 
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study days, subjects received three intradermal injections of approximately 5 units of 
BOTOX® into the volar forearm (approximately 2 mm from the surface), with injection 
sites no farther than approximately 1.5 cm away from each other.  The “ring of effect” 
was identified by the primary investigator and drawn onto the skin surface using a 
permanent marker and photographs were taken to aid in re-identification of BOTOX® 
treated sites on thermal loading study days. Subjects were instructed to re-mark the “ring 
of effect” each day after showering or bathing and waited a period of at least 1 week after 
BOTOX® administration before participating in thermal loading study days.   
General Study Design and Setup  
Each subject participated in both an exercise heat loading study day and a passive 
whole-body heat loading study day. Thermal loading study sequences were randomized 
and a period of at least 1 week separated the two thermal loading studies. All female 
subjects had a negative pregnancy test on the morning of each study day. Women were 
studied during the low hormone phase of their menstrual cycle. Women taking hormonal 
contraceptives (N=4) were studied during the placebo phase and those naturally 
menstruating (N=1) were studied during the early follicular phase of menstruation (self-
reported). In order to study females under consistent hormone levels, females returned 
one full cycle later (i.e. 3-4 weeks apart) for their second study day. 
Prior to thermal loading study days, subjects abstained from food for 4 hours, 
alcohol and caffeine for 12 hours, and exercise and over-the-counter medications for 24 
hours. On thermal loading study days, subjects reported to the Human Cardiovascular 
Control Laboratory in Esslinger Hall on the University of Oregon campus. Upon arrival, 
subjects provided a urine sample to confirm euhydration via urine specific gravity <1.02 
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(Analog Regractometer; Atago, Tokyo, Japan). If urine specific gravity was >1.02, 
subjects drank 5 ml/kg of water prior to study. Dry nude body weight was measured 
before and after thermal loading to calculate mean whole body sweat rate. Subjects were 
instrumented with a sterile rectal thermistor probe (YSI Series 400; Yellow Spring 
Instruments, Yellow Springs, OH) inserted approximately 10 cm past the anal sphincter 
to monitor internal temperature (Tc).   
Skin surface thermistors (MSR145WD, MSR Electronics GmBH, Seuzach, 
Switzerland) were applied to standard locations on the chest, forearm, calf, and quadricep 
to continuously measure skin temperatures. Mean skin temperature (Tsk) was calculated 
using the 4-site weighting method previously developed by Ramanathan (172):  
Tsk = 0.3(tchest + tarm) + 0.2(tthigh + tcalf)       (1) 
Where  
tchest = skin temperature measured at the chest,  
tarm = skin temperature measured at the forearm,  
tthigh = skin temperature measured at the quadricep, and  
tcalf = skin temperature measured at the calf. 
 
Mean body temperature (Tb) was calculated using the internal temperature and mean skin 
temperature weighting method described by Gagge and Gonzalez (57): 
Tb = 0.8(Tc) + 0.2(Tsk)       (2) 
 
Heart rate and ventilatory frequency were monitored using a 3-lead 
electrocardiogram (CardioCap; Datex Ohmeda, Louisville, CO). Baseline blood pressure 
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was measured in triplicate following 20 minutes of rest and every 5-10 minutes 
throughout the thermal loading via brachial oscillation (Datascope Accutorr Plus, Duluth, 
GA) or auscultation as described below.   
Exercise Heat Loading   
Exercise heat loading was accomplished by having subjects exercise in the seated 
position on a stationary bicycle ergometer (Excalibur Sport, Lode) at a constant workload 
that corresponded to 60% of their VO2peak for 60 minutes. This relative workload was 
based on McNamara et al. (148).  During the first approximate 10 minutes of the 60-
minute exercise interval, subjects were attached to a breath-by-breath metabolic 
measurement system (Parvomedics, Sandy, UT) to ensure they were exercising at 60% if 
their VO2peak. Pulmonary gas exchange was then “spot” checked approximately every 20 
minutes for the duration of exercise. During exercise heat loading study days, blood 
pressure in the brachial artery was measured using the auscultatory method (mercury 
sphygmomanometer and stethoscope) due to inaccuracy of oscillometry during physical 
activity (164).  
Passive Whole-body Heat Loading 
Passive whole-body heat loading was accomplished by having subjects wear a 
two-piece nylon water-perfused suit (Med-Eng Systems, Ottawa, Canada) which covered 
all skin surfaces except the experimental arm, face, hands, and feet. In addition, subjects 
wore a water-impermeable plastic garment over the suit to mitigate evaporative heat loss. 
During thermal loading, mean skin temperature was maintained at approximately 39°C 
for 60 minutes using a heated circulating water bath (HT CIRC 7L AD, Polyscience, 
Niles, Illinois) to perfuse hot water (50°C) through the suit. This water temperature was 
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based on previous work from our lab which demonstrated an increase in internal 
temperature of 0.7-1.0 °C above baseline in approximately 60 minutes (22, 218, 224). 
During passive whole-body heat loading studies, blood pressure in the brachial artery was 
measured using the osillometric method. 
Dialysate Recovery   
During thermal loading study days, intradermal microdialysis was used to sample 
the interstitial space at baseline and throughout thermal loading. Placement of 
microdialysis fibers in the volar dermis of the forearm was performed using aseptic 
technique. Two linear microdialysis fibers (CMA 31 linear microdialysis, 10 mm 
membrane, 55Kda or 2000Kda CO; Harvard Bioscience, Holliston, MA) were placed in 
parallel at the BOTOX® treated site and two more fibers were similarly placed at an 
untreated site. Fibers were placed by first introducing a 25-gauge or 23-gauge needle 
approximately 1 mm below the surface of the skin, with entry and exit points 2-3 cm 
apart. Fibers were threaded through the lumen of the needle and the needle was removed 
leaving the dialysis membrane of the fiber centered between the needle entry and exit 
points. A period of 90 minutes was allowed to let needle insertion trauma and the 
resulting transient rise in skin blood flow resolve. This was confirmed by observing a 
plateau in laser-Doppler (described below) flux values. Fibers were continuously 
perfused with Lactated Ringer’s solution at a rate of 2.0 ul/min (CMA 102 Syringe 
Pump; CMA Microdialysis AB, Solna, Sweden). A peristaltic pump (Reglo ICC Digital 
Peristaltic Pump, IMSATEC, Wertheim, Germany) was attached to the distal “receiving” 
end of the fibers to reduce the build-up of back pressure and prevent ultrafiltration and 
improve analyte recovery efficiency (Chapter III, Figure 3.9). Baseline dialysate from 
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the BOTOX® treated and untreated site was collected in 0.5 ml sterile cryotubes for a 
period of approximately 30 minutes. Dialysate at BOTOX® treated and untreated sites 
was then collected for the entire duration (approximately 60 minutes) of thermal loading. 
All samples were immediately frozen at -80 °C for future analysis.   
Skin Blood Flow   
Skin blood flow at the BOTOX® treated and untreated sites was quantified using 
laser-Doppler flowmetry. Local heating units (SH02 Skin Heater/Temperature Monitor; 
Moor Instruments, Axminster, UK) were placed on the skin surface directly above the 
previously placed microdialysis fibers and integrated blunt needle laser-Doppler probes 
(MP12-V2, Moor Instruments) were seated in the local heating units. Laser-Doppler flux 
was continuously recorded at baseline and throughout the study. After either exercise 
heat loading or passive whole-body heat loading, the BOTOX® treated and untreated 
sites were locally heated to 39°C at a rate of 0.1°C/sec. Local heating results in a biphasic 
vasodilator response consisting of an initial peak and secondary plateau that is 
independent of cholinergic/noradrenergic nerve activation. This was done to confirm the 
preservation of each site’s local vasodilator response. Maximal laser-Doppler flux at each 
site was then obtained by locally heating the skin to 44°C as well as infusing 56mM 
sodium nitroprusside.   
Data Analysis  
Skin red blood cell flux (RBCflux) data were digitized and recorded to a 
computer using data acquisition software (Windaq; Dataq Instruments, Akron, OH). The 
RBCflux measurements within each site during the 2-minute baseline period were 
averaged. Starting at the beginning of thermal loading, RBCflux measurements were 
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averaged over each sequential one-minute interval during the approximate 60-minute 
thermal loading period. The RBCflux average values were converted to cutaneous 
vascular conductance (CVC) and expressed as a percent of maximum CVC (%CVCmax). 
%CVCmax was derived as follows:    
CVC = RBCflux / MAP 
%CVCmax = [CVC / CVCmax] x 100 , 
where MAP is mean arterial pressure and was calculated as MAP = !
"
(systolic blood 
pressure) + #
"
(diastolic blood pressure). 
Skin blood flow responses at each site associated with increases in internal 
temperature were characterized using the %CVCmax minute average immediately after 
each 0.1°C increase in internal temperature. Similarly, responses at each site associated 
with 0.1 °C increases in mean body temperature were characterized using the %CVCmax 
minute average immediately after the 0.1 °C increase in mean body temperature.   
Statistics 
Statistical analyses of hemodynamic and temperature data were conducted using 
SigmaPlot 11.0 (Systat Software, San Jose, CA). Because there were no discernable 
differences between men and women, data from the two groups were combined for 
analysis. Hemodynamic and temperature data before and at the end of thermal loading 
were compared using a 2-way repeated measures analysis of variance (Intervention vs. 
Time).  
Statistical analyses of skin blood flow data were conducted using SAS 9.4 (SAS, 
Cary, NC).  %CVCmax as a function of temperature increase during exercise heat 
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loading and passive whole-body heat loading were compared using a correlated errors 
model at the maximum observed temperature increase common to both heat modalities. 
The analysis included treatment sequence, thermal loading modality (passive heating, 
exercise), study period (1, 2), site on the forearm (BOTOX®, Control), and heat 
modality-by-site interaction as fixed effects. Within-subject correlation between forearm 
sites was modeled using an unstructured covariance matrix. 
Within each heat modality, %CVCmax (observed values and change from 
baseline) as a function of internal temperature increase was analyzed using a longitudinal 
repeated measures model. The experimental unit for this analysis was subject, and there 
were two within-subject effects for each subject: site and internal temperature increase. 
The model included site on the forearm (BOTOX® vs. Control), temperature increase 
(increments of 0.1 °C), and site-by-temperature increase interaction as fixed effects. 
Temperature-increase correlations for the two sites were modeled using a first-order 
autoregressive covariance structure [AR(1)].   
To determine the smallest internal temperature increase at which a difference 
between BOTOX® and Control sites was demonstrated for each heat modality, a 
sequential testing procedure that started at the maximum observed temperature increase 
(i.e., 0.7 °C for internal temperature increase) and compared BOTOX® to Control at 
incrementally smaller temperature increases was conducted. Sequential testing proceeded 
until a failure to reject the null hypothesis of no difference between the BOTOX® and 
Control sites occurred at the 2-sided 5% level of significance. No significant differences 
were claimed after the first failure to reject the null hypothesis occurred.  
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A similar sequential testing procedure was followed to determine the smallest 
internal temperature increase at which a %CVCmax change from baseline was 
demonstrated at the BOTOX® and Control sites for each heat modality. The sequential 
testing procedure within each site within heat modality compared the %CVCmax results 
starting at 0.7 °C and compared %CVCmax to baseline (two-sided paired t-test)  at 
incrementally smaller temperature increases.   
Dialysate Analysis  
The Proteomic Shared Resource Facility at Oregon Health Sciences University 
was retained to run a shotgun proteomics analysis on dialysate samples. Due to the 
COVID-19 pandemic (2020), analysis of the samples sent to the proteomics core 
laboratory has been delayed. However, the proteomics core laboratory provided a 
description of the workflow they are using to analyze the samples obtained. The 
workflow is as follows. The skin dialysate samples are ultra-filtrated using 10 kDa cutoff 
Amicon Ultra 0.5 ml ultrafiltration spin cartridges (Cat #UFC501024, Millipore-Sigma) 
to remove higher molecular weight proteins. Since the amount of recovered protein is 
below the limit of accurate detection by a Pierce BCA protein assay (< 0.1 µg/µl), the 
filtrate is divided into two equal portions, dried by vacuum centrifugation and the entirety 
of each sample subsequently analyzed. One portion is analyzed by mass spectrometry 
without digestion, and the other portion is reduced using DTT, alkylated with 
iodoacetamide, and digested overnight with trypsin (0.9 µg per sample) in the presence of 
ProteaseMax™ detergent, as recommended by the manufacturer (ProMega Corporation). 
Following trypsin digestion, samples are filtered (0.22 um) and again dried by vacuum 
centrifugation. 
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 Both dried trypsin digested and non-digested samples are dissolved in 22 µl of 5% 
formic acid and each analyzed by liquid chromatography-mass spectrometry (LC-MS). 
20 µl of each sample is auto-injected and peptides separated using a Dionex NCS-
3500RS UltiMate RSLCnano UPLC system, and mass spectrometric analysis is 
performed using an Orbitrap Fusion Tribrid instrument with an EasySpray nano source 
(Thermo Scientific). Peptides are desalted using an Acclaim PepMap 100 μm x 2 cm 
NanoViper C18, 5 μm trap column on a switching valve. After 5 min of loading and 
washing, the trap column is switched on-line to a PepMap RSLC C18, 2 μm, 75 μm x 25 
cm EasySpray column (Thermo Scientific). Peptides are then separated using a 7.5–30% 
acetonitrile gradient over 60 min in a mobile phase containing 0.1% formic acid at a 300 
nl/min flow rate. Survey MS scans are collected using the instrument’s Orbitrap mass 
analyzer at a resolution of 120,000. Data-dependent MS/MS spectra are collected in the 
instrument’s ion trap using higher-energy dissociation (HCD) following quadrupole 
isolation. The dynamic exclusion feature of the instrument and its top speed mode are 
used to increase the number of unique peptides that are identified.  
 RAW instrument files are processed using Proteome Discoverer version 1.4 
(Thermo Scientific), SEQUEST HT software and a UniProt human database (Swiss 
Bioinformatics Institute, Geneva, Switzerland). For trypsin digested samples, searches 
are configured with a static modification for alkylated cysteines (+57.021 Da), variable 
modifications for oxidation of methionine (+15.995 M residues), and trypsin specificity. 
Undigested samples are similarly searched, except without specifying cysteine alkylation 
and using no enzyme specification. A parent ion tolerance of 10 ppm, fragment ion 
tolerance of 1.0 Da, monoisotopic masses, and for trypsin cleaved samples, a maximum 
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of 2 missed cleavages is allowed. Searches use a reversed sequence decoy strategy to 
control peptide false discovery using Percolator software (48, 102). Results are filtered to 
remove peptide identifications with q-scores > 0.05, to maintain false discovery rates 
below 5%. Differences in protein abundances across samples are estimated by 
comparison of numbers of assigned MS/MS spectra to each protein (135). 
 
Results 
Subject Demographics and Oxygen Uptake 
 Subject demographics and exercise data are presented as means ± S.E. in Table 
5.1.  Five women and three men participated in this study. Subjects were 22 ± 1 years 
old, with a mean height and weight of 173 ± 4 cm and 66 ± 2 kg, respectively. Subjects’ 
average relative oxygen uptake was 43.11 ± 4.13 ml-1kg-1min and peak power achieved 
during the VO2peak test averaged 246 ± 27 W. Subjects’ power during exercise heat 
loading averaged 140 ± 24 W. 
 
Table 5.1. Demographics of subjects who completed Protocol 2. Data are mean ± S.E. 
 Protocol 2 (N=8) 
# of women 5 
Age (years) 22 ± 1 
Height (cm) 173 ± 4 
Weight (kg) 66 ± 2 
BMI (kg/m2) 22.7 ± 0.6 
VO2Peak (ml/kg/min) 43.11 ± 4.13 
VO2Peak peak power (W) 246 ± 27 
Power during exercise (W) 140 ± 24 
cm, centimeters; kg, kilograms; BMI, body mass index; 
S.E., standard error VO2Peak, maximal oxygen 
consumption; W, watts. 
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Hemodynamics and Thermal Loading 
 Mean hemodynamic results for both thermal loading modalities are presented in 
Table 5.2. Baseline heart rate, systolic blood pressure, diastolic blood pressure, mean 
arterial pressure, and pulse pressure were similar between thermal loading modalities. 
Baseline internal temperature was also not different between thermal loading modalities 
(Figure 5.1).  However, baseline mean body temperature (Tb) was significantly higher for 
passive whole-body heat loading than for exercise heat loading (P = 0.004; 36.2 ± 0.1 vs. 
35.6 ± 0.1 C°, respectively). By the end of both thermal loading modalities, heart rate was 
elevated relative to baseline (P < 0.050) but there was a greater rise during exercise heat 
loading than during passive whole-body heating (P < 0.050; 146 ± 4 vs. 100 ± 6 beats 
min-1, respectively). Pulse pressure was elevated relative to baseline (P < 0.050) at the 
end of both thermal loading modalities but was also greater at the end of exercise than the 
end of passive whole-body heating (P < 0.050; 99 ± 5 vs. 63 ± 3 mmHg, respectively). 
Mean body temperature increased relative to baseline (P < 0.050) during both thermal 
loading modalities but increased to a greater extent during passive whole-body heating 
than during exercise (P < 0.05; 38.0 ± 0.1 vs. 36.4 ± 0.2 C°, respectively). Internal 
temperature increased more rapidly during exercise but was not significantly different (P 
= 0.167) from passive whole-body heating by the end of thermal loading (Figure 5.1; 
37.8 ± 0.1 vs. 38.0 ± 0.1, respectively). 
 
 
 
 108 
Table 5.2. Mean hemodynamic and mean body temperature at baseline and end of the 
thermal loading periods (N=8). Data are mean ± S.E. 
 HR (beats 
min-1) 
SBP 
(mmHg) 
DBP 
(mmHg) 
MAP 
(mmHg) 
PP 
(mmHg) 
Tb (C°) 
Exercise       
Baseline 62 ± 3 115 ± 3 63 ± 4 80 ± 2 52 ± 4 35.6 ± 0.1# 
Thermal 
loading 
146 ± 4*# 153 ± 3*# 53 ± 3*# 86 ± 2* 99 ± 5*# 36.4 ± 
0.2*# 
Passive       
Baseline 59 ± 2 117 ± 2 66 ± 2 79 ± 4 51 ± 1 36.1 ± 0.1 
Thermal 
loading 
100 ± 6* 132 ± 3* 62 ± 2 89 ± 2* 63 ± 3* 38.0 ± 0.1* 
HR, heart rate; SBP, systolic blood pressure; DBP, diastolic blood pressure; MAP, mean arterial 
pressure; PP, pulse pressure; Tb, mean body temperature; S.E., standard error. *P < 0.050 vs. 
baseline.  #P < 0.050 vs. passive whole-body heat loading at the same time point.  
 
 
Figure 5.1. Internal temperature during 60 minutes of exercise (open circles; N=8) and passive 
whole-body heating (closed triangles; N=8). Data are mean ± S.E. *P < 0.050 vs. baseline (time 0).  
#P < 0.050 vs. passive whole-body heating at the same time point. 
 
Skin Blood Flow 
 %CVCmax increase as a function of increasing internal temperature from baseline 
to the end of both thermal loading modalities in 0.1 °C increments is presented below in 
Figure 5.2.  There were no differences in %CVCmax between sites at baseline (Exercise; 
BOTOX®: 6 ± 1 vs. Control: 6 ± 1 %CVCmax, Passive whole-body heating; BOTOX®: 
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11 ± 3 vs. Control: 9 ± 2 %CVCmax). %CVCmax was significantly (P<0.001) elevated 
at Control sites by an internal temperature increase of 0.1 °C for exercise heating and by 
0.2 °C for passive whole body heating when compared to baseline (Exercise: 14 ± 1 at 
0.1 °C, Passive whole-body heating: 21 ± 6 %CVCmax at °C) and continued to increase 
throughout thermal loading.    
In contrast, %CVCmax remained relatively constant at BOTOX® treated sites 
throughout both thermal loading modalities. During exercise, %CVCmax at the 
BOTOX® site was significantly greater than baseline by a 0.1 C° increase in internal 
temperature (P < 0.050) but remained relatively constant thereafter. During passive 
whole-body heating, %CVCmax at the BOTOX® site showed no increase relative to 
baseline at any time point (P > 0.050). 
Differences in %CVCmax at the Control sites and their adjacent BOTOX® sites 
occurred beginning at a 0.4 °C increase in internal temperature during both exercise (P < 
0.050 0.032; 21 ± 5 vs. 13 ± 4 %, respectively) and passive whole-body heating (P < 
0.050; 33 ± 5 vs. 15 ± 3, respectively).  
Detection of a difference between BOTOX® and Control for passive whole-body 
heating most likely delayed until the 0.4 °C increase in internal temperature due primarily 
to one subject.  Subject 21 appeared to have an attenuated but not blocked skin blood 
flow response to passive whole body heating at the BOTOX® treated site during the 
second study day. This may have been due to inconsistent remarking of the “ring” of 
effect by the subject, which may have resulted in skin blood flow being assessed at the 
boundary of the “ring” of effect rather than in the middle of the BOTOX® treated skin. 
When Subject 21 was removed from the passive whole body heating %CVCmax 
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analysis, differences between the BOTOX® and Control sites were detected beginning at 
a 0.2 °C internal temperature increase (P<0.050).   
Cholinergic nerve blockade attenuated the skin blood flow response to a 0.7 °C 
increase in internal temperature for both thermal loading modalities (Figure 5.3). At the 
end of thermal loading, there were no differences between thermal loading modalities 
(modality, P = 0.909; modality-by-microdialysis site interaction, P=0.230).  %CVCmax 
at the BOTOX® treated sites (Exercise: 19 ± 2 and Passive whole-body heating: 15 ± 5 
%CVCmax), was significantly less (P<0.001) than at the control sites (Exercise: 35 ± 4 
and Passive whole-body heating: 38 ± 2 %CVCmax).   
 
Figure 5.2. The percentage of maximal cutaneous vascular conductance (%CVCmax) at 
BOTOX® treated (dotted lines) and untreated (solid lines) is shown for each 0.1 °C 
increase in core temperature from rest during exercise (open circles; N=8) and passive 
whole-body (closed triangles; N=8)) heat loading.  Data are mean ± S.E. *P < 0.05 vs. 
baseline for both Exercise and Passive Control sites and for the Exercise BOTOX site. 
The Passive BOTOX site was not significantly different from baseline at any time point. 
#P < 0.05 for BOTOX® vs. Control within heat modality. 
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Figure 5.3. Percentage of maximal cutaneous vascular conductance (%CVCmax) at BOTOX® 
treated (black bars) and untreated (gray bars) sites in response to a 0.7 °C increase in internal 
temperature during exercise (N=8) and passive whole-body heat loading (N=8). Dotted white lines 
represent mean site baselines. Data are mean ± S.E. There were no differences by thermal loading 
modality. *P < 0.05 vs. control site in the same thermal loading modality.  
 
Dialysate Proteomics 
 Prior to the Proteomic Shared Resource Facility at Oregon Health Sciences 
University, samples from one pilot subject who underwent whole-body heating (dialsate 
sampled in untreated dermis) and one pilot subject who underwent whole-body heating 
with BOTOX® treatment (dialysate sampled at BOTOX® treated and untreated sites) 
were analyzed. Within non-trypsin digested samples, 146 protein groups were identified. 
This included syntaxin-4, keratin type I and II, and dermicidin. Trypsin digested samples 
identified even more protein groups. These included calcium-dependent secretion 
activator 1, calmodulin 1, muscarinic acetylcholine receptor M2 and M3, nitric oxide 
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synthase, SNARE-associated protein snapin, synaptic vesicle membrane protein VAT-1, 
syntaxin-binding protein 3, and vesicle transport protein SFT21. A table of the peptide 
spectral matches (psm), which is the total number of identified peptide spectra matched 
for a given protein, by subject condition and sample are provided in Table 5.3. While 
identified, these substances were not present in any discernable way that would suggest 
cholinergic nerve activation or blockade. We are hopeful that continued analysis of 
samples will provide more clarity and allow us to conduct a more in depth analysis of the 
proteomics data. 
Table 5.3. Peptide spectrum numbers for proteins found in dialysate in two pilot subjects 
at baseline (BL) and whole-body heat loading (WBH). Subject 15 had dialysate collected 
at an untreated site only. Subject 16 had dialysate collected at both botulinum toxin type 
A treated (BOTOX®) and untreated (Control) sites. 
Protein s015 s016 
 BL WBH Control 
BL 
Control 
WBH 
BOTOX® 
BL 
BOTOX® 
WBH 
Keratin type I 31 1 2 7 4 5 
Keratin type II 14 - 1 4 3 4 
Dermicidin 8 - 3 13 - 4 
Syntaxin-4 - - 1 - - - 
Syntaxin-binding protein - 1 - - - - 
SNARE-associated protein snapin - - - 1 - - 
Synaptic vesicle membrane protein 
VAT-1 
- - 1 - - - 
Muscarinic ACh receptor M2 - - 1 - - - 
Muscarinic ACh receptor M3 - - 1 - - - 
Nitric oxide synthase - 1 - - - - 
Calmodulin 1 - - 1 - 2 - 
 
Discussion 
This is the first study to investigate cutaneous active vasodilator nerve activation 
in response to different thermal loading modalities. The main findings of the present 
study are 1) CAVD in response to exercise heat loading and passive whole-body heat 
loading are both mediated by cholinergic nerve transmission and 2) differing thermal 
loading modalities did not change cholinergic nerve transduction and the resulting skin 
blood flow response. These conclusions come from the following observations: selective 
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presynaptic cholinergic nerve blockade attenuated the skin blood flow response to 
exercise heat loading and passive whole-body heat loading modalities at the maximum 
temperature increase similarly, and the internal temperature-skin blood flow relationship 
at BOTOX® treated and untreated sites was comparable between thermal loading 
modalities.    
Previous work by Roddie et al. provided the first evidence that the active 
vasodilator system may be mediated by a cholinergic mechanism (175, 176). Continued 
work by Kellogg et al. confirmed that the active vasodilator nerves were indeed 
cholinergic and established the co-transmitter theory of CAVD (114). Their study 
suggested the release of unknown neurotransmitter(s) from the cholinergic nerve 
terminals is the primary mediator of CAVD although this has never been independently 
confirmed and was done in a limited sample size (N=6). Previous convention has held 
that the mechanisms of CAVD operate in a similar manner regardless of the mode by 
which an individual is thermally loaded (98). Hence, the known mechanisms of CAVD 
have been largely characterized by passive whole-body heat loading models and 
generalized to exercise heat loading. It is unknown if the theory of cholinergic co-
transmission theory of CAVD extends to exercise heat loading. Additionally, the 
substance(s) co-transmitted with ACh is still unknown. 
Exercise and Passive Whole-body Heat Loading 
 Increased cardiac output during both exercise as well as thermal stress is well 
documented (5, 25, 93, 132, 221). Increases in cardiac output are largely in service of 
increased blood flow to active muscle and to the skin circulation, respectively. Previous 
research has determined that the observed increase in cardiac output during supine 
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passive whole-body heat loading and exercise is primarily driven by an increased heart 
rate (14, 40, Francisco publication in review). In the present study, heart rate increased to 
approximately 146 beats min-1 by the end of exercise and approximately 100 beats min-1 
by the end of passive whole-body heat loading which is within previously documented 
ranges (14, 18, 40, Francisco publication in review).  Increases in cardiac output act to 
increase systolic blood pressure and the magnitude of the heart rate increases during both 
thermal loading modalities reflect the observed increases in systolic blood pressure 
(Table 5.2). Pulse pressure increased during exercise which is similar to what others have 
shown during 1 hour of dynamic exercise (28, Francisco et al. in review). The present 
study also showed a significant increase in pulse pressure during passive whole-body heat 
loading which is contrary to what others have shown (148). Consideration of this is 
important because pulse pressure represents one of the largest hemodynamic differences 
between the two thermal loading modalities. It has been suggested as a potential 
mechanism to explain previously observed differences in CAVD during exercise and 
passive whole-body heating (27). 
 For both thermal loading modalities, internal temperature increased to similar 
levels upon completing thermal loading (Figure 5.1). However, exercise resulted in a 
quicker internal temperature rise that began to plateau while passive whole-body heat 
loading resulted in a delayed internal temperature rise followed by rapid increase. These 
differences may reflect differences in the thermal loading modalities themselves. During 
exercise heat loading, the ensuing heat from cellular metabolism (i.e., active muscle) 
generates a thermal load that increases internal temperature and initiates a 
thermoregulatory response. When passively whole-body heat loaded, skin temperature 
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begins to rise as the thermal gradient between the skin and the environment diminishes. 
This rise in skin temperature reduces the gradient for heat transfer between the core 
tissues and the environment such that internal temperature will rise. The observed Time 
vs. Internal temperature relationships in the present study (Figure 5.1), suggest that 
exercise resulted in faster thermal loading; whereas passive whole-body heat loading was 
delayed due to the slow reversal of the aforementioned thermal gradients.   
 Mean body temperature was higher at the end of passive whole-body heat loading 
than at the end of exercise heat loading (Table 5.2). This may be because subjects were 
able to engage in evaporative heat loss during exercise which reduced mean skin 
temperature (Chapter 3; Figure 3.2) and subsequently reduced mean body temperature. 
During passive whole-body heat loading, evaporative heat loss was prevented by the 
addition of a water-impermeable plastic garment. This prevented reductions in mean skin 
temperature and subsequently mean body temperature (Chapter 3; Figure 3.3). 
Cutaneous Active Vasodilator Nerve Activation During Passive Whole-Body Heat 
Loading 
It has been previously shown that cholinergic nerve blockade with BOTOX®  
locally abolished the CAVD response to passive whole-body heat loading in humans 
(114). In the study mentioned above, whole body heating for 35-45 minutes with 
concurrent skin blood flow assessment via laser-Doppler flowmetry was done in six 
individuals who had previously received a 5 unit intradermal injection of BOTOX®. Skin 
blood flow in these subjects rose to 52 ± 9% of the maximal level at untreated sites and 
17 ± 2% of the maximal level at BOTOX® treated sites by the end of passive whole-
body heating. In the present study, an hour of passive whole-body loading (an 
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approximate 0.7 C° increase in internal temperature) increased skin blood flow to 38 ± 2  
%CVCmax at untreated sites and 15 ± 5 %CVCmax at BOTOX® treated sites (Figure 
5.3).   
The similar skin blood flow responses at the BOTOX® treated sites suggest that 
we were successful in abolishing the active vasodilator response. The differences in the 
absolute skin blood flow values at the untreated sites between these two studies could be 
due to differences in posture or in the magnitude of thermal loading achieved. The 
aforementioned work by Kellogg et al. reported neither (114); although, similar studies 
from Kellogg et al. suggest that subjects were likely supine while passively heated (116, 
117). Conversely, passive whole-body heat loading in the present study was done in the 
seated position. It is well known that orthostasis causes a rightward shift in the Tc-skin 
blood flow relationship (Chapter II, Figure 2.8) via active vasodilator withdrawal. 
Therefore, differences in posture during heat loading may explain these dissimilar 
findings. It is also possible that subjects in the present study had a smaller rise in internal 
temperature. This would result in a smaller skin blood flow response and also explain the 
differences in the absolute skin blood flow responses at the untreated sites. 
The finding that cholinergic nerve blockade abolished CAVD during passive 
whole-body heat loading in the present study is not novel. However, our understanding of 
the cholinergic active vasodilator nerves involved in thermoregulation was largely based 
on a limited sample size (N=6) and had never been confirmed. Our data corroborate the 
conclusions of Kellogg et al. that CAVD is mediated by cholinergic nerve activation 
(114). 
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Cutaneous Active Vasodilator Nerve Activation During Exercise Heat Loading 
It had previously been assumed that the mechanisms and transducers of CAVD 
were the same regardless of how thermal loading is accomplished. More recent research 
has suggested that this assumption is incorrect and active vasodilator nerve transduction 
and/or the mechanisms of cutaneous vasodilation may vary depending on the source of 
the heat stress (e.g. exercise vs. passive whole-body heat loading) (148). In the present 
study, cholinergic nerve blockade attenuated the skin blood flow response to exercise 
heat loading to a similar extent as during passive whole-body heat loading (Figure 5.3).  
When the differences in the thermal loading modalities and their previously 
proposed impact on CAVD are considered, this is striking for two reasons. First, it had 
been suggested that cyclic circumferential cutaneous vascular wall strain (due to pulse 
pressure) which is likely higher during exercise than passive heating, may result in a 
different local milieu that could affect active vasodilator nerve function at the synaptic 
cleft. Second, it had also been suggested that differences in afferent input to the 
hypothalamic regions regulating efferent active vasodilator nerve activity (e.g. skin 
temperature, blood pressure, etc) could alter vasodilator nerve activity (148). We found 
that differences in pulse pressure and mean body temperature between the two thermal 
loading modalities (Table 5.2) did not change vascular transduction of active vasodilator 
nerve activity (assessed by the Tc-skin blood flow relationships in Figure 5.2).  
There does appear to be a rightward shift (non-significant) in the Tc-skin blood 
flow relationship (Figure 5.2) during exercise which is expected, as exercise is known to 
cause a rightward shift in the internal temperature equilibrium point (Fig 2.8) for active 
vasodilation (97, 110, 125, 204). Despite the shift, the gain and magnitude of the skin 
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blood flow responses at BOTOX® treated and untreated sites for both thermal loading 
modalities was similar. Our data offer conclusive evidence that the same cholinergic 
nerves are responsible for CAVD during exercise heat loading as during passive whole-
body heat loading; and that different modes of thermal loading, does not change 
cholinergic nerve transmission behavior. 
Co-transmitter(s) 
 The current study sought to identify unknown vasoactive substances associated 
with CAVD. Putative cholinergic nerve co-transmitters include substance P (224), 
vasoactive intestinal peptide (VIP) (7, 183, 217, 220), calcitonin gene related 
peptide (183), and histamine (227).  
Analysis of dialysate samples has been delayed due to unprecedented 
circumstances (COVID-19 pandemic of 2020). Results from two subjects have yielded 
nothing definitive. We have identified the syntaxin protein family and the SNARE-
associated protein snapin which are both associated with contact formation between the 
synaptic vesicle and the plasma membrane at the terminal end of the neuron (19). 
Similarly, synaptic vesicle membrane protein VAT-1 is associated with cholinergic 
synaptic vesicles and is thought to be involved in vesicular transport and exocytosis. 
Detection of proteins associated with neurotransmitter release is a positive sign that we 
are able to recover substances from the synaptic cleft. We have identified receptors and 
enzymes associated with CAVD such as muscarinic receptors and eNOS but no 
substances that activate these receptors or enzymes. Interestingly, we detected dermicidin 
which is an anti-microbial peptide secreted by human sweat glands (186).We are 
successfully detecting the receptors and enzymes associated with CAVD and substances 
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secreted from sweat glands yet the substances being released from the active vasodilator 
nerves remain elusive.  
Continued analysis will shed more light on these issues yet more work and new 
methods must be employed to determine the unknown neurotransmitter(s) associated with 
cholinergic active vasodilator nerves. For instance, artificial stimulation of these nerves 
independent of thermal loading may result in larger concentrations of analyte release and 
provide a more stable environment for dialysate recovery studies. 
It has been shown that altering Ca2+, Na+, and K+ concentrations in the perfusate 
can result in quantification of stimulated rather than basal neurotransmitter release (215). 
Of these electrolytes, changing the concentration of K+ in the perfusate has been used to 
induce artificial neurotransmitter release in the brain (208). Perhaps a similar technique in 
conjunction with dialysate recovery at BOTOX® treated and untreated sites in the skin 
could be a new approach to addressing an old question. What is being co-transmitted with 
ACh from these active vasodilator nerves? 
 
Conclusions and Perspectives 
This is the first study to confirm the cholinergic co-transmitter theory of active 
vasodilation during passive whole-body heat loading and investigate this phenomenon 
during exercise heat loading using a crossover study design. We have demonstrated that 
CAVD in response to exercise and passive whole-body heat loading are both mediated by 
cholinergic nerve transmission; and differing thermal loading modalities did not change 
the vascular transduction of active vasodilator nerve activity. Proteomics analysis of the 
collected dialysate samples is ongoing. We are hopeful that this approach will help 
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identify potential neurotransmitter(s) involved in CAVD and provide a more global 
picture of the similarities and differences of CAVD during exercise and passive whole-
body heat loading. 
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CHAPTER VI 
CONCLUSIONS 
 
It was previously assumed that the mechanisms of cutaneous active vasodilation 
(CAVD) operate in a similar manner regardless of the mode by which an individual is 
thermally loaded (98). The known mechanisms and transducers of CAVD have been 
largely characterized using supine passive whole-body heating models and applied to our 
understanding of exercise heat loading. More recent studies have highlighted the 
possibility that CAVD may be unique to the thermal loading modality used (55, 148). 
Specifically, heat introduced endogenously (exercise) versus exogenously (passive 
whole-body heating) are largely different stimuli that result in similar thermoregulatory 
reflexes. The afferent signals they share in common and those that delineate them may 
impact the mechanisms and transducers of CAVD; yet these signals and their impact on 
CAVD have been largely unexplored until now. The overall purpose of this dissertation 
was to assess cutaneous active vasodilation (CAVD) in response to varying thermal 
loading modalities and postures. To this end, two studies were conducted in young, 
healthy, recreationally active subjects.  
In Chapter IV we sought to determine the relative contribution of neuronal nitric 
oxide synthase (nNOS) and endothelial nitric oxide synthase (eNOS) isozymes to 
cutaneous vasodilation during passive whole-body heat loading in the supine and seated 
positions. We found no postural differences in the overall skin blood flow response or 
relative contribution of NO to CAVD. Interestingly, we found that the NO component of 
CAVD was eNOS rather than nNOS mediated. This is in direct conflict with others, who 
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have shown that nNOS is the primary isoform involved in CAVD during passive whole-
body heating (117, 118, 120, 148). 
 It is possible that NO generation in the cutaneous vasculature during thermal 
stress involves both nNOS and eNOS isoforms, but that nNOS contributes to the initial 
cutaneous vasodilation whereas eNOS is responsible for the overall sustained cutaneous 
vasodilation. This may explain why some studies have observed nNOS and others have 
observed eNOS contributions to the NO component of CAVD (55, 117, 118, 120, 148). It 
is also possible that these variable findings represent an often overlooked reality of 
mechanistic research, drugs are not as specific as we think and most likely have diffuse 
effects that are unknown to the investigator. How these drugs, or even individual 
“batches”of drug, change the interstitial milieu and the overall dynamics of the tissue is 
unknown. It is possible that the effects of the drugs themselves are preferentially 
selecting the NOS isozyme utilized in CAVD.  
There is new evidence emerging that suggests fiber insertion results in tissue 
trauma and a sustained proinflammatory response. For example, it has been shown that 
some inflammatory mediators remain elevated up to 4 days after fiber insertion (33). 
Newly emerging intradermal dialysate recovery studies are also demonstrating a bias 
towards proteins relevant to the injury process within dialysate approximately 3 hours 
after fiber placement (33, 60). Microdialysis fiber placement techniques often vary by 
lab. It is possible that post fiber placement wait times, the use of ice before or after fiber 
placement, and needle size used to place microdialysis fibers could affect the magnitude 
and duration of tissue trauma. It is possible that the inflammation inherent with fiber 
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placement could be affecting the NOS isozyme utilized in CAVD; and that different 
research groups are studying variably inflamed tissue. 
 With these things considered, it is clear that we are studying skin blood flow 
responses to thermal challenge in an inflamed tissue with drugs that may not be as 
selective as we think. What is less clear is how these interact with each other and 
independently of each other within the tissue. Do they change physiological function? 
Future research should aim to address these issues in depth. Despite these limitations, our 
study utilized the same drugs and concentrations as used in previous research and still 
found differences in the NOS isozymes contributing to the NO component of CAVD 
during passive whole-body heating. We are the first to show eNOS mediation during 
passive whole-body heating and this is similar to what others have shown during exercise 
(55, 148). We believe that eNOS is the primary mediator of the NO component of CAVD 
with a lesser potential role for nNOS regardless of differences in thermal loading or 
posture. We also believe a fieldwide dialogue about the use of pharmacological agents in 
the determination of mechanistic pathways in vivo and the re-evaluation of what we know 
about the CAVD system is necessary. Perhaps standardization of the intradermal 
microdialysis technique and pharmacological agents used would be a good start to a 
conflicted field.  
In Chapter V, we sought to determine the extent to which cholinergic nerve 
activation mediates CAVD during exercise heat loading and passive whole-body heat 
loading. Secondarily, we sought to identify unknown vasoactive substances associated 
with CAVD. We found that CAVD in response to exercise and passive whole-body heat 
loading are both mediated by cholinergic nerve transmission. Different thermal loading 
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modalities (exercise vs. passive whole-body heat loading) did not change the vascular 
transduction of active vasodilator nerve activity. These are perhaps the most important 
findings of this dissertation; because the cholinergic co-transmitter theory of CAVD had 
never been independently confirmed and its translation to exercise heat loading was 
unknown. We are the first to corroborate the cholinergic co-transmitter theory of CAVD 
during passive whole-body heat loading and extend it to exercise heat loading. We 
believe that cutaneous vasodilator nerves are responsible for similar skin blood flow 
responses regardless of how thermal loading is accomplished. However, we cannot 
definitively say that these nerves are similarly activated or release similar substances. 
Proteomics analysis of the collected dialysate samples is ongoing. We are hopeful that 
this approach will help identify potential neurotransmitter(s) involved in CAVD and 
provide a more global picture of the similarities and differences of CAVD during 
exercise and passive whole-body heat loading.  
It is also possible that we will be unsuccessful in the identification of 
neurotransmitter(s) released from active vasodilator nerves. This possibility is derived 
from previous research demonstrating the effects of the “trauma” layer surrounding 
microdialysis probes in brain dialysate recovery studies (141, 169). It has been shown 
that neurotransmitter release sites adjacent to probes are damaged and neurotransmitter 
release is suppressed in these regions. The aforementioned authors believe that nerve 
disruption associated with probe implantation may extend 1mm from the probe. This may 
minimally impact studies in which the probe is imbedded in purely neural tissue. This 
may have a major impact on neurotransmitter recovery in tissues where nerves are fewer 
and farther between, such as dermal tissue. When this is considered, along with the 
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duration of the inflammatory response mentioned above, it is possible that we may be 
further exacerbating a potential problem acknowledged in Chapter V. Recovered analyte 
concentration (e.g., neurotransmitter(s) associated with CAVD may not be great enough 
to detect. 
Heat introduced endogenously (exercise) verses exogenously (passive whole-
body heating) have largely different hemodynamic profiles. Despite this, different modes 
of thermal loading result in similar thermoregulatory reflexes. The afferent signals they 
share in common and those that delineate them do not appear to impact the mechanisms 
and transducers of CAVD as was originally thought. eNOS appears to regulate the NO 
component of CAVD regardless of posture; and this is similar rather than different with 
exercise. Additionally, CAVD during exercise and passive whole-body heating are both 
mediated by cholinergic nerves and to similar extents. Because of the discordant findings 
presented in this dissertation with past research, more research should be done to 
elucidate the mechanisms of NO generation in CAVD (i.e. nNOS versus eNOS. Lastly, 
future research should develop new approaches to address an old question. What is being 
co-transmitted with ACh from these active vasodilator nerves? 
Artificial stimulation of these cholinergic active vasodilator nerves independent of 
thermal loading may result in larger concentrations of analyte release and a more 
controlled environment in which to conduct dialysate recovery studies. For example, 
changing the concentration of K+ in the perfusate has been used to induce artificial 
neurotransmitter release in the brain (208). Additionally, stimulation of these nerves 
independent of thermal loading could improve analyte recovery by removing the burden 
of time. Because of subject comfort, it is not feasible to induce hyperthermia in a subject 
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for periods longer than an hour. Analyte recovery efficiency could be improved by 
reducing the perfusate flow rates. Slower flow rates would be feasible if dialysate 
recovery was not constrained to approximately 1 hour. It is also possible that the 
unknown co-transmitter(s) is a low molecular weight compound that is the by-product of 
an unknown enzymatic reaction rather than a peptide capable of being detected by 
proteomics. Pending the results of the proteomics analysis currently delayed at OHSU, 
metabolomics analysis of dialysate samples may yield much more informative findings. 
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APPENDIX 
INFORMED CONSENT DOCUMENT 
 
TITLE: “Mechanisms of Cutaneous Vasodilation in Humans” PROTOCOL #4 
INVESTIGATOR: Dr. C.T. Minson and Colleagues 
APPROVED BY INSTITUTIONAL REVIEW BOARD: August, 2019. 
(12102010.027) 
 
This is an important form. Please read it carefully. It tells you what you need to 
know about this study. If you agree to take part in this research study, you need to 
sign this form. Your signature means that you have been told about the study and 
what the risks are. Your signature on this form also means that you want to take 
part in this study. 
 
Why is this study being done? 
 
During sustained exercise and/or conditions of high environmental temperatures, the 
body temperature in humans will increase. If body temperature increases too much, we 
are not able to function properly. This may lead to heat-related illnesses (such as heat 
stroke) and even death. The primary way that humans can combat a big increase in 
core body temperature is to increase skin blood flow to the skin and to sweat. The 
increase in skin blood flow brings warm blood from our deep body core to the surface 
where the heat can be released by the evaporation of sweat. Unfortunately, we still do 
not fully understand how skin blood flow is controlled in humans.  In addition, it is 
unknown if the control of skin blood flow is different during passive whole-body 
heating and active (exercise) heating. The purpose of this study is to gain a better 
understanding of the mechanisms that allow humans to increase skin blood flow during 
heat stress. This knowledge will help us to understand the changes in skin blood flow 
that occur as people age and in certain disease states, such as diabetes. As people age 
or as diabetes progresses, the ability to increase skin blood flow, to shift warm blood 
from the core of the body to the skin surface (to release the heat) is less compared to 
younger, healthy people. This decrease in skin blood flow is the primary reason older 
people and diabetics are at greater risk for heat-related illnesses during climatic heat 
waves. We will further our understanding of these problems by addressing one or more 
of following questions in this protocol: 
 
• Does the mode by which an individual is heated (exercise vs. passive whole-body 
heating) effect the mechanisms by which skin blood flow increases during heat 
stress? 
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What will happen in the study? (You will be asked to participate in sections of the 
protocol that have been circled below) 
 
1. If you are interested in participating in the study, we will schedule an appointment 
with you to meet with one of the investigators of the study to discuss the project, 
to see the laboratory, and to read this form. If we have scheduled this 
appointment, it means you meet all initial subject criteria (based on initial phone 
and/or email conversations). Additionally, during this initial session, you will fill 
out a health history form so that we can ensure you are healthy enough to 
participate in the study and that you meet all subject inclusion/exclusion criteria. 
This form will also be used to provide information to medical personnel in the 
event of an emergency. Investigators will then schedule an aerobic fitness test 
session. This visit should last about 60 minutes.  
 
2. For the aerobic fitness test session, you will report to in the Evonuk 
Environmental Physiology Core (EEPCore) in Esslinger Hall (Room 151). In 
total, you will spend about one hour in the lab on the test (VO2peak test) date. You 
will need to wear a t-shirt, shorts, running shoes, and refrain from eating at least 
two hours prior to arrival. In addition, you will need to refrain from consuming 
caffeine (for example, coffee, tea, red bull, coke, etc.) or medications (except oral 
contraceptives) for 12 hours prior to the study and abstain from alcohol or 
exercise for 24 hours prior to the study. If you use oral contraceptives, you should 
take this when you normally do so.  
 
3. If you are a woman who can still become pregnant, you will be asked to undergo 
a pregnancy test during the exercise test visit (and again during the study visits). 
For this test, you will be asked to collect a sample of urine in the women’s 
restroom near the physiology lab. If the test is “positive,” indicating that you are 
pregnant, you will not be allowed to participate and will be advised to see your 
physician or the University of Oregon Health Center. 
 
4. Aerobic Fitness Test: You will pedal on an exercise bicycle while wearing a 
mouth piece, nose clip, and electrocardiogram electrodes (heart rhythm monitor). 
If you are a woman, the adhesive patches used for this test will be placed on you 
by one of the women in the lab. After a 5-minute warm-up, you will be asked to 
maintain a selected pedaling rate as pedaling resistance (work) is increased every 
minute until you reach your maximum exercise capacity. This is to measure your 
VO2peak which is a measure of your overall aerobic fitness level. It normally takes 
10 to 15 minutes for people to reach their maximum effort. This session will 
establish your maximal exercise tolerance on a bike and will be used to establish 
the appropriate workload for the exercise session on the study visit. 
 
5. At the end of the fitness test, we may administer an intradermal injection of a 
small dose of Botulinum toxin type A (BOTOX) to a 0.5cm2 area of skin on the 
ventral side of your forearm.  The site of BOTOX administration will then be 
marked with a sharpie marker.  You will be sent home with this sharpie marker 
and asked to re-mark the treated site daily (after showering or washing etc.).  This 
is done so that we can relocate the treated site on the subsequent visit. 
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6. You should notify the investigator immediately if you feel any significant 
discomfort or concern about your well-being at any time during the initial visit. 
Some examples of discomfort include fatigue and muscle soreness.  
 
7. On the study day, you will arrive at Dr. Minson’s laboratory in Esslinger Hall at 
the University of Oregon. This testing will take approximately 6 hours. Prior to 
arrival, you will be asked to refrain from all over-the-counter medications for 24 
hours, alcohol and caffeine for 12 hours, and food for 4 hours. Your height and 
weight and resting blood pressure will be measured. You will be asked to provide 
a urine sample, which will be tested by an investigator for urine specific gravity 
(USG) to ensure that you are hydrated.  If you are dehydrated, you will be asked 
to drink 5mL/kg body weight of fluids prior to heating. Female subjects will also 
be asked to take a urine pregnancy test. You cannot participate in the study if the 
pregnancy test is positive, as the study procedures could be harmful to an unborn 
child. Additionally, female subjects will be studied during menses, or during the 
placebo phase, if taking birth control. You will be randomly assigned to a 
treatment sequence (Exercise first and passive Whole-body heating second; or 
passive Whole-body heating first and Exercise second) which are described 
below. Note: You will both Exercise and be passively Whole-body heated during 
the study. 
 
8. Your nude body weight will be measured by a member of the same sex prior to 
study.  You will stand behind a privacy screen while this measurement is taken. 
Your nude body weight will also be measured at the end of the study. This will be 
done so that we can quantify the volume of sweat you lose during the study.  
 
9. To measure your body core temperature, we will give you a rectal probe in a 
sterilized packet labeled with your subject number. It is made of a thin rubber 
(flexible) material that is inserted 10 centimeters (approximately 4 inches) past 
the anal sphincter. The probe will remain in place throughout the entire study 
session (up to 6 hours). The probe has a “tail” that will be connected to an 
external apparatus. The procedure may be a little uncomfortable at first (during 
insertion) but it should not be painful at any time. You will be instructed how to 
self-insert the rectal probe, as well as how to remove it and clean it. If you need 
assistance, a lab researcher of the same sex will help you. Once in place, you may 
not even feel the probe at all. This technique is widely used and it’s considered 
the “gold standard” procedure for measuring body (“core”) temperature. 
 
10. You will have up to 6 small tubes (these are called “microdialysis fibers”, and 
are smaller than the lead of a pencil) placed in the skin of your forearm.  (Note: 
if you previously received an intradermal injection of BOTOX, two of these 
fibers will be placed at this site.)  Microdialysis fiber placement: A small 
needle will be placed just under the surface of your skin and will exit back out 
about 1½ inches from where it entered your skin. The small tubes will be 
threaded through the needle, and the needle will be withdrawn, leaving the 
small tubes under your skin. These will remain in your skin throughout the 
rest of the study. 
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11. We will also put some very small doses of drugs through the small tubes in 
your skin.  These will be infused before heat stress and for the duration of the 
heating period. These drugs will cause the vessels of your skin next to the 
small tubes to either dilate or become narrow. You should not feel anything 
when the drugs are going into your skin. However, it is possible you may feel 
a slight tingling in the skin where the probe is. All of the drugs will be infused 
into the small area of skin and will not circulate through your body. 
 
You will receive the following drugs in your skin (only the ones circled): 
 
a. L-NAME: this stops nitric oxide from being produced and causes the skin vessels 
to narrow 
b. Sodium nitroprusside: this is a substance that is used to lower blood pressure in 
patients and causes the skin vessels to open 
c. Toradol (Ketorolac): this is a substance that may cause your blood vessels to 
narrow. 
d.Tetraethylammonium (TEA): this is a substance that may cause your blood vessels 
to narrow. 
e. Sulfaphenazole: This is a substance that may cause your blood vessels to narrow. 
f. Acetylcholine: This is a substance that may cause your blood vessels to open. 
g. Atropine: This is a substance that may cause your blood vessels to narrow. 
h.Glibenclamide (Glyburide): This is a substance that may cause your blood vessels to 
narrow. 
i. Ebselen: This is a substance that may cause your blood vessels to narrow. 
j. Tempol: This is a substance that may cause your blood vessels to open. 
k. Estradiol: This is a hormone that may alter blood flow. 
l. Progesterone: This is a hormone that may alter blood flow. 
m. Testosterone: This is a hormone that may alter blood flow. 
n. L-NNA: this stops nitric oxide from being produced and causes the skin vessels to 
narrow. 
o. Barium chloride: This is a substance that may cause your blood vessels to narrow. 
p. Potassium chloride: This is a substance that may cause your blood vessels to dilate. 
q. Insulin Aspart: This is a substance that may cause your blood vessels to dilate. 
r. L-NIO: This stops nitric oxide from being produced and causes the skin vessels to 
narrow. 
t. NPLA: This stops nitric oxide from being produced and causes the skin vessels to 
narrow. 
 
12. In addition, we may collect some samples of fluid from the ends of the tubes in 
your skin. The sample is being collected so that we can identify substances 
being released in the skin when people are heat-stressed. The vials will be 
coded such that the investigators can only determine that the samples came from 
the same person and the time each sample was taken. They will not be able to 
determine your identity from the sample. Once the study is completed and all 
samples are analyzed, any remaining or extra sample will be destroyed. 
 
13. We need to wait about 1-2 hours after the small tubes are placed in your skin to 
let the insertion trauma (redness of your skin around the small tubes) go away. 
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During this time, you will be prepared for either exercise or whole-body 
heating.  In addition, a small probe (laser-Doppler probe) and local heater will 
be placed over each area of skin where the small tubes are so that we can 
measure skin blood flow over the small tube. 
 
14. We will place up to 7 wires (called “thermocouples”) over your body in order 
to measure skin temperature. These will be placed directly on your skin at the 
following sites (Circled): upper back, lower back, chest, abdomen, thigh, calf, 
and forearm. They will be held in place with tape. A member of the same sex 
will place these. 
 
15. Whole-Body Heating: You will wear a two-piece nylon suit that has small tubes 
sewn into the inside of the suit for the duration of the passive Whole-body 
heating portion of the study. We will infuse water through these tubes during the 
experiment to control your skin and body temperature. We do not want you to get 
too hot so we will ask you from time-to-time if you are too hot. If you do 
become too hot you need to tell the investigator and we will lower the 
temperature of the water going through the suit. The suit will cover your whole 
body, except for your feet, hands, and head. You will wear a thin t-shirt and 
shorts under the suit. You can bring your own t-shirt and shorts, or we can 
provide a set for you to wear if you prefer. You will also wear a plastic suit over 
the nylon suit. This will help to keep the heat in during heat stress.  We will 
warm your body by running warm water through the suit until your body 
temperature is increased from about 98.6°F (normal temperature) to about 101°F. 
It will take about 40-70 minutes for your body temperature to reach 101°F. 
During the heating, we will measure your heart rhythm (ECG) from the sticky 
electrodes on your chest and abdomen and your body temperature. We will ask 
you to rate your perceived exertion, your thermal comfort, and how wet your 
skin feels.  After heating, we will immediately cool your body by running cool 
water through the suit until your body temperature is back to normal. 
 
16. During the study, we will periodically inflate a small cuff that is placed on your 
middle and ring fingers of one of your hands to measure your blood pressure 
(portapres device). We will only inflate this cuff on one finger for about 10 
minutes at a time. If the cuff becomes uncomfortable, let the investigator know 
and they will turn it off for a few minutes. 
 
17. Blood pressure will also be measured periodically throughout the study using 
an inflation cuff on your upper arm.  We may also stop (occlude) blood flow 
to the experimental arm by inflating a blood pressure cuff on the upper arm 
to 250 mmHg. We will stop blood flow to the arm three times for a period 
of 3-10 minutes with a 20-minute recovery period between each blood flow 
occlusion. 
 
18. We may measure cardiac output non-invasively using the acetylene uptake 
method in which the subject will breathe in a mix of safe gases that we will 
analyze. You will breathe on a mouthpiece for 8-10 breaths during which time 
you will be breathing in a gas mixture containing 0.6 % acetylene, 9.0 % helium, 
20.9 % oxygen, and the rest nitrogen. At the same time, we will collect expired 
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gas through the mouthpiece and analyze the concentrations of acetylene and 
helium you exhale. There are no risks associated with breathing acetylene or 
helium, particularly in such low concentrations. We will measure cardiac output 
three times at baseline, and every 20 minutes while being whole-body heated or 
exercised on the bike. 
 
19. Between treatment’s (Exercise vs. passive Whole-body heating) you will be 
seated in a phlebotomy chair and further cooled until your body temperature has 
returned to resting level.  At this point, you will begin the treatment not 
previously done. 
 
20. Exercise: For the exercise component of this study, you will exercise on a 
recumbent bicycle for one hour at a moderate intensity. The intensity will be set 
by the result of the aerobic fitness test (see item 4 on this list). The workload will 
be set so that you are exercising at 60 percent of your VO2peak score.  We will 
ensure that you are working at the appropriate workload by having you breathe 
into a mouthpiece (similar to that described at item 4) for the first 15 minutes of 
exercise so that we can collect your expired air. We will analyze the levels of 
oxygen and carbon dioxide in your expired air in order to calculate oxygen 
consumption and your exercise workload will be adjusted to meet the desired 60 
percent of VO2peak workload. We will make these measurements (only 2-3 
minute durations after the first 15 minutes) every 20 minutes while exercising. 
During exercise, we will be taking the exact same measures as are taken during 
passive Whole-body heating and outlined above. This means we will be 
collecting skin blood flow measures, skin temperatures, body core temperature, 
and blood pressure data from your arms while you are pedaling. You will be 
provided 500 milliliters of water to drink during exercise. 
 
21. Prior to de-instrumentation, we will heat each of laser-doppler sites with a small 
heater up to 44  Celsius (107 degrees Fahrenheit) to maximally open the 
vessels in the skin. This is below the temperature where heating becomes painful 
(about 110 degrees Fahrenheit) and well below the temperature that may burn the 
skin (about 113 degrees Fahrenheit). If the you think the heater is becoming 
painful, we will lower the temperature 
 
22. After the study, we will remove the small tubes in your skin and a bandage 
will be placed over the area of skin where the tubes were placed. 
 
23. Although you will not be allowed outside food or beverages during the 
study, you will be given a light snack and fluids to drink before you are sent 
home. 
 
How long will I be in the study? 
 
You will come in for an initial visit to learn about the study (20-30 minutes). If you 
qualify for the study, you will be in the study on only one day. The body heating 
experiment will take approximately 5 hours. 
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What are the risks of the study? 
 
Skin Microdialysis: There may be some discomfort during the insertion of the small 
fibers in your skin. Once the needle is in place, the pain should subside. There is also a 
risk of syncope (fainting) during needle placement. You will be sitting in a reclining 
chair during the study, which reduces this risk, and you will be asked to inform the 
investigator if you feel light-headed, nauseous, dizzy, etc. during needle placement. If 
you do experience any of these symptoms, we will discontinue placing the needles and 
ensure the symptoms subside. Infusions through the fibers should not be painful, and 
there should only be minor swelling at the site. At the end of the study, the fibers will 
be withdrawn and a sterile dressing will be applied. Any swelling or redness after the 
study should be gone a few hours after completion of the study. Although the small 
tubes are sterile, there is a slight risk of infection and/or allergic reaction at the sites 
where the small tubes were placed in your skin. You will be instructed how to keep the 
area clean for a day or two following the study. If you see any signs of infection 
(redness, swelling, and/or pain around the sites) or experience some other abnormal 
reaction at the insertion site following the study, please contact us immediately. We will 
show you photos of what normal and abnormal healing looks like at the sites. There is a 
possibility the fibers may break while in your skin of while they are being removed. We 
remove the fibers in a way such that we can still remove the entire fiber, even if it does 
break. However, there is still a slight risk a small part of the fiber could remain in your 
skin. If this occurs, the piece should be able to work its way out of the skin within a few 
days (similar to a splinter), and we will follow-up with you to ensure this has happened. 
If the piece does not work its way out, or if a site seems infected, we will evaluate the 
site(s) and, if necessary, recommend you seek medical treatment with a healthcare 
provider. 
Please note, all medical costs will be your responsibility. 
 
Whole Body Heating: The heat exposure can be physically demanding and can cause 
light- headedness, low blood pressure, fatigue, nausea, or cramps. Therefore, 
investigators will check in with subjects and will instruct subjects not to attempt to 
prolong the heating experiment if they do not feel well. Skin temperature, core 
temperature, heart rate (via ECG), and blood pressure will all be continually monitored 
closely the procedure. Subjects will be given Gatorade® and salty snacks to counteract 
the large amount of sweating they may experience during the protocol. Additionally, we 
will measure body weight before and after heat stress in order to ensure all fluids lost 
due to sweating has been replaced with fluids. 
 
 VO2Peak testing: There is potential risk associated with graded exercise testing that is 
categorized as More than Minimal Risk. The risks associated with graded exercise 
testing include light-headedness, fatigue, shortness of breath, risk of myocardial 
infarction and death. According to the American College of Sports Medicine, these 
general statements can be made regarding the safety of maximal graded exercise 
testing: The risk of death during or immediately after an exercise test is <0.01%. The 
risk of myocardial infarction during or immediately after an exercise test is <0.04%. 
The risk of complication requiring hospitalization (including myocardial infarction) is 
approximately 0.1%. The magnitude of severity for risks of light-headedness, fatigue, 
shortness of breath from the VO2Peak testing is very low, but the probability of these 
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risks occurring is moderate. The magnitude of severity for risks of myocardial 
infarction and death from the VO2Peak testing is very, very high, but the probability of 
these risks occurring is very, very low.  
 
 Aerobic Exercise: Like the graded exercise testing, there is potential risk associated 
with high intensity aerobic cycling exercise that is categorized as More than Minimal 
Risk. The risks associated with this are similar to graded exercise testing. However, 
ECG and blood pressure will be constantly monitored during testing. Procedures will 
be terminated immediately if any subject feels light-headed, nauseated, or experiences 
any other adverse signs or symptoms. In the event of an emergency, we will directly 
call 911. The magnitude of severity for risks of light-headedness, fatigue, shortness of 
breath from the aerobic exercise is very low, but the probability of these risks occurring 
is moderate. The magnitude of severity for risks of myocardial infarction and death 
from the aerobic exercise is very, very high, but the probability of these risks occurring 
is very, very low. 
 
 Rectal temperature probes: The use of rectal probes to measure core temperature 
carries minimal risk. The primary risk is of damage to the lining of the rectum; 
however, this risk is very slight as we use a flexible thermistor that is designed for this 
purpose.  We will exclude any subjects who have had recent rectal, anal, vaginal, or 
prostate surgery. In addition, we will exclude any subjects who have a personal history 
of heart disease, as the use of a rectal thermometer can cause a vagal reaction, 
increasing the potential for arrhythmias and fainting.  There is also the risk of infection, 
either by the subject not washing their hands properly or exposure by others to a poorly 
cleaned probe. Each probe is cleaned by the subject after use, and sterilized by the 
investigators before reuse.  The risk of infection is similar to that of having a bowel 
movement, and is considered minimal (similar to daily experience).  There is also the 
risk of embarrassment. The approach is typically well tolerated by subjects, and the 
investigative team is professional in regard to their treatment of the subjects.    
 
 Blood Flow Occlusion: The inflation of the blood pressure cuff to stop blood flow may 
cause a slight tingling sensation and may cause slight bruising. The sensations with 
prolonged blood flow occlusion greater than 10 minutes are similar to those when a 
limb has “fallen asleep.” During certain surgical procedures, blood flow is often 
stopped for 2 hours without any significant risk to the patient. If, at any time, subjects 
experience any discomfort, they may request that the blood pressure cuff be either 
loosened or removed. 
 
 Local Skin Heating: The local skin heaters may cause some minor skin discomfort. 
The goal is to warm the area of skin to a temperature that has been determined to be 
below the threshold for pain. There is a slight risk of burning the skin at this sight, so 
subjects will be instructed to tell the investigators of any pain they are feeling. If the 
local heating becomes painful, the temperature of the local heater will be lowered. The 
heating device may be removed at any time if the subjects experience any discomfort. 
 
Study Drugs: We will be infusing or placing on the skin (in the cream) very small 
doses of each drug (well below the dosages determined to be safe by the FDA), and 
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only into a very small area of the skin. The drugs are only infused into the small area of 
skin where the microdialysis tubes are placed. Therefore, these drugs will not directly 
cause any systemic (whole body) changes in blood pressure. However, as with any 
infusions or medications, there is the possibility that you are allergic to the drug and 
may have an allergic reaction to the drug including changes in blood pressure and 
difficulty breathing.  
 
Laser-Doppler Probes: These probes send a small light into the skin. You will not feel 
anything except the probe touching the skin. The only risk associated with this 
procedure is that there might be some slight skin irritation (redness) to the adhesive tape 
used to hold the probe on the skin. There are no major risks associated with this device. 
 
Finger Blood Pressure: In some people, this blood pressure cuff causes their finger to 
become red and uncomfortable after a long period (over 40 minutes). We will only 
inflate the cuff for 10 minutes at a time and then give your finger a rest. If your finger 
becomes uncomfortable during the 10 minutes the cuff is inflated, the investigator will 
turn it off for a few minutes. There are no major risks associated with this device. 
 
May I participate if I am pregnant or breast-feeding? 
 
This study may be harmful to an unborn or breast-fed child. There is not enough 
medical information to know what the risks might be to a breast-fed infant or to an 
unborn child in a woman who takes part in this study. Breast-feeding mothers are not 
able to take part in this study. Women who can still become pregnant must have a 
negative pregnancy test no more than 24 hours before taking part in this study. If the 
pregnancy test is positive (meaning that you are pregnant), you will not be able to take 
part in the study. 
 
Are there benefits to taking part in this study? This study will not make your health 
better. 
 
What other choices do I have if I don’t take part in this study? 
 
This study is only being done to gather information. You may choose not to take part 
in this study. 
 
What are the costs of tests and procedures? 
 
You will not need to pay for any tests or procedures that are done just for this research 
study. 
 
You will get $60 for participating in this study.  This money is for the inconvenience 
and time you spent in this study. If you start the study but stop before the study has 
ended, you will get part of this money. The partial amount will be calculated as $10 
per hour participated in the study. 
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Who can answer my questions? 
 
You may talk to Dr. Christopher Minson or one of the Co-Investigators at any time 
about any question you have on this study. You may contact Dr. Minson by calling 
(541) 346-4105 or on his cell phone (541) 953-2231, and the Co-investigators at (541) 
346-4507. 
 
What are my rights if I take part in this study? 
 
Taking part in this research study is your decision. You do not have to take part in this 
study, but if you do, you can stop at any time. Your decision whether or not to 
participate will not affect your relationship with The University of Oregon. 
 
You do not waive any liability rights for personal injury by signing this form. All 
forms of medical diagnosis and treatment whether routine or experimental, involve 
some risk of injury. In spite of all precautions, you might develop medical 
complications from participating in this study. 
 
The investigators may stop you from taking part in this study at any time if it is in your 
best interest, if you do not follow the study rules, or if the study is stopped. You will 
be told of important new findings or any changes in the study or procedures that may 
happen. 
 
If you experience harm because of the project, you can ask the State of Oregon to pay 
you. A law called the Oregon Tort Claims Act limits the amount of money you can 
receive from the State of Oregon if you are harmed. If you have been harmed, there are 
two University representatives you need to contact. Here are their addresses and phone 
numbers: 
Please note, compensation from participation in Human Subjects Research studies is taxable
income. If your compensation totals $600 or more in a calendar year, the University is required 
to report the income to the IRS. The University requires its departments to track participant
compensation and may contact you to complete a Form W-9 for tax reporting purposes. Because
of the federal and University tracking requirements, your name will be associated with 
participation in research. Department and University administrators will have access to this 
information, but will not have access to research data. 
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General Counsel Research 
Compliance Services Office of the President
 University of 
Oregon University of Oregon Eugene, OR 97403 
Eugene, OR 97403 (541) 346-2510 
(541) 346-3082 
 
 
 
 
What about confidentiality? 
 
Any information that is obtained in connection with this study and that can be identified 
with you will remain confidential and will be disclosed only with your permission. 
Subject identities will be kept confidential by assigning you a “subject identification 
number”. The names associated with each subject identification number will be kept in 
a locked file cabinet in Dr. Minson’s office. 
 
I have had an opportunity to have my questions answered. I have been given a copy of 
this form. I agree to take part in this study. 
 
If you have questions regarding your rights as a research subject, contact Research 
Compliance Services, 5219 University of Oregon, Eugene, OR 97403, 541/346-2510. 
 
Your signature indicates that you have read and understand the information provided 
above, that you willingly agree to participate, that you may withdraw your consent at 
any time and discontinue participation without penalty, that you will receive a copy of 
this form, and that you are not waiving any legal claims, rights or remedies. 
 
 
 
  
(Date) (Signature of Participant) 
 
 
 
 
 
(Printed Name of Participant) 
 
 
 
 
 
  
(Date) (Signature of Individual Obtaining Consent) 
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